var title_f5_27_5552="Pyloric stenosis PI";
var content_f5_27_5552=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PI%2F72947&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PI%2F72947&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 482px\">",
"   <div class=\"ttl\">",
"    Upper digestive tract in a baby",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 462px; height: 407px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This drawing shows the upper digestive tract in a baby. The pylorus is the opening between the stomach and the first part of the small intestine.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_27_5552=[""].join("\n");
var outline_f5_27_5552=null;
var title_f5_27_5553="Allergic conjunctivitis";
var content_f5_27_5553=[" <h1 id=\"patTopicTitle\">",
"  Patient information: Allergic conjunctivitis (Beyond the Basics)",
" </h1>",
" <div id=\"patTopicContributors\">",
"  <div class=\"rcTop\">",
"   <div>",
"   </div>",
"  </div>",
"  <div class=\"rcContent\">",
"   <table>",
"    <tr>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?5/27/5553/contributors\">",
"       Author",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?5/27/5553/contributors\" id=\"au2038\">",
"       Reza Dana, MD, MPH, MSc",
"      </a>",
"     </td>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?5/27/5553/contributors\">",
"       Section Editor",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?5/27/5553/contributors\" id=\"se7043\">",
"       Jonathan Trobe, MD",
"      </a>",
"     </td>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?5/27/5553/contributors\">",
"       Deputy Editor",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?5/27/5553/contributors\" id=\"de128\">",
"       Anna M Feldweg, MD",
"      </a>",
"     </td>",
"    </tr>",
"   </table>",
"  </div>",
"  <div class=\"rcBottom\">",
"   <div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"patTopicTool\" id=\"patTopicToolTop\">",
"  <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"   Find",
"  </a>",
"  <a class=\"toolbutton printicon\" href=\"UTD.htm?5/27/5553?view=print\" title=\"Print This Topic\">",
"   Print",
"  </a>",
"  <script src=\"file://w.sharethis.com/button/sharethis.js#publisher=357881b8-c7e3-4c31-b7d2-242aeb1528e1&amp;type=website&amp;post_services=care2%2Cfacebook%2Ctwitter%2Cmyspace%2Cdigg%2Cdelicious%2Cfaves%2Creddit%2Cxanga%2Cstumbleupon%2Cblinklist%2Csimpy%2Cyigg%2Ctechnorati%2Cmeneame%2Corkut%2Cmixx%2Cfunp%2Cfresqui%2Cmister_wong%2Cfriendster%2Cfriendfeed%2Clinkedin%2Coknotizie%2Cgoogle_bmarks%2Cyahoo_bmarks%2Cfark%2Cnewsvine%2Clivejournal%2Ctypepad%2Cbus_exchange%2Cpropeller%2Cwordpress%2Cblogger%2Cblogmarks%2Cwindows_live%2Cfurl%2Cybuzz%2Cdiigo\" type=\"text/javascript\">",
"  </script>",
" </div>",
" <div id=\"patTopicMiddle\">",
"  <div id=\"topicContent\">",
"   <div id=\"topicText\">",
"    <p class=\"headingAnchor\" id=\"H1\">",
"     <span class=\"h1\">",
"      ALLERGIC CONJUNCTIVITIS OVERVIEW",
"     </span>",
"    </p>",
"    <p>",
"     Conjunctivitis, also called \"pink eye,\" is defined as an inflammation of the conjunctiva. The conjunctiva is the thin membrane that lines the inner surface of the eyelids and the whites of the eyes (called the sclera) (",
"     <a class=\"graphic graphic_figure graphicRef81619 \" href=\"UTD.htm?38/47/39664\">",
"      figure 1",
"     </a>",
"     ). Conjunctivitis can affect children and adults. The most common symptoms of conjunctivitis include a red eye and discharge.",
"    </p>",
"    <p>",
"     There are many potential causes of conjunctivitis, including bacterial or viral infections and allergies. All types of conjunctivitis cause a red eye, although not everyone with a red eye has conjunctivitis. The term &ldquo;pink eye&rdquo; refers primarily to conjunctivitis caused by viruses (such as adenoviruses), rather than other causes. Therefore, this term should not be used when the underlying cause of the conjunctivitis is unknown or is not thought to be viral.",
"    </p>",
"    <p>",
"     This topic review discusses the signs and symptoms, evaluation, and treatment of allergic conjunctivitis. Other types of conjunctivitis are discussed separately. (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?19/51/20274?source=see_link\">",
"      \"Patient information: Conjunctivitis (pinkeye) (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H2\">",
"     <span class=\"h1\">",
"      ALLERGIC CONJUNCTIVITIS CAUSES",
"     </span>",
"    </p>",
"    <p>",
"     Allergic conjunctivitis is caused by airborne allergens that come in contact with the eye. Symptoms may be sudden in onset (acute), seasonal, or present year-round (perennial), depending upon the allergen.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H3\">",
"     <span class=\"h2\">",
"      Acute allergic conjunctivitis",
"     </span>",
"     &nbsp;&mdash;&nbsp;Acute allergic conjunctivitis is a sudden-onset reaction that occurs when a person comes in contact with a known allergen, such as cat dander. Symptoms include intense episodes of itching, redness, tearing, and swelling of the eyelid. Symptoms can be severe, although they usually resolve within 24 hours of removal of the allergen.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H4\">",
"     <span class=\"h2\">",
"      Seasonal allergic conjunctivitis",
"     </span>",
"     &nbsp;&mdash;&nbsp;Seasonal allergic conjunctivitis (SAC) is a form of eye allergy that usually causes milder but more persistent symptoms during a particular pollen season(s).",
"    </p>",
"    <p>",
"     Seasonal allergens include tree pollens in the spring, grass pollens in the summer, and weed pollens in the late summer and fall, although there is some variation based upon geographic location (",
"     <a class=\"graphic graphic_figure graphicRef75293 \" href=\"UTD.htm?25/32/26127\">",
"      figure 2",
"     </a>",
"     ).",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H5\">",
"     <span class=\"h2\">",
"      Perennial allergic conjunctivitis",
"     </span>",
"     &nbsp;&mdash;&nbsp;Perennial allergic conjunctivitis (PAC) is a mild, chronic, allergic conjunctivitis related to year-round environmental, usually indoor, allergens such as dust mites, animal danders, and molds.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H6\">",
"     <span class=\"h1\">",
"      ALLERGIC CONJUNCTIVITIS SYMPTOMS",
"     </span>",
"    </p>",
"    <p>",
"     The most common symptoms of allergic conjunctivitis include redness, watery discharge, and itching of both eyes. Other symptoms can include burning, sensitivity to light, and swelling of the eyelids. Both eyes are usually affected, although symptoms may be worse in one eye. Rubbing the eyes can worsen symptoms.",
"    </p>",
"    <p>",
"     People with allergic conjunctivitis often have a history of other allergic conditions, such as eczema, seasonal allergies, or a specific allergy (eg, to cats).",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H7\">",
"     <span class=\"h1\">",
"      ALLERGIC CONJUNCTIVITIS TREATMENT",
"     </span>",
"    </p>",
"    <p>",
"     There are a number of treatments available for the symptoms of allergic conjunctivitis. In addition, basic eye care is important.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H8\">",
"     <span class=\"h2\">",
"      Basic eye care",
"     </span>",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Avoid rubbing the eyes. If itching is bothersome, use artificial tears, a cool compress, or antihistamine eye drops. (See",
"       <a class=\"local\" href=\"#H9\">",
"        'Medications'",
"       </a>",
"       below.)",
"      </li>",
"      <li>",
"       Minimize exposure to pollen by staying inside when possible, using air conditioning, and keeping car and home windows closed during the peak allergy seasons (",
"       <a class=\"graphic graphic_figure graphicRef75293 \" href=\"UTD.htm?25/32/26127\">",
"        figure 2",
"       </a>",
"       ). (See",
"       <a class=\"medical medical_patient\" href=\"UTD.htm?40/8/41092?source=see_link\">",
"        \"Patient information: Allergic rhinitis (seasonal allergies) (Beyond the Basics)\"",
"       </a>",
"       .)",
"      </li>",
"      <li>",
"       People with year round allergic conjunctivitis should consider consulting an allergy specialist to determine which allergens are responsible for their symptoms (eg, dust mites, cat dander, others).",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H9\">",
"     <span class=\"h2\">",
"      Medications",
"     </span>",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       People with sudden-onset symptoms can use a combination",
"       <span class=\"nowrap\">",
"        antihistamine/vasoconstrictor",
"       </span>",
"       eye drop four times daily for up to two weeks. These are available without a prescription.",
"      </li>",
"      <li>",
"       People with seasonal or year round symptoms are usually treated with a combination",
"       <span class=\"nowrap\">",
"        antihistamine/mast",
"       </span>",
"       cell stabilizer eye drop. Most of these require a prescription. Ketotifen is an eye drop in this category that is available without a prescription.",
"      </li>",
"      <li>",
"       An oral antihistamine may be most helpful when it is taken preventively (before symptoms develop). However, antihistamines may also be used to treat symptoms after they have started, although the greatest benefit may not be seen for several days.",
"       <br/>",
"       <br/>",
"       Non-sedating oral antihistamines include fexofenadine (generic, Allegra&reg;), loratadine (generic, Claritin&reg;), desloratadine (Clarinex&reg;), cetirizine (generic, Zyrtec&reg;), and levocetirizine (Xyzal&reg;). Loratadine and cetirizine are available in the United States without a prescription.",
"       <br/>",
"       <br/>",
"       Diphenhydramine (Benadryl&reg;) is a short-acting, sedating antihistamine that can be taken at bedtime to reduce night-time itching.",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     If symptoms of allergic conjunctivitis do not improve after two to three weeks of the above treatments, the person should see an ophthalmologist for evaluation.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H10\">",
"     <span class=\"h2\">",
"      Treat dry eyes",
"     </span>",
"     &nbsp;&mdash;&nbsp;People with allergic conjunctivitis often produce an inadequate amount of tears, which can cause dryness of the eye. This can worsen symptoms of allergic conjunctivitis. However, it is not always possible to know if a person has inadequate tear production unless an eye examination is performed.",
"    </p>",
"    <p>",
"     If inadequate tear production is diagnosed, treatment often includes use of a lubricant eye drop or ointment. These products are available without a prescription in most pharmacies. Preservative-free preparations are more expensive and are necessary only for people with a severe case of dry eye and those who are allergic to preservatives.",
"    </p>",
"    <p>",
"     Lubricant drops can be used as often as hourly with no side effects. The ointment provides longer lasting relief but blurs vision temporarily. For this reason, some people use ointment only at bedtime. It may be worthwhile to switch brands if one brand of drop or ointment is irritating, since each preparation contains different active and inactive ingredients and preservatives.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H11\">",
"     <span class=\"h1\">",
"      WHERE TO GET MORE INFORMATION",
"     </span>",
"    </p>",
"    <p>",
"     Your healthcare provider is the best source of information for questions and concerns related to your medical problem.",
"    </p>",
"    <p>",
"     This article will be updated as needed on our web site (",
"     <a class=\"external\" href=\"file://www.uptodate.com/patients\">",
"      www.uptodate.com/patients",
"     </a>",
"     ). Related topics for patients, as well as selected articles written for healthcare professionals, are also available. Some of the most relevant are listed below.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H1804398558\">",
"     <span class=\"h2\">",
"      Patient level information",
"     </span>",
"     &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H12676223\">",
"     <span class=\"h3\">",
"      The Basics",
"     </span>",
"     &nbsp;&mdash;&nbsp;The Basics patient education pieces answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?26/6/26721?source=see_link\">",
"      Patient information: Conjunctivitis (pinkeye) (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?36/38/37474?source=see_link\">",
"      Patient information: Seasonal allergies in adults (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?28/61/29649?source=see_link\">",
"      Patient information: Photokeratitis (Arc eye) (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?13/10/13475?source=see_link\">",
"      Patient information: Seasonal allergies in children (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?41/5/42066?source=see_link\">",
"      Patient information: Allergy shots (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?41/24/42370?source=see_link\">",
"      Patient information: Allergy skin testing (The Basics)",
"     </a>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H12676250\">",
"     <span class=\"h3\">",
"      Beyond the Basics",
"     </span>",
"     &nbsp;&mdash;&nbsp;Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are best for patients who want in-depth information and are comfortable with some medical jargon.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?19/51/20274?source=see_link\">",
"      Patient information: Conjunctivitis (pinkeye) (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?40/8/41092?source=see_link\">",
"      Patient information: Allergic rhinitis (seasonal allergies) (Beyond the Basics)",
"     </a>",
"     <br/>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H12\">",
"     <span class=\"h2\">",
"      Professional level information",
"     </span>",
"     &nbsp;&mdash;&nbsp;Professional level articles are designed to keep doctors and other health professionals up-to-date on the latest medical findings. These articles are thorough, long, and complex, and they contain multiple references to the research on which they are based. Professional level articles are best for people who are comfortable with a lot of medical terminology and who want to read the same materials their doctors are reading.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/2/34856?source=see_link\">",
"      Allergic conjunctivitis",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/17/20760?source=see_link\">",
"      Conjunctivitis",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/12/17607?source=see_link\">",
"      Evaluation of the red eye",
"     </a>",
"     <br/>",
"    </p>",
"    <p>",
"     The following organizations also provide reliable health information.",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       National Library of Medicine",
"       <br/>",
"       <br/>",
"       (",
"       <a class=\"external\" href=\"file://www.nlm.nih.gov/medlineplus/healthtopics.html\">",
"        www.nlm.nih.gov/medlineplus/healthtopics.html",
"       </a>",
"       )",
"      </li>",
"      <li>",
"       National Institute of Allergy and Infectious Diseases (NIAID)",
"       <br/>",
"       <br/>",
"       (",
"       <a class=\"external\" href=\"file://www.niaid.nih.gov/\">",
"        www.niaid.nih.gov",
"       </a>",
"       )",
"      </li>",
"      <li>",
"       Allergy, Asthma, and Immunology Online",
"       <br/>",
"       <br/>",
"       (",
"       <a class=\"external\" href=\"file://www.acaai.org/\">",
"        www.acaai.org",
"       </a>",
"       )",
"      </li>",
"      <li>",
"       American Academy of Allergy, Asthma, and Immunology",
"       <br/>",
"       <br/>",
"       (",
"       <a class=\"external\" href=\"file://www.aaaai.org\">",
"        www.aaaai.org",
"       </a>",
"       )",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     [",
"     <a class=\"abstract\" href=\"UTD.htm?5/27/5553/abstract/1-3\">",
"      1-3",
"     </a>",
"     ]",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 8, 2013.",
"  </div>",
"  <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"   <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"    Find",
"   </a>",
"   <a class=\"toolbutton printicon\" href=\"UTD.htm?5/27/5553?view=print\" title=\"Print This Topic\">",
"    Print",
"   </a>",
"  </div>",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <div id=\"patTopicRefHeader\">",
"    <div id=\"patTopicRefHeaderHeader\">",
"     References",
"    </div>",
"    <div id=\"patTopicRefHeaderTop\">",
"     <a href=\"#top\">",
"      <img alt=\"\" src=\"./../images/top_arrow.myextg\">",
"       Top",
"      </img>",
"     </a>",
"    </div>",
"   </div>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/27/5553/abstract/1\">",
"      Greiner JV, Michaelson C, McWhirter CL, Shams NB. Single dose of ketotifen fumarate .025% vs 2 weeks of cromolyn sodium 4% for allergic conjunctivitis. Adv Ther 2002; 19:185.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/27/5553/abstract/2\">",
"      Ousler GW 3rd, Workman DA, Torkildsen GL. An open-label, investigator-masked, crossover study of the ocular drying effects of two antihistamines, topical epinastine and systemic loratadine, in adult volunteers with seasonal allergic conjunctivitis. Clin Ther 2007; 29:611.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/27/5553/abstract/3\">",
"      Yaylali V, Demirlenk I, Tatlipinar S, et al. Comparative study of 0.1% olopatadine hydrochloride and 0.5% ketorolac tromethamine in the treatment of seasonal allergic conjunctivitis. Acta Ophthalmol Scand 2003; 81:378.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
" </div>",
" <!-- patTopicMiddle -->",
"</div>"].join("\n");
var script_f5_27_5553=[""].join("\n");
var outline_f5_27_5553=[" <div class=\"patTopicFancyTop\">",
"  <div class=\"rcTop\">",
"   <div>",
"   </div>",
"  </div>",
"  <div class=\"rcContent\">",
"   <p>",
"    Contents of this article",
"   </p>",
"  </div>",
" </div>",
" <div class=\"patTopicFancySpacer\">",
" </div>",
" <div class=\"patTopicOutline\">",
"  <div class=\"rcbBottom\">",
"   <div class=\"rcbLeft\">",
"    <div class=\"rcbRight\">",
"     <div class=\"rcbBottomLeft\">",
"      <div class=\"rcbBottomRight rcbBottomRightBottomOnly\">",
"       <div id=\"outline\">",
"        <ul>",
"         <li class=\"plainItem\">",
"          <a href=\"#H1\">",
"           ALLERGIC CONJUNCTIVITIS OVERVIEW",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H2\">",
"           ALLERGIC CONJUNCTIVITIS CAUSES",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H6\">",
"           ALLERGIC CONJUNCTIVITIS SYMPTOMS",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H7\">",
"           ALLERGIC CONJUNCTIVITIS TREATMENT",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H11\">",
"           WHERE TO GET MORE INFORMATION",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#references\">",
"           REFERENCES",
"          </a>",
"         </li>",
"        </ul>",
"       </div>",
"       <h1>",
"        GRAPHICS",
"       </h1>",
"       <div id=\"relatedGraphics\">",
"        <ul>",
"         <li class=\"plainItem\">",
"          FIGURES",
"         </li>",
"         <li class=\"bulletItem\">",
"          <a class=\"graphic graphic_figure\" href=\"UTD.htm?38/47/39664\" title=\"figure 1\">",
"           Conjunctiva anatomy PI",
"          </a>",
"         </li>",
"         <li class=\"bulletItem\">",
"          <a class=\"graphic graphic_figure\" href=\"UTD.htm?25/32/26127\" title=\"figure 2\">",
"           Peak pollen periods US PI",
"          </a>",
"         </li>",
"        </ul>",
"       </div>",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"  </div>",
" </div>"].join("\n");
var title_f5_27_5554="Patient information: Iliotibial band syndrome (The Basics)";
var content_f5_27_5554=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div id=\"basics-graphics\">",
"      <span class=\"basics-box-top\">",
"      </span>",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-graphics-title.png\"/>",
"       <span class=\"openRelatedGraphics\" id=\"PI/86738\" rel=\"graphic_box\">",
"        <a href=\"#\" title=\"View All Related Graphics\">",
"         View All",
"        </a>",
"       </span>",
"      </h4>",
"      <ul>",
"       <li>",
"        <a class=\"graphic graphic_figure\" href=\"UTD.htm?34/52/35648\">",
"         Iliotibial band",
"        </a>",
"       </li>",
"      </ul>",
"      <a href=\"#\" id=\"basics-seeall\">",
"       See All Graphics",
"      </a>",
"     </div>",
"     <script type=\"text/javascript\">",
"      if ($(\"#basics-graphics li\").length &lt;= 4) {",
"				$(\"#basics-seeall\").remove();",
"			} else {",
"				$(\"#basics-graphics li:gt(3)\").addClass(\"hidden\");",
"				$(\"#basics-seeall\").click(function(){",
"					$(\"#basics-graphics li.hidden\").removeClass(\"hidden\");",
"					$(this).remove();",
"					return false;",
"				});",
"			}",
"     </script>",
"     <div class=\"ieSpacer\">",
"     </div>",
"     <div id=\"basics-more\">",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-more-title.png\"/>",
"      </h4>",
"      <dl>",
"       <dt class=\"basics\">",
"        The Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?35/21/36179\">",
"         Patient information: Giving your child over-the-counter medicines (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?7/36/7747\">",
"         Patient information: Knee pain (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?39/15/40178\">",
"         Patient information: Nonsteroidal antiinflammatory drugs (NSAIDs) (The Basics)",
"        </a>",
"       </dd>",
"       <dt class=\"beyondthebasics\">",
"        Beyond the Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?24/4/24642\">",
"         Patient information: Knee pain (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?2/13/2262\">",
"         Patient information: Nonsteroidal antiinflammatory drugs (NSAIDs) (Beyond the Basics)",
"        </a>",
"       </dd>",
"      </dl>",
"      <div id=\"tooltipper\">",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: Iliotibial band syndrome (The Basics)",
"    </div>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H87498871\">",
"      <span class=\"h1\">",
"       What is iliotibial band syndrome?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Iliotibial band syndrome is a condition that causes pain on the outside of the knee.",
"     </p>",
"     <p>",
"      This condition involves a strong band of tissue called the &ldquo;iliotibial band&rdquo; (",
"      <a class=\"graphic graphic_figure graphicRef86674 \" href=\"UTD.htm?34/52/35648\">",
"       figure 1",
"      </a>",
"      ). The iliotibial band runs down the outside of the thigh, from the hip bone to the top of the shinbone.",
"     </p>",
"     <p>",
"      Iliotibial band syndrome commonly happens in runners, especially after they increase their workouts.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H87498903\">",
"      <span class=\"h1\">",
"       What are the symptoms of iliotibial band syndrome?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Iliotibial band syndrome causes an aching, burning pain on the outside of the knee. The pain sometimes spreads up the thigh to the hip. The pain happens when people run (or do other physical activity).",
"     </p>",
"     <p>",
"      For some people, the pain lasts even after they finish their workout. Movements that make the pain worse include going up and down stairs, and standing up from a seated position.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H87498918\">",
"      <span class=\"h1\">",
"       Will I need tests?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Probably not. Your doctor or nurse should be able to tell if you have this condition by learning about your symptoms and doing an exam.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H87498933\">",
"      <span class=\"h1\">",
"       How is iliotibial band syndrome treated?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Treatment usually involves a few parts.",
"     </p>",
"     <p>",
"      The first part of treatment involves things you can do on your own to reduce your pain. To ease your symptoms, you can:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Rest your knee and avoid activities or movements that make the pain worse.",
"       </li>",
"       <li>",
"        Put ice on the outside of your knee when it hurts or after activities that cause pain. You can put a cold gel pack, bag of ice, or bag of frozen vegetables on the painful area every 1 to 2 hours, for 15 minutes each time. Put a thin towel between the ice (or other cold object) and your skin.",
"       </li>",
"       <li>",
"        Take a pain-relieving medicine. Over-the-counter medicines include",
"        <a class=\"drug drug_patient\" href=\"UTD.htm?19/35/20021?source=see_link\">",
"         acetaminophen",
"        </a>",
"        (sample brand name: Tylenol) or",
"        <a class=\"drug drug_patient\" href=\"UTD.htm?14/17/14614?source=see_link\">",
"         ibuprofen",
"        </a>",
"        (sample brand names: Advil, Motrin).",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      Another part of treatment involves exercises to stretch and strengthen the muscles around your hip and knee. You can start these when your pain improves. Your doctor or nurse will show you which exercises and stretches to do. Or he or she will have you work with a physical therapist (exercise expert).",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H87498948\">",
"      <span class=\"h1\">",
"       Can iliotibial band syndrome be prevented?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Yes. To help prevent getting iliotibial band syndrome again, you can:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Replace your sneakers when they wear out.",
"       </li>",
"       <li>",
"        Run on even surfaces (and not on uneven surfaces).",
"       </li>",
"       <li>",
"        Run around a track in both directions (and not only in 1 direction).",
"       </li>",
"       <li>",
"        Ease up on your training and not run as far or as hard.",
"       </li>",
"       <li>",
"        Have an expert check how you run to make sure you run the correct way.",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H87498963\">",
"      <span class=\"h1\">",
"       More on this topic",
"      </span>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?7/36/7747?source=see_link\">",
"       Patient information: Knee pain (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?39/15/40178?source=see_link\">",
"       Patient information: Nonsteroidal antiinflammatory drugs (NSAIDs) (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?35/21/36179?source=see_link\">",
"       Patient information: Giving your child over-the-counter medicines (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?24/4/24642?source=see_link\">",
"       Patient information: Knee pain (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?2/13/2262?source=see_link\">",
"       Patient information: Nonsteroidal antiinflammatory drugs (NSAIDs) (Beyond the Basics)",
"      </a>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 20, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"UTD.htm?5/27/5554?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 86738 Version 1.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1105-220.255.2.135-793AA7D34B-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_27_5554=[""].join("\n");
var outline_f5_27_5554=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H87498871\">",
"      What is iliotibial band syndrome?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H87498903\">",
"      What are the symptoms of iliotibial band syndrome?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H87498918\">",
"      Will I need tests?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H87498933\">",
"      How is iliotibial band syndrome treated?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H87498948\">",
"      Can iliotibial band syndrome be prevented?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H87498963\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PI/86738\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li>",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?34/52/35648\">",
"      Iliotibial band",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?35/21/36179?source=related_link\">",
"      Patient information: Giving your child over-the-counter medicines (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?24/4/24642?source=related_link\">",
"      Patient information: Knee pain (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?7/36/7747?source=related_link\">",
"      Patient information: Knee pain (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?2/13/2262?source=related_link\">",
"      Patient information: Nonsteroidal antiinflammatory drugs (NSAIDs) (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?39/15/40178?source=related_link\">",
"      Patient information: Nonsteroidal antiinflammatory drugs (NSAIDs) (The Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f5_27_5555="Lodoxamide tromethamine: Drug information";
var content_f5_27_5555=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Lodoxamide tromethamine: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?0/40/644?source=see_link\">",
"    see \"Lodoxamide tromethamine: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F189444\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Alomide&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F189445\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Alomide&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F189472\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Mast Cell Stabilizer",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F189446\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Vernal conjunctivitis, keratitis:",
"     </b>",
"     Ophthalmic: Instill 1-2 drops in eye(s) 4 times/day for up to 3 months",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F189459\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Children &gt;2 years: Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F189447\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F16265657\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in manufacturer&rsquo;s labeling. However, dosage adjustment unlikely due to low systemic absorption.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F16265658\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in manufacturer&rsquo;s labeling. However, dosage adjustment unlikely due to low systemic absorption.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F189435\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Solution, ophthalmic [drops]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Alomide&reg;: 0.1% (10 mL) [contains benzalkonium chloride]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F189422\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F189436\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of vernal keratoconjunctivitis, vernal conjunctivitis, and vernal keratitis",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F3264535\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      International issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Thilomide [Greece, Turkey] may be confused with Thalomid brand name for thalidomide [U.S., Canada]",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F189470\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &gt;10%: Local: Transient burning, stinging, discomfort",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Headache",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Ocular: Blurred vision, crystalline deposits, dry eye, edema, foreign body sensation, hyperemia, itching, tearing",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &lt;1% (Limited to important or life-threatening): Blepharitis, chemosis, corneal abrasion, corneal erosion/ulcer, dizziness, dry nose, epitheliopathy, eye pain, eye swelling, keratitis, ocular fatigue, ocular feeling of warmth, nausea, rash, sneezing, somnolence, stomach discomfort",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F189439\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to lodoxamide tromethamine or any component of the formulation",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F189426\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Irritation: May cause transient burning or stinging.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Contact lens wearers: Contains benzalkonium chloride which may be absorbed by contact lenses; remove contacts prior to administration and wait 15 minutes before reinserting.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Appropriate use: For ophthalmic use only; not for injection.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299615\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F189431\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:0em;display:inline\">",
"     There are no known significant interactions.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F189432\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     B (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F13823800\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No adverse events were observed in animal reproduction studies following oral administration. The amount of lodoxamide available systemically following ophthalmic administration is below the level of detection.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F12990165\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/use caution",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F189440\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Alomide Ophthalmic)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.1% (10 mL): $140.94",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F189441\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Alconmide (PH);",
"     </li>",
"     <li>",
"      Almide (FR);",
"     </li>",
"     <li>",
"      Alomide (AR, AT, BE, BF, BG, BJ, BR, CH, CI, CL, CN, CO, CZ, DE, DK, ES, ET, FI, GB, GH, GM, GN, GR, HK, HN, HU, ID, IE, IL, IT, KE, LR, LU, MA, ML, MR, MU, MW, MX, MY, NE, NG, NO, PE, PK, PL, PT, PY, RU, SC, SD, SG, SL, SN, TH, TN, TR, TW, TZ, UG, UY, VE, ZA, ZM, ZW);",
"     </li>",
"     <li>",
"      Lomide (AU, NZ)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F189425\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Mast cell stabilizer that inhibits the",
"     <i>",
"      in vivo",
"     </i>",
"     type I immediate hypersensitivity reaction to increase cutaneous vascular permeability associated with IgE and antigen-mediated reactions",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F189438\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Absorption: Topical: Negligible",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9567 Version 33.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-200.131.240.2-C7EAEF3114-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_27_5555=[""].join("\n");
var outline_f5_27_5555=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F189444\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F189445\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F189472\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F189446\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F189459\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F189447\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16265657\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16265658\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F189435\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F189422\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F189436\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3264535\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F189470\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F189439\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F189426\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299615\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F189431\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F189432\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13823800\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12990165\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F189440\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F189441\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F189425\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F189438\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9567\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9567|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?0/40/644?source=related_link\">",
"      Lodoxamide tromethamine: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f5_27_5556="Renal disease in the setting of infective endocarditis or an infected ventriculoatrial shunt";
var content_f5_27_5556=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Renal disease in the setting of infective endocarditis or an infected ventriculoatrial shunt",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?5/27/5556/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?5/27/5556/contributors\">",
"     Jai Radhakrishnan, MD, MS",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?5/27/5556/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?5/27/5556/contributors\">",
"     Richard J Glassock, MD, MACP",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?5/27/5556/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?5/27/5556/contributors\">",
"     John P Forman, MD, MSc",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?5/27/5556/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 24, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with infective endocarditis (IE) can develop several forms of renal disease: a bacterial infection-related immune complex-mediated glomerulonephritis, which can also occur with an infected ventriculoatrial shunt [",
"    <a class=\"abstract\" href=\"UTD.htm?5/27/5556/abstract/1-4\">",
"     1-4",
"    </a>",
"    ]. In addition, a drug-induced acute interstitial nephritis or, with aminoglycosides, acute kidney injury (due to acute tubular necrosis) can develop.",
"   </p>",
"   <p>",
"    Based upon the population studied and the severity of disease, additional renal histologic lesions may be observed. Among kidneys evaluated at autopsy, for example, localized infarcts, particularly due to septic emboli, as well as renal cortical necrosis have been described [",
"    <a class=\"abstract\" href=\"UTD.htm?5/27/5556/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The frequency of renal involvement in patients was illustrated in a retrospective study of over 200 consecutive episodes of bacterial endocarditis [",
"    <a class=\"abstract\" href=\"UTD.htm?5/27/5556/abstract/6\">",
"     6",
"    </a>",
"    ]. Approximately one-third of patients developed acute kidney injury (of any cause), a complication observed most often among older patients and those with Staphylococcus aureus infection.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     GLOMERULONEPHRITIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;A variety of organisms may be involved in patients developing glomerulonephritis. The most common are Staphylococcus aureus in acute infective endocarditis (IE), Streptococcus viridans in subacute IE, and Staphylococcus epidermidis in shunt nephritis.",
"   </p>",
"   <p>",
"    The histologic findings in the glomerulonephritis are similar to those in poststreptococcal glomerulonephritis or membranoproliferative glomerulonephritis: hypercellularity (due in part to the influx of circulating inflammatory cells) and immune deposits in the glomerular capillary wall. Diffuse crescent formation can occur [",
"    <a class=\"abstract\" href=\"UTD.htm?5/27/5556/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In comparison to poststreptococcal disease, the duration of antigenemia is often prolonged in patients with endocarditis or an infected shunt due to delays in diagnosis and treatment. As a result, there may be a greater degree of immune complex deposition, with subendothelial as well as subepithelial deposits and thickening of the capillary wall. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/51/43833?source=see_link\">",
"     \"Clinical presentation, classification, and causes of membranoproliferative glomerulonephritis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The clinical manifestations are similar to those in other forms of acute glomerulonephritis: hematuria, red cell and other cellular casts, and variable degrees of hypertension and renal insufficiency (",
"    <a class=\"graphic graphic_picture graphicRef55778 \" href=\"UTD.htm?34/38/35424\">",
"     picture 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?5/27/5556/abstract/1-4\">",
"     1-4",
"    </a>",
"    ]. The nephrotic syndrome is unusual in endocarditis but occurs in up to 30 percent of patients with shunt nephritis [",
"    <a class=\"abstract\" href=\"UTD.htm?5/27/5556/abstract/2\">",
"     2",
"    </a>",
"    ]. The plasma C3, C4, and C2 levels are typically reduced in both conditions, indicating activation of the classic complement pathway.",
"   </p>",
"   <p>",
"    There are a few case reports of patients with bacterial endocarditis and glomerulonephritis who developed pulmonary hemorrhage, potentially mimicking other systemic diseases such as ANCA-positive vasculitis and anti-glomerular basement membrane antibody disease [",
"    <a class=\"abstract\" href=\"UTD.htm?5/27/5556/abstract/8,9\">",
"     8,9",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/31/27130?source=see_link&amp;anchor=H14577579#H14577579\">",
"     \"Differential diagnosis and evaluation of glomerular disease\", section on 'Acute glomerulonephritis and pulmonary hemorrhage'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The presence of infective endocarditis (IE) or shunt nephritis is usually suggested from the history (including the presence of a ventriculoatrial shunt), urinary findings, and positive blood cultures. However, the glomerulonephritis must be distinguished from other renal diseases that can occur in this setting:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Drug-induced interstitial nephritis, usually with a penicillin, cephalosporin, or quinolone, shares many of the clinical findings of acute glomerulonephritis: hematuria (occasionally but not usually with red cell casts), mild proteinuria, and renal insufficiency. Pyuria and white cell casts can be seen in both disorders but are typically the major finding in acute interstitial nephritis (",
"      <a class=\"graphic graphic_picture graphicRef54319 graphicRef68147 \" href=\"UTD.htm?27/1/27669\">",
"       picture 2A-B",
"      </a>",
"      ).",
"      <br/>",
"      <br/>",
"      The distinction between these disorders can usually be made from the",
"      <strong>",
"       timing",
"      </strong>",
"      of the renal manifestations. Glomerular involvement is typically near or at its peak of severity just before the institution of appropriate antimicrobial therapy. In contrast, acute interstitial nephritis is a later event, generally requiring 10 or more days of drug treatment [",
"      <a class=\"abstract\" href=\"UTD.htm?5/27/5556/abstract/10,11\">",
"       10,11",
"      </a>",
"      ]. If present, eosinophilia and eosinophiluria also point toward this disorder. Recurrent fever may be seen and may erroneously suggest failure of antibiotic therapy. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?26/36/27209?source=see_link\">",
"       \"Clinical manifestations and diagnosis of acute interstitial nephritis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Aminoglycoside-induced acute tubular necrosis also occurs late (after at least five to seven days of therapy) and is associated with different urinary findings from either the glomerulonephritis or interstitial nephritis. The urinalysis can vary from a bland sediment to one showing multiple muddy brown granular casts, renal epithelial cells, and epithelial cell casts (",
"      <a class=\"graphic graphic_picture graphicRef56438 \" href=\"UTD.htm?37/63/38900\">",
"       picture 3",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?11/54/12138?source=see_link\">",
"       \"Etiology and diagnosis of prerenal disease and acute tubular necrosis in acute kidney injury (acute renal failure)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?19/47/20215?source=see_link\">",
"       \"Manifestations of and risk factors for aminoglycoside nephrotoxicity\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Renal emboli, which can occur as late as several months after bacteriologic cure, should be suspected if there is acute, often unilateral flank pain or evidence of other peripheral emboli. The diagnosis can be confirmed by the finding of focal perfusion defects on radionuclide scan.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     OUTCOME",
"    </span>",
"    &nbsp;&mdash;&nbsp;The severity of the glomerulonephritis is primarily related to the duration of infection prior to the institution of antimicrobial therapy. Control of the infection (including removal of an infected shunt) usually leads to rapid resolution, with return of renal function to or near the previous baseline. However, irreversible renal failure can occur if appropriate therapy is delayed [",
"    <a class=\"abstract\" href=\"UTD.htm?5/27/5556/abstract/1,4,5\">",
"     1,4,5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Thus, to preserve renal function in patients whose disease is due to infective endocarditis (IE) or an infected ventriculoatrial shunt, the responsible infection should be promptly eradicated [",
"    <a class=\"abstract\" href=\"UTD.htm?5/27/5556/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H139433\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Renal manifestations associated with infective endocarditis (IE) can be associated with several patterns of disease:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Immune complex-mediated glomerulonephritis (often of a crescentic variety)",
"     </li>",
"     <li>",
"      Drug-induced acute interstitial nephritis as a result of antibiotic therapy",
"     </li>",
"     <li>",
"      Acute kidney injury (due to acute tubular necrosis)",
"     </li>",
"     <li>",
"      Thromboembolic disease",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      These disorders may be distinguished by the timing of the renal manifestations, the urinary sediment, and other clinical features. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H3\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The most common organisms involved in patients developing glomerulonephritis include Staphylococcus aureus in acute IE, Streptococcus viridans in subacute IE, and Staphylococcus epidermidis in shunt nephritis. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Glomerulonephritis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The histologic findings in the glomerulonephritis include hypercellularity and immune deposits in the glomerular capillary wall. Compared with poststreptococcal disease, there may be a greater degree of immune complex deposition with subendothelial as well as subepithelial deposits and thickening of the capillary wall due to a greater duration of antigenemia. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Glomerulonephritis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The clinical manifestations include hematuria, red cell and other cellular casts, and variable degrees of hypertension and renal insufficiency. The nephrotic syndrome is unusual in endocarditis but occurs in up to 30 percent of patients with shunt nephritis. The plasma C3, C4, and C2 levels are typically reduced in both conditions, indicating activation of the classic complement pathway. Rapidly progressive glomerulonephritis can occur. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Glomerulonephritis'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/27/5556/abstract/1\">",
"      Neugarten J, Baldwin DS. Glomerulonephritis in bacterial endocarditis. Am J Med 1984; 77:297.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/27/5556/abstract/2\">",
"      Arze RS, Rashid H, Morley R, et al. Shunt nephritis: report of two cases and review of the literature. Clin Nephrol 1983; 19:48.",
"     </a>",
"    </li>",
"    <li>",
"     Rose, BD. Pathophysiology of Renal Disease, 2nd ed, McGraw-Hill, New York City 1987. p.229.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/27/5556/abstract/4\">",
"      Haffner D, Schindera F, Aschoff A, et al. The clinical spectrum of shunt nephritis. Nephrol Dial Transplant 1997; 12:1143.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/27/5556/abstract/5\">",
"      Majumdar A, Chowdhary S, Ferreira MA, et al. Renal pathological findings in infective endocarditis. Nephrol Dial Transplant 2000; 15:1782.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/27/5556/abstract/6\">",
"      Conlon PJ, Jefferies F, Krigman HR, et al. Predictors of prognosis and risk of acute renal failure in bacterial endocarditis. Clin Nephrol 1998; 49:96.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/27/5556/abstract/7\">",
"      Kannan S, Mattoo TK. Diffuse crescentic glomerulonephritis in bacterial endocarditis. Pediatr Nephrol 2001; 16:423.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/27/5556/abstract/8\">",
"      Griffin KA, Schwartz MM, Korbet SM. Pulmonary-renal syndrome of bacterial endocarditis mimicking Goodpasture's syndrome. Am J Kidney Dis 1989; 14:329.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/27/5556/abstract/9\">",
"      Wu HC, Wen YK, Chen ML, Fan CS. Pulmonary-renal syndrome in a patient with bacterial endocarditis. J Formos Med Assoc 2005; 104:588.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/27/5556/abstract/10\">",
"      Nolan CM, Abernathy RS. Nephropathy associated with methicillin therapy. Prevalence and determinants in patients with staphylococcal bacteremia. Arch Intern Med 1977; 137:997.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/27/5556/abstract/11\">",
"      Neilson EG. Pathogenesis and therapy of interstitial nephritis. Kidney Int 1989; 35:1257.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/27/5556/abstract/12\">",
"      KDIGO. KDIGO Clinical Practice Guideline for Glomerulonephritis. Kidney Int Suppl 2012; 2:209.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3054 Version 10.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-190.92.87.104-A2ED1F3088-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_27_5556=[""].join("\n");
var outline_f5_27_5556=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H139433\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      GLOMERULONEPHRITIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      OUTCOME",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H139433\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"NEPH/3054\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEPH/3054|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?34/38/35424\" title=\"picture 1\">",
"      Photomicrograph of urine sediment with a red cell cast",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?24/51/25393\" title=\"picture 2A\">",
"      White blood cell cast I",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?33/49/34591\" title=\"picture 2B\">",
"      White blood cell cast II",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?37/63/38900\" title=\"picture 3\">",
"      Urinary sediment in acute tubular necrosis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/36/27209?source=related_link\">",
"      Clinical manifestations and diagnosis of acute interstitial nephritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/51/43833?source=related_link\">",
"      Clinical presentation, classification, and causes of membranoproliferative glomerulonephritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/31/27130?source=related_link\">",
"      Differential diagnosis and evaluation of glomerular disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/54/12138?source=related_link\">",
"      Etiology and diagnosis of prerenal disease and acute tubular necrosis in acute kidney injury (acute renal failure)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/47/20215?source=related_link\">",
"      Manifestations of and risk factors for aminoglycoside nephrotoxicity",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f5_27_5557="Empyema liver biopsy Lateral";
var content_f5_27_5557=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F76849&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F76849&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic2\" style=\"width: 1040px;\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Empyema after liver biopsy",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 324px; height: 319px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Typical characteristics of a pleural mass are shown: a \"one-edged\" mass, sharply marginated against the lung and with obtuse angles of interface towards the chest wall. Slight \"drooping\" of the mass caudad is present.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Paul Stark, MD.",
"    </div>",
"   </div>",
"  </div>",
"  <div class=\"figure\" style=\"width: 450px\">",
"   <div class=\"ttl\">",
"    Normal lateral chest radiograph",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 252px; height: 368px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Steven Weinberger, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_27_5557=[""].join("\n");
var outline_f5_27_5557=null;
var title_f5_27_5558="Tricuspid stenosis: Clinical features, diagnosis, and percutaneous tricuspid balloon valvotomy";
var content_f5_27_5558=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Tricuspid stenosis: Clinical features, diagnosis, and percutaneous tricuspid balloon valvotomy",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?5/27/5558/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?5/27/5558/contributors\">",
"     William H Gaasch, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?5/27/5558/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?5/27/5558/contributors\">",
"     Catherine M Otto, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?5/27/5558/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?5/27/5558/contributors\">",
"     Susan B Yeon, MD, JD, FACC",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?5/27/5558/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 27, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Tricuspid stenosis is an uncommon valvular abnormality that most commonly occurs in association with other valvular lesions. For many years, surgical commissurotomy and valvuloplasty were the only available methods to correct tricuspid stenosis. The development of balloon valvotomy techniques has revolutionized the management of mitral stenosis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/45/33497?source=see_link\">",
"     \"Percutaneous mitral balloon valvotomy for mitral stenosis\"",
"    </a>",
"    .) Similar techniques can be used to treat tricuspid stenosis. The clinical features of tricuspid stenosis and the management of patients with this lesion, with emphasis on tricuspid balloon valvotomy, will be reviewed here.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     ETIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Tricuspid stenosis is most commonly of rheumatic etiology; the majority of cases present with tricuspid regurgitation or a combination of regurgitation and stenosis [",
"    <a class=\"abstract\" href=\"UTD.htm?5/27/5558/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. Rheumatic tricuspid stenosis almost never occurs as an isolated lesion, but is generally associated with mitral valve disease and, in some cases, the aortic valve [",
"    <a class=\"abstract\" href=\"UTD.htm?5/27/5558/abstract/3,4\">",
"     3,4",
"    </a>",
"    ]. In an angiographic study of 525 patients with rheumatic heart disease, 9 percent had tricuspid stenosis; all had significant tricuspid regurgitation [",
"    <a class=\"abstract\" href=\"UTD.htm?5/27/5558/abstract/5\">",
"     5",
"    </a>",
"    ]. A higher prevalence (15 percent) has been noted in an autopsy study [",
"    <a class=\"abstract\" href=\"UTD.htm?5/27/5558/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Other causes of flow obstruction at the level of the tricuspid valve include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Congenital atresia or stenosis of the valve [",
"      <a class=\"abstract\" href=\"UTD.htm?5/27/5558/abstract/7,8\">",
"       7,8",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Right atrial or metastatic tumors.",
"     </li>",
"     <li>",
"      The carcinoid syndrome, which may cause stenosis, although tricuspid regurgitation is more common. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?8/63/9206?source=see_link\">",
"       \"Clinical features of the carcinoid syndrome\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Bacterial endocarditis, particularly in association with a permanent pacemaker lead [",
"      <a class=\"abstract\" href=\"UTD.htm?5/27/5558/abstract/9-11\">",
"       9-11",
"      </a>",
"      ] or a prosthetic valve [",
"      <a class=\"abstract\" href=\"UTD.htm?5/27/5558/abstract/12\">",
"       12",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?43/19/44345?source=see_link\">",
"       \"Infections involving cardiac implantable electronic devices\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     PATHOPHYSIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;As a result of valvular stenosis, there is a persistent diastolic pressure gradient between the right atrium and right ventricle. This gradient increases when blood flow across the tricuspid valve increases, as occurs with inspiration and exercise, and decreases when blood flow decreases, such as with expiration. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/41/3737?source=see_link\">",
"     \"Hemodynamics of valvular disorders as measured by cardiac catheterization\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A mean pressure gradient as low as 2 mmHg is sufficient to establish the diagnosis of tricuspid stenosis. Since the pressures in the right-sided cardiac chambers are usually low, even a gradient as small as 5 mmHg can be sufficient to elevate mean right atrial pressure. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/60/36807?source=see_link\">",
"     \"Cardiac catheterization techniques: Normal hemodynamics\"",
"    </a>",
"    .) As a result, most patients with significant tricuspid stenosis have systemic venous congestion with jugular venous distension, ascites, and peripheral edema. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/59/33719?source=see_link\">",
"     \"Examination of the jugular venous pulse\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    During sinus rhythm, the right atrial \"a\" wave is increased and may approach the level of right ventricular systolic pressure. The resting cardiac output may be reduced and fails to increase with exercise. This may account for the only modestly elevated left atrial and pulmonary arterial pressures seen when mitral valve disease is also present.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Aside from systemic venous congestion, the symptoms and findings on physical and laboratory examination largely depend upon the presence and severity of associated aortic",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    mitral valve disease.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Clinical manifestations",
"    </span>",
"    &nbsp;&mdash;&nbsp;Obstruction to tricuspid flow limits cardiac output, causes fatigue, and produces signs of systemic venous hypertension. In the absence of mitral valve disease, such findings are generally well out of proportion to dyspnea. However, most patients with tricuspid stenosis have significant mitral",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    aortic valve disease [",
"    <a class=\"abstract\" href=\"UTD.htm?5/27/5558/abstract/3,4\">",
"     3,4",
"    </a>",
"    ]. Such patients often complain of abdominal discomfort, which is due to hepatomegaly and hepatic congestion. Some patients may sense a fluttering discomfort in the neck, caused by tall \"a\" waves in the jugular venous pulse.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Physical examination",
"    </span>",
"    &nbsp;&mdash;&nbsp;The findings seen on physical examination in patients with tricuspid stenosis are similar to those of mitral stenosis. Since these two lesions often coexist, the diagnosis of tricuspid stenosis may be missed.",
"   </p>",
"   <p>",
"    Obstruction to flow across the tricuspid valve produces an increase in right atrial and jugular venous pressure. Jugular venous pulsations often exhibit a prominent presystolic \"a\" wave, which may be confused with an arterial pulsation. The \"y\" descent is slow and barely appreciated. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/59/33719?source=see_link\">",
"     \"Examination of the jugular venous pulse\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The lungs are usually clear, despite the presence of jugular venous distension, hepatomegaly and hepatic pulsations, ascites, peripheral edema, and, occasionally, anasarca. A right ventricular parasternal lift is usually not obvious.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Auscultation",
"    </span>",
"    &nbsp;&mdash;&nbsp;An opening snap of the tricuspid valve may be heard but, when mitral stenosis is also present, it may be difficult to distinguish from the opening snap of mitral stenosis. The tricuspid opening snap usually follows the opening snap of the mitral valve and is localized to the lower left sternal border.",
"   </p>",
"   <p>",
"    A low frequency diastolic murmur is heard at the lower left sternal border in the fourth intercostal space; it is usually softer, higher pitched, and shorter in duration than the murmur of mitral stenosis. The intensity of the murmur and opening snap in tricuspid stenosis increase with maneuvers that increase blood flow across the tricuspid valve, especially with inspiration (Carvallo sign) and also with leg raising, inhalation of amyl nitrate, squatting, or isotonic exercise. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/57/41876?source=see_link\">",
"     \"Physiologic and pharmacologic maneuvers in the differential diagnosis of heart murmurs and sounds\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Echocardiography",
"    </span>",
"    &nbsp;&mdash;&nbsp;The role of echocardiography in the evaluation of the tricuspid valve is discussed in detail elsewhere but the major findings in tricuspid stenosis will be summarized here. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/2/14378?source=see_link&amp;anchor=H5#H5\">",
"     \"Echocardiographic evaluation of the tricuspid valve\", section on 'Tricuspid stenosis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Echocardiographic features of tricuspid stenosis include limited mobility of the leaflets, reduced separation of the leaflet tips, a reduction in the diameter of the tricuspid annulus, and diastolic doming of the valve. Although leaflet thickening is seen, the degree of thickening and calcification is generally less pronounced than in rheumatic mitral stenosis.",
"   </p>",
"   <p>",
"    Doppler echocardiography reveals high velocity turbulent diastolic flow across the stenotic orifice and prolonged pressure half-time. A tricuspid valve area less than 1.0 cm2 indicates severe tricuspid stenosis [",
"    <a class=\"abstract\" href=\"UTD.htm?5/27/5558/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    It is important to assess the presence and severity of tricuspid regurgitation, since this can influence the decision to proceed with balloon valvotomy. (See",
"    <a class=\"local\" href=\"#H10\">",
"     'Patient selection for valvotomy'",
"    </a>",
"    below and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/2/14378?source=see_link\">",
"     \"Echocardiographic evaluation of the tricuspid valve\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Cardiac catheterization",
"    </span>",
"    &nbsp;&mdash;&nbsp;Right heart catheterization is performed with two catheters or one double lumen catheter. After calibration of the two transducers, it is important to first document identical simultaneous recordings of right atrial pressure and then to advance one of the catheters into the right ventricular cavity. Simultaneous recordings of atrial and ventricular pressure are made in at least 8 to 10 cardiac cycles. Diastolic pressure gradients as low as 2 to 6 mmHg are common in severe tricuspid stenosis; gradients rarely exceed 10 mmHg. Thus, respiratory variation of a relatively low pressure gradient or non-simultaneous measurements may provide misleading data. A single catheter \"pull-back\" from the ventricle to the atrium does",
"    <strong>",
"     NOT",
"    </strong>",
"    provide a sufficiently accurate measurement of the pressure gradient. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/41/3737?source=see_link\">",
"     \"Hemodynamics of valvular disorders as measured by cardiac catheterization\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Cardiac output is measured using the Fick principle for oxygen, and the valve area is calculated with the standard Gorlin equation. Measurement of cardiac output with thermodilution techniques is less accurate, especially if tricuspid regurgitation is present. A tricuspid valve area less than 1.0 cm2 indicates severe tricuspid stenosis [",
"    <a class=\"abstract\" href=\"UTD.htm?5/27/5558/abstract/13\">",
"     13",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/11/1208?source=see_link&amp;anchor=H3#H3\">",
"     \"Aortic valve area in aortic stenosis\", section on 'Gorlin equation for aortic valve area'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     PATIENT SELECTION FOR VALVOTOMY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with signs and symptoms of systemic venous hypertension and congestion should be considered for balloon valvotomy. Transvalvular pressure gradients as low as 3 mmHg and valve areas less than 1.5 cm2 can indicate serious, but treatable, stenosis. Tricuspid regurgitation that is greater than mild is generally thought to be a contraindication to valvotomy, but a few patients with moderate regurgitation have been successfully treated with this technique. Tumor masses, vegetations, and thrombi are contraindications to valvotomy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Pregnancy",
"    </span>",
"    &nbsp;&mdash;&nbsp;It is not infrequent that signs and symptoms of rheumatic heart disease first occur during pregnancy, when the cardiac output increases because of the rise in blood volume and heart rate. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/32/24072?source=see_link\">",
"     \"Renal and urinary tract physiology in normal pregnancy\"",
"    </a>",
"    .) There is little experience with balloon valvotomy during pregnancy, but it appears to be effective in patients with refractory systemic venous congestion. Isolated balloon tricuspid valvotomy and concurrent balloon valvotomy of mitral and tricuspid valves have been successfully performed during pregnancy [",
"    <a class=\"abstract\" href=\"UTD.htm?5/27/5558/abstract/14,15\">",
"     14,15",
"    </a>",
"    ]. Great care must be taken to limit radiation exposure.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     RESULTS OF BALLOON VALVOTOMY",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is far less experience with tricuspid valvotomy than with mitral valvotomy. Valve areas generally increase from less than 1 to almost 2 cm2. While some stenosis persists, this change in area is sufficient to produce a significant reduction in the transvalvular pressure gradient and a decrease in right atrial pressure.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a report of four patients, tricuspid valvotomy, performed with two balloons, produced a rise in valve area from a mean of 0.8 to 1.8 cm2 [",
"      <a class=\"abstract\" href=\"UTD.htm?5/27/5558/abstract/16\">",
"       16",
"      </a>",
"      ]. There was no increase in the severity of tricuspid regurgitation. Follow-up at 8 to 20 weeks showed persistence of the early beneficial effects; valve area was 1.9 cm2 and cardiac output was significantly higher at rest and during exercise. Symptomatic improvement was reported in all four patients.",
"     </li>",
"     <li>",
"      Another study evaluated the use of one, two, and three balloons to perform valvotomy [",
"      <a class=\"abstract\" href=\"UTD.htm?5/27/5558/abstract/17\">",
"       17",
"      </a>",
"      ]. The single patient treated with one balloon did not show improvement, but the three treated with two balloons and the one treated with three balloons all exhibited significant improvement in valve area and symptoms without increase in tricuspid regurgitation. The authors concluded that the combined use of two balloons (23 to 25 mm) are adequate for most patients. Later experience with the Inoue balloon indicated that single balloon techniques may be as effective as the previous double balloon techniques [",
"      <a class=\"abstract\" href=\"UTD.htm?5/27/5558/abstract/18\">",
"       18",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Similar beneficial results have been described when balloon valvotomy is used to treat combined mitral and tricuspid stenosis, as well as in cases of combined aortic, mitral, and tricuspid stenosis [",
"    <a class=\"abstract\" href=\"UTD.htm?5/27/5558/abstract/19,20\">",
"     19,20",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?13/52/14146?source=see_link\">",
"       \"Patient information: Tricuspid stenosis (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Recognizing that there are no published studies that compare percutaneous balloon valvotomy with surgical valvuloplasty, and that only limited long-term results have been published [",
"    <a class=\"abstract\" href=\"UTD.htm?5/27/5558/abstract/19\">",
"     19",
"    </a>",
"    ], limited conclusions are appropriate. The available data indicate that balloon valvotomy for tricuspid stenosis is effective and is associated with a low morbidity. Thus, if symptoms of systemic venous hypertension and congestion are not adequately controlled with diuretics and ACE inhibitors or angiotensin receptor antagonists, balloon valvotomy of the stenotic tricuspid valve should be performed. Surgical correction of the stenotic lesion is indicated in patients whose valve is not treatable with balloon techniques.",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/27/5558/abstract/1\">",
"      Hauck AJ, Freeman DP, Ackermann DM, et al. Surgical pathology of the tricuspid valve: a study of 363 cases spanning 25 years. Mayo Clin Proc 1988; 63:851.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/27/5558/abstract/2\">",
"      Daniels SJ, Mintz GS, Kotler MN. Rheumatic tricuspid valve disease: two-dimensional echocardiographic, hemodynamic, and angiographic correlations. Am J Cardiol 1983; 51:492.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/27/5558/abstract/3\">",
"      Roguin A, Rinkevich D, Milo S, et al. Long-term follow-up of patients with severe rheumatic tricuspid stenosis. Am Heart J 1998; 136:103.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/27/5558/abstract/4\">",
"      Sharma S, Loya YS, Desai DM, Pinto RJ. Percutaneous double-valve balloon valvotomy for multivalve stenosis: immediate results and intermediate-term follow-up. Am Heart J 1997; 133:64.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/27/5558/abstract/5\">",
"      Yousof AM, Shafei MZ, Endrys G, et al. Tricuspid stenosis and regurgitation in rheumatic heart disease: a prospective cardiac catheterization study in 525 patients. Am Heart J 1985; 110:60.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/27/5558/abstract/6\">",
"      KITCHIN A, TURNER R. DIAGNOSIS AND TREATMENT OF TRICUSPID STENOSIS. Br Heart J 1964; 26:354.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/27/5558/abstract/7\">",
"      Cohen ML, Spray T, Gutierrez F, et al. Congenital tricuspid valve stenosis with atrial septal defect and left anterior fascicular block. Clin Cardiol 1990; 13:497.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/27/5558/abstract/8\">",
"      Tennstedt C, Chaoui R, K&ouml;rner H, Dietel M. Spectrum of congenital heart defects and extracardiac malformations associated with chromosomal abnormalities: results of a seven year necropsy study. Heart 1999; 82:34.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/27/5558/abstract/9\">",
"      Nisanci Y, Yilmaz E, Oncul A, Ozsaruhan O. Predominant tricuspid stenosis secondary to bacterial endocarditis in a patient with permanent pacemaker and balloon dilatation of the stenosis. Pacing Clin Electrophysiol 1999; 22:393.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/27/5558/abstract/10\">",
"      Unger P, Clevenbergh P, Crasset V, et al. Pacemaker-related endocarditis inducing tricuspid stenosis. Am Heart J 1997; 133:605.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/27/5558/abstract/11\">",
"      Hagers Y, Koole M, Schoors D, Van Camp G. Tricuspid stenosis: a rare complication of pacemaker-related endocarditis. J Am Soc Echocardiogr 2000; 13:66.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/27/5558/abstract/12\">",
"      Lewis JF, Peniston RL, Randall OS, et al. Tricuspid stenosis in prosthetic valve endocarditis. Diagnosis by Doppler echocardiography. Chest 1987; 91:276.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/27/5558/abstract/13\">",
"      Bonow RO, Carabello BA, Chatterjee K, et al. 2008 Focused update incorporated into the ACC/AHA 2006 guidelines for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 1998 Guidelines for the Management of Patients With Valvular Heart Disease): endorsed by the Society of Cardiovascular Anesthesiologists, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. Circulation 2008; 118:e523.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/27/5558/abstract/14\">",
"      Gamra H, Betbout F, Ayari M, et al. Recurrent miscarriages as an indication for percutaneous tricuspid valvuloplasty during pregnancy. Cathet Cardiovasc Diagn 1997; 40:283.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/27/5558/abstract/15\">",
"      Bahl VK, Chandra S, Mishra S. Concurrent balloon dilatation of mitral and tricuspid stenosis during pregnancy using an Inoue balloon. Int J Cardiol 1997; 59:199.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/27/5558/abstract/16\">",
"      Ribeiro PA, Al Zaibag M, Al Kasab S, et al. Percutaneous double balloon valvotomy for rheumatic tricuspid stenosis. Am J Cardiol 1988; 61:660.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/27/5558/abstract/17\">",
"      Orbe LC, Sobrino N, Arcas R, et al. Initial outcome of percutaneous balloon valvuloplasty in rheumatic tricuspid valve stenosis. Am J Cardiol 1993; 71:353.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/27/5558/abstract/18\">",
"      Patel TM, Dani SI, Shah SC, Patel TK. Tricuspid balloon valvuloplasty: a more simplified approach using inoue balloon. Cathet Cardiovasc Diagn 1996; 37:86.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/27/5558/abstract/19\">",
"      Sancaktar O, Kumbasar SD, Semiz E, Yal&ccedil;inkaya S. Late results of combined percutaneous balloon valvuloplasty of mitral and tricuspid valves. Cathet Cardiovasc Diagn 1998; 45:246.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/27/5558/abstract/20\">",
"      Sobrino N, Calvo Orbe L, Merino JL, et al. Percutaneous balloon valvuloplasty for concurrent mitral, aortic and tricuspid rheumatic stenosis. Eur Heart J 1995; 16:711.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8136 Version 4.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-183.166.191.243-4563C940AB-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_27_5558=[""].join("\n");
var outline_f5_27_5558=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H13\" id=\"summRecButton\">",
"      <span>",
"       RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      ETIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      PATHOPHYSIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Clinical manifestations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Physical examination",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Auscultation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Echocardiography",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Cardiac catheterization",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      PATIENT SELECTION FOR VALVOTOMY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      RESULTS OF BALLOON VALVOTOMY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/11/1208?source=related_link\">",
"      Aortic valve area in aortic stenosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/60/36807?source=related_link\">",
"      Cardiac catheterization techniques: Normal hemodynamics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/63/9206?source=related_link\">",
"      Clinical features of the carcinoid syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/2/14378?source=related_link\">",
"      Echocardiographic evaluation of the tricuspid valve",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/59/33719?source=related_link\">",
"      Examination of the jugular venous pulse",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/41/3737?source=related_link\">",
"      Hemodynamics of valvular disorders as measured by cardiac catheterization",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/19/44345?source=related_link\">",
"      Infections involving cardiac implantable electronic devices",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?13/52/14146?source=related_link\">",
"      Patient information: Tricuspid stenosis (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/45/33497?source=related_link\">",
"      Percutaneous mitral balloon valvotomy for mitral stenosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/57/41876?source=related_link\">",
"      Physiologic and pharmacologic maneuvers in the differential diagnosis of heart murmurs and sounds",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/32/24072?source=related_link\">",
"      Renal and urinary tract physiology in normal pregnancy",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f5_27_5559="Parasternal long axis view of VSD";
var content_f5_27_5559=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F75794%7ECARD%2F86958&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F75794%7ECARD%2F86958&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Parasternal long axis view of membranous VSD",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 442px; height: 298px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Parasternal long axis view with Color Flow Doppler demonstrating membranous VSD (arrow) underneath the aortic valve with Color Flow Doppler demonstrating a left-to-right shunt from the left ventricular outflow tract into the right ventricle (double arrow).",
"    <div class=\"footnotes\">",
"     LA: left atrium; LV: left ventricle; RV: right ventricle; Ao: aorta.",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Dr. Naser Ammash.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 533px\">",
"   <div class=\"ttl\">",
"    Parasternal echocardiographic views of a membranous ventricular septal defect and an infundibular ventricular septal defect",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 513px; height: 237px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    (A) Parasternal short axis echocardiographic view with color flow Doppler demonstrating a membranous ventricular septal defect with a left-to-right shunt in proximity to the tricuspid valve (TV) (turbulent flow from LV to RV).",
"    <br/>",
"    (B) Color flow Doppler demonstrating infundibular ventricular septal defect in the right ventricular outflow tract in proximity to the pulmonary valve (PV).",
"    <div class=\"footnotes\">",
"     AO: aorta; LA: left atrium; PA: pulmonary artery; RA: right atrium; RV: right ventricle.",
"    </div>",
"    <div class=\"reference\">",
"     Reprinted with permission: Ammash N. Ventricular Septal Defects. In: Adult Congenital Heart Disease, Warnes CA (Ed). &copy; 2009 American Heart Association, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_27_5559=[""].join("\n");
var outline_f5_27_5559=null;
var title_f5_27_5560="Vaginal intraepithelial neoplasia";
var content_f5_27_5560=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Vaginal intraepithelial neoplasia",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?5/27/5560/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?5/27/5560/contributors\">",
"     Christine H Holschneider, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?5/27/5560/contributors\">",
"     Jonathan S Berek, MD, MMS",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?5/27/5560/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?5/27/5560/contributors\">",
"     Barbara Goff, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?5/27/5560/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?5/27/5560/contributors\">",
"     Sandy J Falk, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?5/27/5560/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Aug 9, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of vaginal intraepithelial neoplasia (VAIN) has increased steadily over the past several decades as a result of heightened awareness, expanded cytologic screening, and the liberal use of colposcopy. The relative rarity of VAIN, which is far less common than cervical intraepithelial neoplasia (CIN, also called cervical squamous intraepithelial lesions) or vulvar intraepithelial neoplasia (VIN), is an impediment to a thorough understanding of the disease process and its natural course. As a result, much of this information is an extrapolation of our knowledge of the pathophysiology of cervical and vulvar intraepithelial neoplasia.",
"   </p>",
"   <p>",
"    Diagnosis and management of women with VAIN is reviewed here. VIN and CIN are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/11/32952?source=see_link\">",
"     \"Vulvar intraepithelial neoplasia\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/2/30762?source=see_link\">",
"     \"Cervical intraepithelial neoplasia: Management\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     CLASSIFICATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Vaginal intraepithelial neoplasia is defined by the presence of squamous cell atypia without invasion. The disease is classified according to the depth of epithelial involvement: VAIN 1 and 2 involve the lower one-third and two-thirds of the epithelium, respectively, and VAIN 3 involves more than two-thirds of the epithelium (",
"    <a class=\"graphic graphic_picture graphicRef68837 \" href=\"UTD.htm?18/22/18790\">",
"     picture 1",
"    </a>",
"    ). Carcinoma in situ, which encompasses the full thickness of the epithelium, is included under VAIN 3.",
"   </p>",
"   <p>",
"    Intraepithelial dysplasia of glandular origin, or atypical vaginal adenosis, is a separate entity. This lesion has a well-established association with in utero diethylstilbestrol (DES) exposure. In addition, it may be a precursor to DES-associated clear-cell adenocarcinoma [",
"    <a class=\"abstract\" href=\"UTD.htm?5/27/5560/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The true incidence of VAIN is unknown, but is estimated at 0.2 to 0.3 cases per 100,000 women in the United States [",
"    <a class=\"abstract\" href=\"UTD.htm?5/27/5560/abstract/2\">",
"     2",
"    </a>",
"    ]. The average patient is between 43 and 60 years of age [",
"    <a class=\"abstract\" href=\"UTD.htm?5/27/5560/abstract/3-5\">",
"     3-5",
"    </a>",
"    ]. Based on data from the United States (US) Centers for Disease Control and Prevention's National Program of Cancer Registries and the National Cancer Institute's Surveillance, Epidemiology and End Results Program, the incidence of vaginal carcinoma in situ in the US is estimated at 0.1 cases per 100,000 women. Vaginal carcinoma in situ incidence peaks at age 70 to 79 years, slightly younger than the peak incidence age for vaginal carcinoma [",
"    <a class=\"abstract\" href=\"UTD.htm?5/27/5560/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Risk factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although multiple risk factors have been implicated in the genesis of lower genital tract neoplasias, infection with human papillomavirus (HPV) is a common association (see",
"    <a class=\"local\" href=\"#H5\">",
"     'Etiology'",
"    </a>",
"    below)&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?5/27/5560/abstract/3\">",
"     3",
"    </a>",
"    ]. As an example, in a case-control study of 19 patients, low level of education, low family income, and history of vaginal condyloma were all risk factors for developing VAIN, but are also dependent variables predicting exposure to HPV [",
"    <a class=\"abstract\" href=\"UTD.htm?5/27/5560/abstract/7\">",
"     7",
"    </a>",
"    ]. Genetic and acquired immunosuppression, including human immunodeficiency virus (HIV) infection, are risk factors for developing both VAIN and HPV infection, as with CIN [",
"    <a class=\"abstract\" href=\"UTD.htm?5/27/5560/abstract/8-10\">",
"     8-10",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/19/6455?source=see_link&amp;anchor=H3#H3\">",
"     \"Vulvar and vaginal intraepithelial neoplasia in HIV-infected women\", section on 'Incidence'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/32/35337?source=see_link&amp;anchor=H7#H7\">",
"     \"Cervical cancer screening tests: Techniques and test characteristics of cervical cytology and human papillomavirus testing\", section on 'HPV testing'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    VAIN is consistently associated with prior or concurrent neoplasia elsewhere in the lower genital tract. In most studies, 50 to 90 percent of patients with VAIN had or currently have either intraepithelial neoplasia or carcinoma of the cervix or vulva [",
"    <a class=\"abstract\" href=\"UTD.htm?5/27/5560/abstract/4,11,12\">",
"     4,11,12",
"    </a>",
"    ]. In addition, approximately 1 to 7 percent of patients undergoing hysterectomy for CIN develop VAIN a few months to several years after surgery [",
"    <a class=\"abstract\" href=\"UTD.htm?5/27/5560/abstract/13-16\">",
"     13-16",
"    </a>",
"    ]. As an example, one study found VAIN in 5 percent of 793 patients followed for 10 years after surgery for CIN 3 [",
"    <a class=\"abstract\" href=\"UTD.htm?5/27/5560/abstract/17\">",
"     17",
"    </a>",
"    ]. There is evidence that some high grade vulvar and vaginal intraepithelial neoplasia is a monoclonal lesion derived from high grade or malignant cervical disease [",
"    <a class=\"abstract\" href=\"UTD.htm?5/27/5560/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Women who undergo hysterectomy for benign conditions other than CIN are at lower risk for developing VAIN than women with CIN or cancer. In one report, the average time to diagnosis of VAIN after hysterectomy in women with benign disease was 11 years, compared with one year among women with CIN [",
"    <a class=\"abstract\" href=\"UTD.htm?5/27/5560/abstract/19\">",
"     19",
"    </a>",
"    ]. Subsequent occult vaginal invasion appears to be more common in patients with CIN treated with hysterectomy than in those whose cervix was retained [",
"    <a class=\"abstract\" href=\"UTD.htm?5/27/5560/abstract/19\">",
"     19",
"    </a>",
"    ]. This may be the result of lower rates of follow-up cytology and more difficult examination of the vaginal apex in hysterectomized women. It may also be a result of selection bias, as only women with no cervical dysplasia are likely to have their cervix retained. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/32/35337?source=see_link\">",
"     \"Cervical cancer screening tests: Techniques and test characteristics of cervical cytology and human papillomavirus testing\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Some data suggest an increased risk for VAIN",
"    <span class=\"nowrap\">",
"     2/3",
"    </span>",
"    in high risk HP-positive women who smoke compared to high risk HPV-positive non-smokers [",
"    <a class=\"abstract\" href=\"UTD.htm?5/27/5560/abstract/20\">",
"     20",
"    </a>",
"    ]. The data regarding the role of previous radiation treatment in the development of secondary neoplasia of the vagina are conflicting [",
"    <a class=\"abstract\" href=\"UTD.htm?5/27/5560/abstract/21,22\">",
"     21,22",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     ETIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Two etiologies have been proposed to explain the strong association between VAIN and neoplasia elsewhere in the lower genital tract. One possibility is that women who develop VAIN shortly after surgery for CIN may simply have vaginal extension of cervical disease that was not detected and treated. However, VAIN is frequently multifocal, can occur several years after a hysterectomy for neoplasia, is independent of the amount of vaginal cuff excised, and is often observed de novo in the absence of cervical disease [",
"    <a class=\"abstract\" href=\"UTD.htm?5/27/5560/abstract/23\">",
"     23",
"    </a>",
"    ]. Thus, it is unlikely that the condition is the result of extension from the cervix in every case.",
"   </p>",
"   <p>",
"    A second theory is that lower genital tract neoplasias share common etiologic factors, since approximately one-half of VAIN lesions are associated with concomitant cervical or vulvar neoplasia [",
"    <a class=\"abstract\" href=\"UTD.htm?5/27/5560/abstract/11\">",
"     11",
"    </a>",
"    ]. This field effect is based upon the principle that tissues of common embryological origin are susceptible to neoplasia from exposure to similar carcinogenic stimuli. In particular, exposure to HPV appears to induce neoplasms in all three locations of the lower female genital tract (cervix, vagina, vulva) [",
"    <a class=\"abstract\" href=\"UTD.htm?5/27/5560/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     HPV infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;HPV-associated lesions are often multifocal (originating within several discrete foci at one anatomic site) and multicentric (involving several distinct anatomic sites of the lower genital tract). Although the relationship between HPV infection and intraepithelial neoplasia of the cervix is well known, there are less data available regarding vaginal neoplasia [",
"    <a class=\"abstract\" href=\"UTD.htm?5/27/5560/abstract/25\">",
"     25",
"    </a>",
"    ]. &nbsp;A review of 232 published VAIN cases reported a high prevalence of HPV in these lesions as detected by either polymerase chain reaction or hybrid capture assays for HPV DNA detection: 92.6 percent in VAIN",
"    <span class=\"nowrap\">",
"     2/3,",
"    </span>",
"    and 98.5 percent in VAIN 1 [",
"    <a class=\"abstract\" href=\"UTD.htm?5/27/5560/abstract/26\">",
"     26",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Several viral subtypes are associated with VAIN (",
"    <a class=\"graphic graphic_table graphicRef57576 \" href=\"UTD.htm?36/29/37339\">",
"     table 1",
"    </a>",
"    ), with HPV 16 and 18 being the most prevalent HPV types [",
"    <a class=\"abstract\" href=\"UTD.htm?5/27/5560/abstract/27\">",
"     27",
"    </a>",
"    ]. The prevalence of oncogenic HPV subtypes in the vagina is similar in women who have and have not undergone hysterectomy [",
"    <a class=\"abstract\" href=\"UTD.htm?5/27/5560/abstract/28\">",
"     28",
"    </a>",
"    ]. Thus, presence of the cervix does not appear to be necessary for oncogenic HPV to infect the genital tract. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/32/35337?source=see_link&amp;anchor=H7#H7\">",
"     \"Cervical cancer screening tests: Techniques and test characteristics of cervical cytology and human papillomavirus testing\", section on 'HPV testing'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The disparity between the relatively high incidence of CIN and rarity of VAIN in women who test positive for HPV may be due to increased susceptibility of the metaplastic transformation zone of the cervix to oncogenic stimuli. In contrast, the mature, stable, squamous epithelium of the vagina may be less vulnerable to the same stimuli [",
"    <a class=\"abstract\" href=\"UTD.htm?5/27/5560/abstract/29\">",
"     29",
"    </a>",
"    ]. Women who have been exposed to DES in utero often have squamous metaplasia of the vagina, instead of normal columnar epithelium; this observation may explain the increased incidence of VAIN noted in some studies of these women [",
"    <a class=\"abstract\" href=\"UTD.htm?5/27/5560/abstract/30,31\">",
"     30,31",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Vaginal intraepithelial neoplasia is usually asymptomatic, although patients can present with postcoital spotting or vaginal discharge. It should be excluded in all women with an abnormal Pap smear who are posthysterectomy or who do not have identifiable cervical lesions that could account for the abnormality.",
"   </p>",
"   <p>",
"    The examination should include digital palpation to assess for thickening or irregularity of the vaginal wall and a thorough colposcopic assessment of the entire vagina. In the postmenopausal patient, a few weeks of topical estrogen treatment will often accentuate visualization and improve detection of VAIN. After the insertion of a speculum and the application of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/36/19011?source=see_link\">",
"     acetic acid",
"    </a>",
"    , lesions will appear as raised or flat white, granular epithelium with sharply demarcated borders and may contain areas of vascular punctation. A biopsy should be taken from any suspicious areas.",
"   </p>",
"   <p>",
"    The majority of lesions are located in the upper one-third of the vagina [",
"    <a class=\"abstract\" href=\"UTD.htm?5/27/5560/abstract/32\">",
"     32",
"    </a>",
"    ]. Lesions located in post-hysterectomy vaginal recesses can be difficult to visualize; skin hooks may be used to gently evert these areas. The presence of a markedly irregular surface or severe vascular abnormalities with unusual branching suggests an invasive process, which warrants an excisional biopsy. Schiller's or Lugol's iodine solution can be used to detect lesions and confirm boundaries prior to excision.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Biopsy technique",
"    </span>",
"    &nbsp;&mdash;&nbsp;A speculum is placed in the vagina and the planned biopsy site is prepared with iodine (or an alternative preparation solution, if the patient is allergic to iodine). When biopsy is attempted, it is helpful to partially close the speculum to allow the vagina to fold in on itself. Keeping the vagina taut makes performing a biopsy difficult. Local anesthetic is injected (eg, 1 percent",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/34/35360?source=see_link\">",
"     lidocaine",
"    </a>",
"    <strong>",
"     without",
"    </strong>",
"    epinephrine).",
"   </p>",
"   <p>",
"    For sessile lesions, the biopsy is taken using a cervical biopsy forceps (eg, Kevorkian). Some raised or pedunculated lesions can be grasped with a forceps and biopsied using a fine scissor (eg, Metzenbaum). Hemostasis is usually obtained with application of Monsel's solution or use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/53/42834?source=see_link\">",
"     silver nitrate",
"    </a>",
"    . If bleeding persists, a suture may be necessary.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     PROGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The natural course of VAIN has not been fully characterized. Although there have been no prospective studies, several retrospective investigations have described cases of progression from VAIN to invasive vaginal carcinoma [",
"    <a class=\"abstract\" href=\"UTD.htm?5/27/5560/abstract/11,33-35\">",
"     11,33-35",
"    </a>",
"    ]. One study, as an example, found that 9 of 32 patients undergoing vaginectomy for VAIN 3 had foci of invasive carcinoma upon histologic examination [",
"    <a class=\"abstract\" href=\"UTD.htm?5/27/5560/abstract/33\">",
"     33",
"    </a>",
"    ]. In another series, 18 of 23 patients with VAIN followed expectantly for at least three years had complete regression of their lesions, three patients had persistent disease, and two (one with VAIN 3 and another with a lower grade lesion) progressed to invasive carcinoma [",
"    <a class=\"abstract\" href=\"UTD.htm?5/27/5560/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;A broad range of treatment options are available for therapy of VAIN: excision, ablation, topical chemotherapy, and radiation of lesions. Previous treatment failures, the presence of multifocal disease, the patient's general health, her medical risks from surgery, her desire to preserve sexual function, and the certainty with which invasive disease has been excluded are factors to consider in selecting a therapeutic course. We manage women with VAIN 1 with close surveillance, rather than treatment. Treatment options for VAIN",
"    <span class=\"nowrap\">",
"     2/3",
"    </span>",
"    are reviewed in this section.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Surgical therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Surgical excision is the mainstay of VAIN treatment (",
"    <a class=\"graphic graphic_table graphicRef58294 \" href=\"UTD.htm?15/17/15645\">",
"     table 2",
"    </a>",
"    ). This approach permits histologic diagnosis, a significant advantage over other treatments since invasive foci have been detected in up to 28 percent of specimens [",
"    <a class=\"abstract\" href=\"UTD.htm?5/27/5560/abstract/19\">",
"     19",
"    </a>",
"    ]. Surgical approaches include local excision, partial vaginectomy, and, rarely, total vaginectomy for extensive and persistent disease. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/46/6885?source=see_link\">",
"     \"Vaginectomy\"",
"    </a>",
"    .) Most excisions are performed transvaginally, although at times an abdominal approach is necessary. A partial vaginectomy is often required when VAIN is buried in the post-hysterectomy vaginal vault recesses, as these lesions are frequently inaccessible to other forms of treatment. Presurgical administration of topical therapy may reduce lesion size, allow loosening of epithelial-stromal adherence, and enable VAIN to be stripped from the underlying tissue during local excision [",
"    <a class=\"abstract\" href=\"UTD.htm?5/27/5560/abstract/12\">",
"     12",
"    </a>",
"    ]. Partial vaginectomy is required when VAIN is buried in posthysterectomy suture recesses, as these lesions are frequently inaccessible to other forms of treatment.",
"   </p>",
"   <p>",
"    Complications of surgical therapy range from shortening or stenosis of the vagina due to wide local excisions, to significant postoperative morbidity following abdominal procedures. The risk of complications is significantly increased in previously irradiated patients [",
"    <a class=\"abstract\" href=\"UTD.htm?5/27/5560/abstract/4\">",
"     4",
"    </a>",
"    ]. Electrosurgical loop excision, laser vaginectomy, and ultrasonic surgical aspiration are modifications of the cold-knife approach that may promote rapid healing and reduce the frequency of complications [",
"    <a class=\"abstract\" href=\"UTD.htm?5/27/5560/abstract/36-39\">",
"     36-39",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A literature review of surgical treatment of VAIN reported an 18 percent incidence (range 0 to 50 percent) of recurrent disease during follow-up periods of three months to 18 years (",
"    <a class=\"graphic graphic_table graphicRef58294 \" href=\"UTD.htm?15/17/15645\">",
"     table 2",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?5/27/5560/abstract/4,12,13,19,33,34,37\">",
"     4,12,13,19,33,34,37",
"    </a>",
"    ]. Recurrences of VAIN have also been described in vaginal tissue grafts performed to repair the vagina after vaginectomy [",
"    <a class=\"abstract\" href=\"UTD.htm?5/27/5560/abstract/40\">",
"     40",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Ablation",
"    </span>",
"    &nbsp;&mdash;&nbsp;The CO2 laser has been the preferred technique for local tissue ablation. Although approximately one-third of patients will require more than one treatment, the procedure is generally well tolerated, heals satisfactorily, and results in minimal sexual dysfunction (",
"    <a class=\"graphic graphic_table graphicRef57738 \" href=\"UTD.htm?6/1/6173\">",
"     table 3",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?5/27/5560/abstract/41-48\">",
"     41-48",
"    </a>",
"    ]. Pain and bleeding are the most frequent complications, requiring intervention in 20 percent of patients in one series [",
"    <a class=\"abstract\" href=\"UTD.htm?5/27/5560/abstract/49\">",
"     49",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A randomized controlled trial of carbon dioxide laser versus ultrasonic surgical aspiration involving 110 patients demonstrated no difference in recurrence of dysplasia during a one-year follow-up period (26 versus 24 percent); there was less postoperative pain and less vulvar scarring with the ultrasonic surgical aspiration [",
"    <a class=\"abstract\" href=\"UTD.htm?5/27/5560/abstract/50\">",
"     50",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Ablative therapy should",
"    <strong>",
"     not",
"    </strong>",
"    be performed if the entire area of abnormal epithelium cannot be visualized or if there is any suspicion of invasion during thorough colposcopy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Topical therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;While partial or total vaginectomy appears to be the safest method of treating multifocal high-grade VAIN, a variety of alternate less radical modalities have been used and studied. Topical application of therapeutic agents has the advantage of treating the entire vaginal mucosa with good coverage of multifocal disease and disease in folds and recesses of the vagina. There are no guidelines clearly defining the ideal treatment for multifocal high-grade VAIN. Topical therapy appears to be an appropriate first-line therapy in women with early lesions and multifocal disease or those who are poor surgical candidates. As with ablation, it is a prerequisite for topical treatment that invasion be excluded by thorough colposcopic examination and biopsy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Imiquimod",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are several small case series on the use of topical application of 5 percent",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/59/20406?source=see_link\">",
"     imiquimod",
"    </a>",
"    cream for the treatment of vaginal intraepithelial neoplasia with promising results [",
"    <a class=\"abstract\" href=\"UTD.htm?5/27/5560/abstract/51-54\">",
"     51-54",
"    </a>",
"    ]. In these reports variable imiquimod treatment regimens lead to complete response in a considerable percentage of patients with a reported 22 to 29 percent persistence or recurrence rate. In addition, patients who experienced partial response required less extensive excision. In one reported regimen, 5 percent imiquimod cream is applied to the vaginal lesions three times a week for eight weeks [",
"    <a class=\"abstract\" href=\"UTD.htm?5/27/5560/abstract/52\">",
"     52",
"    </a>",
"    ]. &nbsp;The most common adverse events are local burning and soreness, which are generally not severe enough for patients to discontinue treatment. Based on the available data, imiquimod may be a reasonably effective and well-tolerated topical therapy option in the treatment of VAIN. However, larger studies with standardized treatment protocols and longer follow-up are needed to make safe conclusions regarding the effectiveness, recurrence rates, and durability (recurrence free interval) of this treatment.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     5-fluorouracil (5-FU)",
"    </span>",
"    &nbsp;&mdash;&nbsp;Failure rates are comparable to other techniques (",
"    <a class=\"graphic graphic_table graphicRef56109 \" href=\"UTD.htm?31/3/31804\">",
"     table 4",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?5/27/5560/abstract/45,47,55-59\">",
"     45,47,55-59",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Complications of topical 5-FU include vaginal irritation or burning and ulcerations [",
"    <a class=\"abstract\" href=\"UTD.htm?5/27/5560/abstract/56,60\">",
"     56,60",
"    </a>",
"    ]. External",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/53/15187?source=see_link\">",
"     zinc oxide",
"    </a>",
"    cream or petroleum jelly can be used as a barrier to help protect against ulceration. Topical estrogen also may reduce patient discomfort. Columnar metaplasia of the vaginal mucosa can occur after topical 5-FU; the clinical significance of this finding is not known [",
"    <a class=\"abstract\" href=\"UTD.htm?5/27/5560/abstract/61\">",
"     61",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Several dosing protocols have been suggested, ranging from twice daily application for fourteen days to once weekly for 10 weeks.",
"   </p>",
"   <p>",
"    Vaccines directed against HPV are another investigational approach. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/17/19738?source=see_link\">",
"     \"Recommendations for the use of human papillomavirus vaccines\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Radiation therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Intracavitary radiation therapy, while an effective form of treatment, is rarely used because because simple resection of the cuff or ablative therapy is usually successful and it is associated with higher rates of morbidity than other therapies. Radiation therapy is reserved for patients who have failed previous treatments, are poor surgical candidates, or who have extensive, multifocal disease. The optimum dose is unclear. In one study of 14 patients who received high dose rate brachytherapy for VAIN 3, disease regressed, progressed to invasive cancer, or persisted in 12, one, and one patients, respectively, during a median follow-up of 46 months [",
"    <a class=\"abstract\" href=\"UTD.htm?5/27/5560/abstract/62\">",
"     62",
"    </a>",
"    ]. In another series with median follow-up of 77 months, regression occurred in 17 of 22 patients who received medium dose rate brachytherapy for VAIN 3 [",
"    <a class=\"abstract\" href=\"UTD.htm?5/27/5560/abstract/63\">",
"     63",
"    </a>",
"    ]. Low dose rate brachytherapy has also been used.",
"   </p>",
"   <p>",
"    Vaginal complications caused by intracavitary radiation include atrophy, stenosis, and shortening. These anatomic distortions can interfere with sexual function and are an impediment to thorough colposcopic follow-up. Bowel and bladder changes and the induction of menopause also can occur. Poor wound healing of irradiated tissue is a concern for patients who subsequently require surgical intervention [",
"    <a class=\"abstract\" href=\"UTD.htm?5/27/5560/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Posttreatment surveillance",
"    </span>",
"    &nbsp;&mdash;&nbsp;Posttreatment follow-up with cytological smears every six months for one to two years and annually thereafter is reasonable. Given the high prevalence of HPV in VAIN, there may be a role for HPV-testing in the posttreatment follow-up of patients with VAIN similar to that observed post CIN treatment. In a study of 44 women with VAIN, posttreatment HPV testing had a sensitivity of 90 percent and specificity of 78 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?5/27/5560/abstract/64\">",
"     64",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Management of these lesions requires long term follow-up. A study of multicentric dysplasias including CIN with VAIN",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    VIN reported a particularly high rate of residual lesions (55 percent) and recurrence (44 percent) in these patients [",
"    <a class=\"abstract\" href=\"UTD.htm?5/27/5560/abstract/65\">",
"     65",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Vaginal intraepithelial neoplasia (VAIN) is defined by the presence of squamous cell atypia without invasion. The disease is classified according to the depth of epithelial involvement: VAIN 1 and 2 involve the lower one-third and two-thirds of the epithelium, respectively, and VAIN 3 involves more than two-thirds of the epithelium (",
"      <a class=\"graphic graphic_picture graphicRef68837 \" href=\"UTD.htm?18/22/18790\">",
"       picture 1",
"      </a>",
"      ). Carcinoma in situ, which encompasses the full thickness of the epithelium, is included under VAIN 3. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Classification'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The true incidence of VAIN is unknown, but is estimated at 0.2 to 0.3 cases per 100,000 women in the United States. The average patient is between 43 and 60 years of age. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Epidemiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      VAIN is usually asymptomatic, although patients can present with postcoital spotting or vaginal discharge. It should be excluded in all women with an abnormal Pap smear who are posthysterectomy or who do not have identifiable cervical lesions that could account for the abnormality. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      VAIN is a histologic diagnosis, typically made based upon colposcopically directed biopsy of the vagina. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Once high-grade VAIN is diagnosed, invasive disease must be excluded by colposcopy and biopsy, especially before undertaking nonexcisional therapy that does not permit histologic confirmation of disease. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?24/14/24808?source=see_link\">",
"       \"Colposcopy\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Surgical excision, laser ablation, 5-FU, and intracavitary radiation successfully eliminate the lesion in approximately 80 percent of women; there is a 20 percent recurrence rate. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Treatment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The choice of therapy depends upon the patient's general health, surgical risks, desire for vaginal sexual function, presence of multifocal disease, and the certainty with which invasive disease has been excluded. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Treatment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Following therapy, gynecologic examination and vaginal cytology should be performed every six months for one to two years and annually thereafter to evaluate for persistent or progressive disease. Thereafter, patients can be followed at annual intervals. (See",
"      <a class=\"local\" href=\"#H17\">",
"       'Posttreatment surveillance'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/27/5560/abstract/1\">",
"      Robboy SJ, Young RH, Welch WR, et al. Atypical vaginal adenosis and cervical ectropion. Association with clear cell adenocarcinoma in diethylstilbestrol-exposed offspring. Cancer 1984; 54:869.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/27/5560/abstract/2\">",
"      Henson D, Tarone R. An epidemiologic study of cancer of the cervix, vagina, and vulva based on the Third National Cancer Survey in the United States. Am J Obstet Gynecol 1977; 129:525.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/27/5560/abstract/3\">",
"      Sugase M, Matsukura T. Distinct manifestations of human papillomaviruses in the vagina. Int J Cancer 1997; 72:412.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/27/5560/abstract/4\">",
"      Cheng D, Ng TY, Ngan HY, Wong LC. Wide local excision (WLE) for vaginal intraepithelial neoplasia (VAIN). Acta Obstet Gynecol Scand 1999; 78:648.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/27/5560/abstract/5\">",
"      Herbst AL, Green TH Jr, Ulfelder H. Primary carcinoma of the vagina. An analysis of 68 cases. Am J Obstet Gynecol 1970; 106:210.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/27/5560/abstract/6\">",
"      Watson M, Saraiya M, Wu X. Update of HPV-associated female genital cancers in the United States, 1999-2004. J Womens Health (Larchmt) 2009; 18:1731.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/27/5560/abstract/7\">",
"      Brinton LA, Nasca PC, Mallin K, et al. Case-control study of in situ and invasive carcinoma of the vagina. Gynecol Oncol 1990; 38:49.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/27/5560/abstract/8\">",
"      Sillman F, Stanek A, Sedlis A, et al. The relationship between human papillomavirus and lower genital intraepithelial neoplasia in immunosuppressed women. Am J Obstet Gynecol 1984; 150:300.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/27/5560/abstract/9\">",
"      Spitzer M. Lower genital tract intraepithelial neoplasia in HIV-infected women: guidelines for evaluation and management. Obstet Gynecol Surv 1999; 54:131.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/27/5560/abstract/10\">",
"      Conley LJ, Ellerbrock TV, Bush TJ, et al. HIV-1 infection and risk of vulvovaginal and perianal condylomata acuminata and intraepithelial neoplasia: a prospective cohort study. Lancet 2002; 359:108.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/27/5560/abstract/11\">",
"      Aho M, Vesterinen E, Meyer B, et al. Natural history of vaginal intraepithelial neoplasia. Cancer 1991; 68:195.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/27/5560/abstract/12\">",
"      Sillman FH, Fruchter RG, Chen YS, et al. Vaginal intraepithelial neoplasia: risk factors for persistence, recurrence, and invasion and its management. Am J Obstet Gynecol 1997; 176:93.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/27/5560/abstract/13\">",
"      Lenehan PM, Meffe F, Lickrish GM. Vaginal intraepithelial neoplasia: biologic aspects and management. Obstet Gynecol 1986; 68:333.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/27/5560/abstract/14\">",
"      Nwabineli NJ, Monaghan JM. Vaginal epithelial abnormalities in patients with CIN: clinical and pathological features and management. Br J Obstet Gynaecol 1991; 98:25.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/27/5560/abstract/15\">",
"      Ogino I, Kitamura T, Okajima H, Matsubara S. High-dose-rate intracavitary brachytherapy in the management of cervical and vaginal intraepithelial neoplasia. Int J Radiat Oncol Biol Phys 1998; 40:881.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/27/5560/abstract/16\">",
"      Schockaert S, Poppe W, Arbyn M, et al. Incidence of vaginal intraepithelial neoplasia after hysterectomy for cervical intraepithelial neoplasia: a retrospective study. Am J Obstet Gynecol 2008; 199:113.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/27/5560/abstract/17\">",
"      Kalogirou D, Antoniou G, Karakitsos P, et al. Vaginal intraepithelial neoplasia (VAIN) following hysterectomy in patients treated for carcinoma in situ of the cervix. Eur J Gynaecol Oncol 1997; 18:188.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/27/5560/abstract/18\">",
"      Vinokurova S, Wentzensen N, Einenkel J, et al. Clonal history of papillomavirus-induced dysplasia in the female lower genital tract. J Natl Cancer Inst 2005; 97:1816.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/27/5560/abstract/19\">",
"      Ireland D, Monaghan JM. The management of the patient with abnormal vaginal cytology following hysterectomy. Br J Obstet Gynaecol 1988; 95:973.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/27/5560/abstract/20\">",
"      Sherman JF, Mount SL, Evans MF, et al. Smoking increases the risk of high-grade vaginal intraepithelial neoplasia in women with oncogenic human papillomavirus. Gynecol Oncol 2008; 110:396.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/27/5560/abstract/21\">",
"      Boice JD Jr, Engholm G, Kleinerman RA, et al. Radiation dose and second cancer risk in patients treated for cancer of the cervix. Radiat Res 1988; 116:3.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/27/5560/abstract/22\">",
"      Lee JY, Perez CA, Ettinger N, Fineberg BB. The risk of second primaries subsequent to irradiation for cervix cancer. Int J Radiat Oncol Biol Phys 1982; 8:207.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/27/5560/abstract/23\">",
"      Creasman WT, Rutledge F. Carcinoma in situ of the cervix. An analysis of 861 patients. Obstet Gynecol 1972; 39:373.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/27/5560/abstract/24\">",
"      Sturgeon SR, Curtis RE, Johnson K, et al. Second primary cancers after vulvar and vaginal cancers. Am J Obstet Gynecol 1996; 174:929.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/27/5560/abstract/25\">",
"      Matsukura T, Sugase M. Identification of genital human papillomaviruses in cervical biopsy specimens: segregation of specific virus types in specific clinicopathologic lesions. Int J Cancer 1995; 61:13.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/27/5560/abstract/26\">",
"      Smith JS, Backes DM, Hoots BE, et al. Human papillomavirus type-distribution in vulvar and vaginal cancers and their associated precursors. Obstet Gynecol 2009; 113:917.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/27/5560/abstract/27\">",
"      Insinga RP, Liaw KL, Johnson LG, Madeleine MM. A systematic review of the prevalence and attribution of human papillomavirus types among cervical, vaginal, and vulvar precancers and cancers in the United States. Cancer Epidemiol Biomarkers Prev 2008; 17:1611.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/27/5560/abstract/28\">",
"      Castle PE, Schiffman M, Bratti MC, et al. A population-based study of vaginal human papillomavirus infection in hysterectomized women. J Infect Dis 2004; 190:458.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/27/5560/abstract/29\">",
"      Schneider A, de Villiers EM, Schneider V. Multifocal squamous neoplasia of the female genital tract: significance of human papillomavirus infection of the vagina after hysterectomy. Obstet Gynecol 1987; 70:294.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/27/5560/abstract/30\">",
"      Bornstein J, Adam E, Adler-Storthz K, Kaufman RH. Development of cervical and vaginal squamous cell neoplasia as a late consequence of in utero exposure to diethylstilbestrol. Obstet Gynecol Surv 1988; 43:15.",
"     </a>",
"    </li>",
"    <li>",
"     Townsend DE. Intraepithelial neoplasia of the vagina. In: Gynecologic oncology: Fundamental principles and clinical practice, Coppleson M (Ed), Churchill Livingstone, Edinburgh 1992. p.493.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/27/5560/abstract/32\">",
"      Boonlikit S, Noinual N. Vaginal intraepithelial neoplasia: a retrospective analysis of clinical features and colpohistology. J Obstet Gynaecol Res 2010; 36:94.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/27/5560/abstract/33\">",
"      Hoffman MS, DeCesare SL, Roberts WS, et al. Upper vaginectomy for in situ and occult, superficially invasive carcinoma of the vagina. Am J Obstet Gynecol 1992; 166:30.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/27/5560/abstract/34\">",
"      Benedet JL, Sanders BH. Carcinoma in situ of the vagina. Am J Obstet Gynecol 1984; 148:695.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/27/5560/abstract/35\">",
"      Wharton JT, Tortolero-Luna G, Linares AC, et al. Vaginal intraepithelial neoplasia and vaginal cancer. Obstet Gynecol Clin North Am 1996; 23:325.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/27/5560/abstract/36\">",
"      Patsner B. Treatment of vaginal dysplasia with loop excision: report of five cases. Am J Obstet Gynecol 1993; 169:179.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/27/5560/abstract/37\">",
"      Julian TM, O'Connell BJ, Gosewehr JA. Indications, techniques, and advantages of partial laser vaginectomy. Obstet Gynecol 1992; 80:140.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/27/5560/abstract/38\">",
"      von Gruenigen VE, Gibbons HE, Gibbins K, et al. Surgical treatments for vulvar and vaginal dysplasia: a randomized controlled trial. Obstet Gynecol 2007; 109:942.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/27/5560/abstract/39\">",
"      Robinson JB, Sun CC, Bodurka-Bevers D, et al. Cavitational ultrasonic surgical aspiration for the treatment of vaginal intraepithelial neoplasia. Gynecol Oncol 2000; 78:235.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/27/5560/abstract/40\">",
"      Lathrop JC, Ree HJ, McDuff HC Jr. Intraepithelial neoplasia of the neovagina. Obstet Gynecol 1985; 65:91S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/27/5560/abstract/41\">",
"      Woodman CB, Jordan JA, Wade-Evans T. The management of vaginal intraepithelial neoplasia after hysterectomy. Br J Obstet Gynaecol 1984; 91:707.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/27/5560/abstract/42\">",
"      Townsend DE, Levine RU, Crum CP, Richart RM. Treatment of vaginal carcinoma in situ with the carbon dioxide laser. Am J Obstet Gynecol 1982; 143:565.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/27/5560/abstract/43\">",
"      Diakomanolis E, Rodolakis A, Sakellaropoulos G, et al. Conservative management of vaginal intraepithelial neoplasia (VAIN) by laser CO2. Eur J Gynaecol Oncol 1996; 17:389.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/27/5560/abstract/44\">",
"      Campagnutta E, Parin A, De Piero G, et al. Treatment of vaginal intraepithelial neoplasia (VAIN) with the carbon dioxide laser. Clin Exp Obstet Gynecol 1999; 26:127.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/27/5560/abstract/45\">",
"      Krebs HB. Treatment of vaginal intraepithelial neoplasia with laser and topical 5-fluorouracil. Obstet Gynecol 1989; 73:657.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/27/5560/abstract/46\">",
"      Stuart GC, Flagler EA, Nation JG, et al. Laser vaporization of vaginal intraepithelial neoplasia. Am J Obstet Gynecol 1988; 158:240.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/27/5560/abstract/47\">",
"      Audet-Lapointe P, Body G, Vauclair R, et al. Vaginal intraepithelial neoplasia. Gynecol Oncol 1990; 36:232.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/27/5560/abstract/48\">",
"      Hoffman MS, Roberts WS, LaPolla JP, et al. Laser vaporization of grade 3 vaginal intraepithelial neoplasia. Am J Obstet Gynecol 1991; 165:1342.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/27/5560/abstract/49\">",
"      Sherman AI. Laser therapy for vaginal intraepithelial neoplasia after hysterectomy. J Reprod Med 1990; 35:941.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/27/5560/abstract/50\">",
"      Indermaur MD, Martino MA, Fiorica JV, et al. Upper vaginectomy for the treatment of vaginal intraepithelial neoplasia. Am J Obstet Gynecol 2005; 193:577.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/27/5560/abstract/51\">",
"      Buck HW, Guth KJ. Treatment of vaginal intraepithelial neoplasia (primarily low grade) with imiquimod 5% cream. J Low Genit Tract Dis 2003; 7:290.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/27/5560/abstract/52\">",
"      Haidopoulos D, Diakomanolis E, Rodolakis A, et al. Can local application of imiquimod cream be an alternative mode of therapy for patients with high-grade intraepithelial lesions of the vagina? Int J Gynecol Cancer 2005; 15:898.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/27/5560/abstract/53\">",
"      Diakomanolis E, Haidopoulos D, Stefanidis K. Treatment of high-grade vaginal intraepithelial neoplasia with imiquimod cream. N Engl J Med 2002; 347:374.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/27/5560/abstract/54\">",
"      Iavazzo C, Pitsouni E, Athanasiou S, Falagas ME. Imiquimod for treatment of vulvar and vaginal intraepithelial neoplasia. Int J Gynaecol Obstet 2008; 101:3.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/27/5560/abstract/55\">",
"      Petrilli ES, Townsend DE, Morrow CP, Nakao CY. Vaginal intraepithelial neoplasia: Biologic aspects and treatment with topical 5-fluorouracil and the carbon dioxide laser. Am J Obstet Gynecol 1980; 138:321.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/27/5560/abstract/56\">",
"      Caglar H, Hertzog RW, Hreshchyshyn MM. Topical 5-fluorouracil treatment of vaginal intraepithelial neoplasia. Obstet Gynecol 1981; 58:580.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/27/5560/abstract/57\">",
"      Daly JW, Ellis GF. Treatment of vaginal dysplasia and carcinoma in situ with topical 5-fluorouracil. Obstet Gynecol 1980; 55:350.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/27/5560/abstract/58\">",
"      Kirwan P, Naftalin NJ. Topical 5-fluorouracil in the treatment of vaginal intraepithelial neoplasia. Br J Obstet Gynaecol 1985; 92:287.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/27/5560/abstract/59\">",
"      Stefanon B, Pallucca A, Merola M, Bandieramonte G. Treatment with 5-fluorouracil of 35 patients with clinical or subclinical HPV infection of the vagina. Eur J Gynaecol Oncol 1996; 17:534.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/27/5560/abstract/60\">",
"      Woodruff JD, Parmley TH, Julian CG. Topical 5-fluorouracil in the treatment of vaginal carcinoma-in-situ. Gynecol Oncol 1975; 3:124.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/27/5560/abstract/61\">",
"      Dungar CF, Wilkinson EJ. Vaginal columnar cell metaplasia. An acquired adenosis associated with topical 5-fluorouracil therapy. J Reprod Med 1995; 40:361.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/27/5560/abstract/62\">",
"      MacLeod C, Fowler A, Dalrymple C, et al. High-dose-rate brachytherapy in the management of high-grade intraepithelial neoplasia of the vagina. Gynecol Oncol 1997; 65:74.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/27/5560/abstract/63\">",
"      Graham K, Wright K, Cadwallader B, et al. 20-year retrospective review of medium dose rate intracavitary brachytherapy in VAIN3. Gynecol Oncol 2007; 106:105.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/27/5560/abstract/64\">",
"      Frega A, French D, Piazze J, et al. Prediction of persistent vaginal intraepithelial neoplasia in previously hysterectomized women by high-risk HPV DNA detection. Cancer Lett 2007; 249:235.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/27/5560/abstract/65\">",
"      Ait Menguellet S, Collinet P, Houfflin Debarge V, et al. Management of multicentric lesions of the lower genital tract. Eur J Obstet Gynecol Reprod Biol 2007; 132:116.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3233 Version 5.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-183.166.191.243-2F5800EE8D-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_27_5560=[""].join("\n");
var outline_f5_27_5560=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H18\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      CLASSIFICATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Risk factors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      ETIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      HPV infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Biopsy technique",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      PROGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Surgical therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Ablation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Topical therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Imiquimod",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      5-fluorouracil (5-FU)",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Radiation therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Posttreatment surveillance",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ONC/3233\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/3233|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?18/22/18790\" title=\"picture 1\">",
"      Micrograph of VAIN",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/3233|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?36/29/37339\" title=\"table 1\">",
"      HPV types in VAIN",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?15/17/15645\" title=\"table 2\">",
"      Surgical treatment VAIN",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?6/1/6173\" title=\"table 3\">",
"      Laser treatment VAIN",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?31/3/31804\" title=\"table 4\">",
"      5-FU treatment VAIN",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/32/35337?source=related_link\">",
"      Cervical cancer screening tests: Techniques and test characteristics of cervical cytology and human papillomavirus testing",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/2/30762?source=related_link\">",
"      Cervical intraepithelial neoplasia: Management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/14/24808?source=related_link\">",
"      Colposcopy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/17/19738?source=related_link\">",
"      Recommendations for the use of human papillomavirus vaccines",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/46/6885?source=related_link\">",
"      Vaginectomy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/19/6455?source=related_link\">",
"      Vulvar and vaginal intraepithelial neoplasia in HIV-infected women",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/11/32952?source=related_link\">",
"      Vulvar intraepithelial neoplasia",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f5_27_5561="Topiramate: Drug information";
var content_f5_27_5561=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Topiramate: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?8/31/8694?source=see_link\">",
"    see \"Topiramate: Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"UTD.htm?20/60/21448?source=see_link\">",
"    see \"Topiramate: Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F229206\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Topamax&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F229207\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Apo-Topiramate&reg;;",
"     </li>",
"     <li>",
"      CO Topiramate;",
"     </li>",
"     <li>",
"      Dom-Topiramate;",
"     </li>",
"     <li>",
"      Mint-Topiramate;",
"     </li>",
"     <li>",
"      Mylan-Topiramate;",
"     </li>",
"     <li>",
"      Novo-Topiramate;",
"     </li>",
"     <li>",
"      PHL-Topiramate;",
"     </li>",
"     <li>",
"      PMS-Topiramate;",
"     </li>",
"     <li>",
"      PRO-Topiramate;",
"     </li>",
"     <li>",
"      ratio-Topiramate;",
"     </li>",
"     <li>",
"      Sandoz-Topiramate;",
"     </li>",
"     <li>",
"      Topamax&reg;;",
"     </li>",
"     <li>",
"      ZYM-Topiramate",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F229242\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Anticonvulsant, Miscellaneous",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F229211\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     Do not abruptly discontinue therapy; taper dosage gradually to prevent rebound effects. (In clinical trials, adult doses were withdrawn by decreasing in weekly intervals of 50-100 mg/day gradually over 2-8 weeks for seizure treatment, and by decreasing in weekly intervals by 25-50 mg/day for migraine prophylaxis.)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Epilepsy, monotherapy:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Partial onset seizure and primary generalized tonic-clonic seizure:",
"     </b>",
"     Oral: Initial: 25 mg twice daily; may increase weekly by 50 mg/day up to 100 mg twice daily (week 4 dose); thereafter, may further increase weekly by 100 mg/day up to the recommended maximum of 200 mg twice daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Canadian labeling:",
"     </b>",
"     Oral: Initial: 25 mg once daily (in evening); may increase to 25 mg twice daily in weeks 2 or 3 and up to 50 mg twice daily by weeks 3 or 4; may further increase weekly in increments of 50 mg/day up to recommended maximum of 200 mg twice daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Epilepsy, adjunctive therapy:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     <b>",
"      Partial onset seizure:",
"     </b>",
"     Oral: Initial: 25 mg once or twice daily for 1 week; may increase weekly by 25-50 mg/day until response; usual maintenance dose: 100-200 mg twice daily. Doses &gt;1600 mg/day have not been studied",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     <b>",
"      Primary generalized tonic-clonic seizure:",
"     </b>",
"     Oral: Use initial dose as listed above for partial onset seizures, but use slower initial titration rate; titrate upwards to recommended dose by the end of 8 weeks; usual maintenance dose: 200 mg twice daily. Doses &gt;1600 mg/day have not been studied.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     <b>",
"      Canadian labeling:",
"     </b>",
"     Oral: Initial: 25 mg once or twice daily; may increase weekly by 50 mg/day up to the recommended dose of 100-200 mg twice daily (maximum recommended dose: 800 mg/day; doses &gt;400 mg/day have shown no additional benefit)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Migraine prophylaxis:",
"      </i>",
"     </b>",
"     Oral: Initial: 25 mg once daily (in evening); may increase weekly by 25 mg/day up to the recommended dose of 100 mg/day given in 2 divided doses. Doses &gt;100 mg/day have shown no additional benefit.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Cluster headache prophylaxis (unlabeled use):",
"      </i>",
"     </b>",
"     Oral: Initial: 25 mg/day, titrated at weekly intervals in 25 mg increments, up to 200 mg/day (Pascual, 2007)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Diabetic neuropathy (unlabeled use):",
"      </i>",
"     </b>",
"     Oral: Initial: 25 mg/day, titrated at weekly intervals in 25-50 mg increments to target dose of 400 mg daily in 2 divided doses (Raskin, 2004; Thienel, 2004)",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F229228\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?20/60/21448?source=see_link\">",
"      see \"Topiramate: Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     Do not abruptly discontinue therapy; taper dosage gradually to prevent rebound effects.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Epilepsy, monotherapy:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     <b>",
"      Partial onset seizure and primary generalized tonic-clonic seizure:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Children 2-9 years: Partial onset seizure and primary generalized tonic-clonic seizure:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Initial: 25 mg once daily (in evening); may increase to 25 mg twice daily in week 2; thereafter, may increase by 25-50 mg/day at weekly intervals over 5-7 weeks up to the following minimum recommended maintenance dose:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     &le;11 kg: 150 mg/day in 2 divided doses",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     12-22 kg: 200 mg/day in 2 divided doses",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     23-31 kg: 200 mg/day in 2 divided doses",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     32-38 kg: 250 mg/day in 2 divided doses",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     &ge;39 kg: 250 mg/day in 2 divided doses",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Maximum maintenance dose: If additional seizure control is needed and therapy is tolerated, may further increase by 25-50 mg/day at weekly intervals up to the following maximum recommended maintenance dose:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     &le;11 kg: 250 mg/day in 2 divided doses",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     12-22 kg: 300 mg/day in 2 divided doses",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     23-31 kg: 350 mg/day in 2 divided doses",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     32-38 kg: 350 mg/day in 2 divided doses",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     &ge;39 kg: 400 mg/day in 2 divided doses",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     Children &ge;10 years: Oral: Refer to adult dosing.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     <b>",
"      Canadian labeling:",
"     </b>",
"     Children &ge;6 years: Refer to adult dosing.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-right:0em;margin-top:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Epilepsy, adjunctive therapy:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     <b>",
"      Partial onset seizure or seizure associated with Lennox-Gastaut syndrome:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     Children 2-16 years: Oral: Initial: 25 mg (1-3 mg/kg/day) once daily (in evening); may increase every 1-2 weeks in increments of 1-3 mg/kg/day up to the recommended maximum of 5-9 mg/kg/day in 2 divided doses",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     Adolescents &ge;17 years: Refer to adult dosing.",
"    </p>",
"    <p style=\"text-indent:-4em;margin-left:6em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     <b>",
"      Primary generalized tonic-clonic seizure:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-4em;margin-left:8em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     Children 2-16 years: Oral: Use initial dose listed above for partial onset seizures, but use slower initial titration rate; titrate to the recommended maintenance dose of 6 mg/kg/day by the end of 8 weeks",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     Adolescents &ge;17 years: Refer to adult dosing.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     <b>",
"      Canadian labeling:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     Children 2-16 years: Oral: Initial: 25 mg (1-3 mg/kg/day) once daily (in evening); may increase every 1-2 weeks in increments of 1-3 mg/kg/day up to the recommended maximum of 5-9 mg/kg/day in 2 divided doses",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     Adolescents &ge;17 years: Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F229212\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Most older adults have creatinine clearances &lt;70 mL/minute/1.73 m",
"     <sup>",
"      2",
"     </sup>",
"     ; obtain a serum creatinine and calculate creatinine clearance prior to initiation of therapy. An initial dose of 25 mg/day may be recommended, followed by incremental increases of 25 mg at weekly intervals until an effective dose is reached; refer to adult dosing for titration schedule.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F229213\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;70 mL/minute/1.73 m",
"     <sup>",
"      2",
"     </sup>",
"     : Administer 50% dose and titrate more slowly.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hemodialysis: Supplemental dose may be needed during hemodialysis",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F229214\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Clearance may be reduced; however the manufacturer&rsquo;s labeling provides no specific dosing recommendations.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F229180\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Capsule, sprinkle, oral: 15 mg, 25 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Topamax&reg;: 15 mg, 25 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral: 25 mg, 50 mg, 100 mg, 200 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Topamax&reg;: 25 mg, 50 mg, 100 mg, 200 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F229165\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block meg drugH1Div\" id=\"F7874884\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Guide",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     An FDA-approved patient medication guide, which is available with the product information and at",
"     <a href=\"file://www.fda.gov/downloads/Drugs/DrugSafety/UCM152837.pdf\" target=\"_blank\">",
"      file://www.fda.gov/downloads/Drugs/DrugSafety/UCM152837.pdf,",
"     </a>",
"     must be dispensed with this medication.",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F229184\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Oral: May be administered without regard to meals",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Capsule sprinkles: May be swallowed whole or opened to sprinkle the contents on a small amount (~1 teaspoon) of soft food (drug/food mixture should not be chewed; swallow immediately).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet: Because of bitter taste, tablets should not be broken or chewed.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F229183\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Monotherapy or adjunctive therapy for partial onset seizures and primary generalized tonic-clonic seizures; adjunctive treatment of seizures associated with Lennox-Gastaut syndrome; prophylaxis of migraine headache",
"    </p>",
"   </div>",
"   <div class=\"block usu drugH1Div\" id=\"F229238\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use - Unlabeled",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Diabetic neuropathy, infantile spasms, neuropathic pain; prophylaxis of cluster headache",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F229250\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Topamax&reg; may be confused with Sporanox&reg;, TEGretol&reg;, TEGretol&reg;-XR, Toprol-XL&reg;",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F229240\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;margin-left:0em;margin-right:0em;margin-top:0em;text-align:justify;display:inline\">",
"     Adverse events are reported for placebo-controlled trials of adjunctive therapy in adult and pediatric patients. Unless otherwise noted, the percentages refer to incidence in epilepsy trials.",
"     <b>",
"      Note:",
"     </b>",
"     A wide range of dosages were studied; incidence of adverse events was frequently lower in the pediatric population studied.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-right:0em;margin-top:2em;text-align:justify;\">",
"     &gt;10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Somnolence (15% to 29%), dizziness (4% to 25%; dose dependent), fatigue (9% to 16%; dose-dependent), nervousness (9% to 18%), ataxia (6% to 16%), psychomotor slowing (3% to 13%; dose dependent), speech problems (2% to 13%), memory difficulties (2% to 12%), behavior problems (children 11%), confusion (4% to 11%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Serum bicarbonate decreased (dose related: 7% to 67%;  marked reductions [to &lt;17 mEq/L] 1% to 11%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Anorexia (4% to 24%; dose dependent), nausea (6% to 10%; migraine trial: 9% to 14%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Paresthesia (1% to 11%; migraine trial: 35% to 51%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Ocular: Abnormal vision (2% to 13%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Respiratory: Upper respiratory infection (migraine trial: 12% to 14%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Miscellaneous: Injury (14%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cardiovascular: Chest pain (2% to 4%), edema (2%), hypertension (1% to 2%), bradycardia (1%), pallor (1%), syncope (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Difficulty concentrating (5% to 10%), aggressive reactions (2% to 9%), depression (5% to 9%; dose dependent, insomnia (4% to 8%), mood problems (&le;6%), abnormal coordination (4%), agitation (3%), cognitive problems (3%), emotional lability (3%), anxiety (2% to 3%; dose dependent), hypoesthesia (2%; migraine trial: 6% to 8%), stupor (2%), vertigo (2%), fever (migraine trial: 1% to 2%), apathy (1%), hallucination (1%), neurosis (1%), psychosis (1%), seizure (1%), suicide attempt (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dermatologic: Pruritus (migraine trial: 2% to 4%), skin disorder (2% to 3%), alopecia (2%), dermatitis (2%), hypertrichosis (2%), rash erythematous (1% to 2%), eczema (1%), seborrhea (1%), skin discoloration (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Breast pain (4%), hot flashes (1% to 2%), libido decreased (&lt;1% to 2%), menstrual irregularities (1% to 2%), hypoglycemia (1%), metabolic acidosis (hyperchloremia, nonanion gap)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Weight loss (4% to 9%), dyspepsia (2% to 7%), abdominal pain (5% to 6%), salivation increased (6%), constipation (4% to 5%), gastroenteritis (2% to 3%), vomiting (migraine trial: 1% to 3%), diarrhea (2%; migraine trial: 9% to 11%), dysgeusia (2%; migraine trial: 8% to 15%), xerostomia (2%), loss of taste (migraine trial: &le;2%), appetite increased (1%), dysphagia (1%), fecal incontinence (1%), flatulence (1%), GERD (1%), gingivitis (1%), glossitis (1%), gum hyperplasia (1%), weight gain (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Genitourinary: Incontinence (2% to 4%), UTI (2%), premature ejaculation (migraine trial: &le;3%), cystitis (2%), leukorrhea (2%), impotence (1%), nocturia (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hematologic: Purpura (8%), leukopenia (2%), anemia (1%), hematoma (1%), prothrombin time increased (1%), thrombocytopenia (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Tremor (3% to 9%), gait abnormal (3% to 8%), arthralgia (migraine trial: 1% to 7%), weakness (6%), hyperkinesia (5%), back pain (1% to 5%), involuntary muscle contractions (2%; migraine trial: 2% to 4%), leg cramps (2%), leg pain (2%), myalgia (2%), hyporeflexia (2%), rigors (1%), skeletal pain (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Ocular: Diplopia (1% to 10%), nystagmus (10%), conjunctivitis (1%), lacrimation abnormal (1%), myopia (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Otic: Hearing decreased (2%), tinnitus (2%), otitis media (migraine trial: 1% to 2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Renal: Hematuria (2%), renal calculus (migraine trial &le;2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Respiratory: Rhinitis (4% to 7%), pharyngitis (6%), sinusitis (5%; migraine trial: 6% to 10%), pneumonia (5%), epistaxis (2% to 4%), cough (migraine trial: 2% to 4%), bronchitis (migraine trial: 3%), dyspnea (migraine trial: 1% to 3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Miscellaneous: Viral infection (2% to 7%: migraine trial: 3% to 4%), flu-like syndrome (3%), allergy (2%), infection (2%), thirst (2%), body odor (1%), diaphoresis (1%), moniliasis (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &lt;1% (Limited to important or life-threatening): Angina, apraxia, AV block, bone marrow depression, deep vein thrombosis, dehydration, delirium, delusion, diabetes mellitus, dyskinesia, eosinophilia, erythema multiforme, euphoria, granulocytopenia, hepatic failure, hepatitis, hyperammonemia/encephalopathy (with or without valproate therapy), hyperesthesia, hyperthermia (severe), hypokalemia, hypotension, lymphadenopathy, lymphopenia, maculopathy, manic reaction, neuropathy, oligohydrosis, pancreatitis, pancytopenia, paranoid reaction, pemphigus, photosensitivity, pulmonary embolism, renal tubular acidosis, Stevens-Johnson syndrome, suicidal behavior, suicide, suicidal ideation, syndrome of acute myopia/secondary angle-closure glaucoma, tongue edema, toxic epidermal necrolysis",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F229187\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     There are no contraindications listed in the manufacturer's labeling.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Canadian labeling (not in U.S. labeling): Hypersensitivity to topiramate or any component of the formulation or container; pregnancy and women in childbearing years not using effective contraception (migraine prophylaxis only)",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F229169\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; CNS effects: Cognitive dysfunction, psychiatric disturbances (mood disorders), and sedation (somnolence or fatigue) may occur with use; incidence may be related to rapid titration and higher doses; patients must be cautioned about performing tasks which require mental alertness (eg, operating machinery or driving). May also cause paresthesia, dizziness, and ataxia.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Glaucoma: Has been associated with acute myopia and secondary angle-closure glaucoma in adults and children, typically within 1 month of initiation; discontinue in patients with acute onset of decreased visual acuity or ocular pain.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hyperammonemia/encephalopathy: Hyperammonemia with or without encephalopathy may occur with monotherapy or in combination with valproic acid and has been documented in patients who have tolerated each drug alone. Risk may be increased in patients with inborn errors of metabolism or decreased hepatic mitochondrial activity. Monitor for lethargy, vomiting, or unexplained changes in mental status.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hyperthermia: May be associated (rarely) with severe oligohydrosis and hyperthermia, most frequently in children; use caution and monitor closely during strenuous exercise, during exposure to high environmental temperature, or in patients receiving other carbonic anhydrase inhibitors and drugs with anticholinergic activity.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Metabolic acidosis (hyperchloremic, nonanion gap): May decrease serum bicarbonate concentrations, due to inhibition of carbonic anhydrase and increased renal bicarbonate loss. Decreases in serum bicarbonate are relatively common (7% to 67%) but usually mild-to-moderate (average decrease of 4 mEq/L at dose of 400 mg/day in adults and 6 mg/kg/day in children). Treatment-emergent metabolic acidosis is less common; however, risk may  be increased in patients with a predisposing condition (renal, respiratory and/or hepatic impairment), ketogenic diet, or concurrent treatment with other drugs which may cause acidosis. Metabolic acidosis may occur at dosages as low as 50 mg/day. Serum bicarbonate should be monitored, as well as potential complications of chronic acidosis (nephrolithiasis, osteomalacia, and reduced growth rates in children). Dose reduction or discontinuation (by tapering dose) should be considered in patients with persistent or severe metabolic acidosis. If treatment is continued, alkali supplementation should be considered.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal calculus: Topiramate exhibits weak carbonic anhydrase inhibitory properties and may increase the risk of kidney stones about 2-4 times that of the untreated population. Kidney stones have been reported in children and adults (incidence higher in males). The risk of stones may be reduced by increasing fluid intake.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Suicidal ideation: Pooled analysis of trials involving various antiepileptics (regardless of indication) showed an increased risk of suicidal thoughts/behavior (incidence rate: 0.43% treated patients compared to 0.24% of patients receiving placebo); risk observed as early as 1 week after initiation and continued through duration of trials (most trials &le;24 weeks). Monitor all patients for notable changes in behavior that might indicate suicidal thoughts or depression; notify healthcare provider immediately if symptoms occur.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatic impairment: Use with caution in patients with hepatic impairment; clearance may be reduced. Dosage adjustment may be required.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal impairment: Use with caution in patients with renal impairment; dosage adjustment may be required.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hydrochlorothiazide: Concurrent use of topiramate and hydrochlorothiazide may increase the risk for hypokalemia; monitor potassium closely.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Sedatives: Effects with other sedative drugs or ethanol may be potentiated.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Valproic acid: Concurrent use of topiramate and valproic acid may increase the risk of hyperammonemia and associated encephalopathy; valproic acid dose-dependency was observed in limited pediatric studies. Additionally, hypothermia (core body temperature &lt;35&deg;C [95&deg;F]) has been reported with concomitant use of topiramate and valproic acid; may occur with or without associated hyperammonemia, and may develop after topiramate initiation or dosage increase. If hypothermia develops, discontinuation of topiramate or valproic acid may be necessary.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Pediatrics: Safety and efficacy have not been established in children &lt;2 years of age for treatment of seizures. Safety and efficacy have not been established in children for migraine prophylaxis. Weight loss may occur most often early in therapy; in clinical trials of at least 1 year, the majority of patients with weight loss had a resumption of weight gain within the study period.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Withdrawal: Anticonvulsants should not be discontinued abruptly because of the possibility of increasing seizure frequency; therapy should be withdrawn gradually to minimize the potential of increased seizure frequency, unless safety concerns require a more rapid withdrawal. Doses were also gradually withdrawn in migraine prophylaxis studies (decreased in weekly intervals by 25-50 mg/day).",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F229235\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Inhibits",
"     </b>",
"     CYP2C19 (weak);",
"     <b>",
"      Induces",
"     </b>",
"     CYP3A4 (weak/moderate)",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F229174\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alcohol (Ethyl): CNS Depressants may enhance the CNS depressant effect of Alcohol (Ethyl).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alpha-/Beta-Agonists: Carbonic Anhydrase Inhibitors may decrease the excretion of Alpha-/Beta-Agonists.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Dipivefrin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Amphetamines: Carbonic Anhydrase Inhibitors may decrease the excretion of Amphetamines.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Anticholinergic Agents: May enhance the adverse/toxic effect of Topiramate. Specifically, the risk of oligohidrosis and hyperthermia may be enhanced.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Anticonvulsants (Barbiturate): Carbonic Anhydrase Inhibitors may enhance the adverse/toxic effect of Anticonvulsants (Barbiturate). Specifically, osteomalacia and rickets.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Anticonvulsants (Hydantoin): Carbonic Anhydrase Inhibitors may enhance the adverse/toxic effect of Anticonvulsants (Hydantoin). Specifically, osteomalacia and rickets.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ARIPiprazole: CYP3A4 Inducers may decrease the serum concentration of ARIPiprazole.  Management: Double the oral aripiprazole dose and closely monitor clinical response.  Reduce the oral aripiprazole dose to 10-15 mg/day if the inducer is discontinued. Avoid use of CYP3A4 inducers for more than 14 days with extended-release injectable aripiprazole.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Axitinib: CYP3A4 Inducers (Weakly to Moderately Effective) may decrease the serum concentration of Axitinib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Azelastine (Nasal): CNS Depressants may enhance the CNS depressant effect of Azelastine (Nasal).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Buprenorphine: CNS Depressants may enhance the CNS depressant effect of Buprenorphine.  Management: Consider reduced doses of CNS depressants used in combination with buprenorphine.  Consider avoiding other CNS depressants in patients thought to be at high risk of buprenorphine overuse or self-injection.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CarBAMazepine: May decrease the serum concentration of Topiramate.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Carbonic Anhydrase Inhibitors: May enhance the adverse/toxic effect of other Carbonic Anhydrase Inhibitors. The development of acid-base disorders with concurrent use of ophthalmic and oral carbonic anhydrase inhibitors has been reported. Management: Avoid concurrent use of different carbonic anhydrase inhibitors if possible.  Monitor patients closely for the occurrence of kidney stones and with regards to severity of metabolic acidosis.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CNS Depressants: May enhance the adverse/toxic effect of other CNS Depressants.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Levocabastine (Nasal).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Contraceptives (Estrogens): Topiramate may decrease the serum concentration of Contraceptives (Estrogens). Contraceptive failure is possible.  Management: Risk appears greatest for higher topiramate doses (200 mg/day or greater).  Some have recommended using at least 50 mcg/day of ethinyl estradiol, but the effectiveness of this is unclear.  Consider a nonhormonal form of contraception.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Contraceptives (Progestins): Topiramate may decrease the serum concentration of Contraceptives (Progestins).  Management: Caution patients that this combination may be associated with reduced contraceptive effectiveness.  Consider adding an additional (non-hormonal) contraceptive method.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Divalproex: May enhance the adverse/toxic effect of Topiramate.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Droperidol: May enhance the CNS depressant effect of CNS Depressants. Management: Consider dose reductions of droperidol or of other CNS agents (e.g., opioids, barbiturates) with concomitant use.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Flecainide: Carbonic Anhydrase Inhibitors may increase the serum concentration of Flecainide.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fosphenytoin: May decrease the serum concentration of Topiramate. Topiramate may increase the serum concentration of Fosphenytoin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     HydrOXYzine: May enhance the CNS depressant effect of CNS Depressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ketorolac (Nasal): May diminish the therapeutic effect of Anticonvulsants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ketorolac (Systemic): May diminish the therapeutic effect of Anticonvulsants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lithium: Topiramate may increase the serum concentration of Lithium.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Loop Diuretics: May enhance the hypokalemic effect of Topiramate.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Magnesium Sulfate: May enhance the CNS depressant effect of CNS Depressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mefloquine: May diminish the therapeutic effect of Anticonvulsants. Mefloquine may decrease the serum concentration of Anticonvulsants. Management: Mefloquine is contraindicated for malaria prophylaxis in persons with a history of convulsions.  Monitor anticonvulsant concentrations and treatment response closely with concurrent use.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Memantine: Carbonic Anhydrase Inhibitors may decrease the excretion of Memantine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     MetFORMIN: Carbonic Anhydrase Inhibitors may enhance the adverse/toxic effect of MetFORMIN. Specifically, the risk of developing lactic acidosis may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methenamine: Carbonic Anhydrase Inhibitors may diminish the therapeutic effect of Methenamine.  Management: Consider avoiding this combination. Monitor for decreased therapeutic effects of methenamine if used concomitant with a carbonic anhydrase inhibitor.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methotrimeprazine: CNS Depressants may enhance the CNS depressant effect of Methotrimeprazine. Methotrimeprazine may enhance the CNS depressant effect of CNS Depressants.  Management: Reduce adult dose of CNS depressant agents by 50% with initiation of concomitant methotrimeprazine therapy. Further CNS depressant dosage adjustments should be initiated only after clinically effective methotrimeprazine dose is established.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metyrosine: CNS Depressants may enhance the sedative effect of Metyrosine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mirtazapine: CNS Depressants may enhance the CNS depressant effect of Mirtazapine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Paraldehyde: CNS Depressants may enhance the CNS depressant effect of Paraldehyde.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Perampanel: May enhance the CNS depressant effect of CNS Depressants. Management: Patients taking perampanel with any other drug that has CNS depressant activities should avoid complex and high-risk activities, particularly those such as driving that require alertness and coordination, until they have experience using the combination.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Phenytoin: May decrease the serum concentration of Topiramate. Topiramate may increase the serum concentration of Phenytoin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pramipexole: CNS Depressants may enhance the sedative effect of Pramipexole.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Primidone: Carbonic Anhydrase Inhibitors may enhance the adverse/toxic effect of Primidone. Specifically, osteomalacia and rickets. Carbonic Anhydrase Inhibitors may decrease the serum concentration of Primidone.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     QuiNIDine: Carbonic Anhydrase Inhibitors may decrease the excretion of QuiNIDine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ROPINIRole: CNS Depressants may enhance the sedative effect of ROPINIRole.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rotigotine: CNS Depressants may enhance the sedative effect of Rotigotine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Salicylates: May enhance the adverse/toxic effect of Carbonic Anhydrase Inhibitors. Salicylate toxicity might be enhanced by this same combination.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Saxagliptin: CYP3A4 Inducers may decrease the serum concentration of Saxagliptin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Selective Serotonin Reuptake Inhibitors: CNS Depressants may enhance the adverse/toxic effect of Selective Serotonin Reuptake Inhibitors. Specifically, the risk of psychomotor impairment may be enhanced.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Oxybate: May enhance the CNS depressant effect of CNS Depressants. Management: Consider alternatives to combined use. When combined use is needed, consider minimizing doses of one or more drugs. Use of sodium oxybate with alcohol or sedative hypnotics is contraindicated.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Thiazide Diuretics: May enhance the hypokalemic effect of Topiramate. Thiazide Diuretics may increase the serum concentration of Topiramate. Management: Monitor for increased topiramate levels/adverse effects (e.g., hypokalemia) with initiation/dose increase of a thiazide diuretic. Closely monitor serum potassium concentrations with concomitant therapy. Topiramate dose reductions may be necessary.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Valproic Acid: Topiramate may enhance the adverse/toxic effect of Valproic Acid.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Zolpidem: CNS Depressants may enhance the CNS depressant effect of Zolpidem.  Management: Reduce the Intermezzo brand sublingual zolpidem dose to 1.75 mg for men who are also receiving other CNS depressants.  No such dose change is recommended for women.  Avoid use with other CNS depressants at bedtime; avoid use with alcohol.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F229202\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ethanol: May increase CNS depression; monitor for increased effects with coadministration. Caution patients about effects.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Food: Ketogenic diet may increase the possibility of acidosis and/or kidney stones.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Herb/Nutraceutical: Avoid evening primrose (seizure threshold decreased).",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F229176\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     D (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F229191\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Topiramate was found to be teratogenic in animal studies. Based on limited data, topiramate was found to cross the placenta. An increase risk of oral clefts (cleft lip and/or palate) has been observed following first trimester exposure. Data, from the North American Antiepileptic Drug (NAAED) Pregnancy Registry, reported that the prevalence of oral clefts was 1.4% for infants exposed to topiramate during the first trimester of pregnancy, versus 0.38% to 0.55% for infants exposed to other antiepileptic drugs and 0.07% with no exposure. Hypospadias and other congenital anomalies have also been reported. Although not evaluated during pregnancy, metabolic acidosis may be induced by topiramate. In general, metabolic acidosis during pregnancy may result in adverse effects and fetal death. Pregnant women and their newborns should be monitored for metabolic acidosis.  Maternal serum concentrations may decrease during the second and third trimesters of pregnancy therefore therapeutic drug monitoring should be considered in pregnant women who require therapy.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Patients exposed to topiramate during pregnancy are encouraged to enroll themselves into the AED Pregnancy Registry by calling 1-888-233-2334. Additional information is available at www.aedpregnancyregistry.org.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F229218\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Enters breast milk/use caution",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F229192\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Based on limited data, topiramate was found in breast milk. Infant plasma concentrations of topiramate have been reported as 10% to 20% of the maternal plasma concentration.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F229190\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Capsule, sprinkles",
"     </b>",
"     (Topamax Sprinkle Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     15 mg (60): $234.64",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     25 mg (60): $283.66",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Capsule, sprinkles",
"     </b>",
"     (Topiramate Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     15 mg (60): $144.97",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     25 mg (60): $175.26",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Topamax Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     25 mg (60): $248.10",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     50 mg (60): $495.16",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     100 mg (60): $676.21",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     200 mg (60): $791.63",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Topiragen Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     25 mg (60): $127.72",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     50 mg (60): $254.90",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     100 mg (60): $348.11",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     200 mg (60): $407.53",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Topiramate Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     25 mg (60): $153.25",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     50 mg (60): $305.90",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     100 mg (60): $417.75",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     200 mg (60): $489.06",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F229178\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Seizure frequency, hydration status; electrolytes (recommended monitoring includes serum bicarbonate at baseline and periodically during treatment), serum creatinine; monitor for symptoms of acute acidosis and complications of long-term acidosis (nephrolithiasis, osteomalacia, and reduced growth rates in children); ammonia level in patients with unexplained lethargy, vomiting, or mental status changes; intraocular pressure, symptoms of secondary angle closure glaucoma; suicidality (eg, suicidal thoughts, depression, behavioral changes)",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F229193\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Epilramate (TW);",
"     </li>",
"     <li>",
"      Epimate (PH);",
"     </li>",
"     <li>",
"      Epiramax (AU);",
"     </li>",
"     <li>",
"      Epitomax (FI, FR);",
"     </li>",
"     <li>",
"      Epitop (PH);",
"     </li>",
"     <li>",
"      Gabatopa (KP);",
"     </li>",
"     <li>",
"      Tiramate (NZ);",
"     </li>",
"     <li>",
"      Topamac (AR, CO, IN, PE, PY, UY);",
"     </li>",
"     <li>",
"      Topamax (AE, AT, AU, BE, BG, BH, BR, CH, CL, CN, CY, CZ, DE, EE, EG, ES, FI, GB, HK, IE, IL, IQ, IR, IT, JM, JO, KP, KW, LB, LY, MX, MY, NL, NZ, OM, PH, PK, PL, PT, QA, RU, SA, SG, SY, TH, TR, TW, VE, YE, ZA);",
"     </li>",
"     <li>",
"      Topamax Sprinkle (HK, IL, KP, NZ);",
"     </li>",
"     <li>",
"      Topictal (CR, EC, GT, HN, NI, PA, SV);",
"     </li>",
"     <li>",
"      Topimax (CR, DK, DO, GT, HN, NI, NO, PA, SE, SV);",
"     </li>",
"     <li>",
"      Topinmate (TW);",
"     </li>",
"     <li>",
"      Topitrim (IL);",
"     </li>",
"     <li>",
"      Topmate (KP);",
"     </li>",
"     <li>",
"      Topomac (GR);",
"     </li>",
"     <li>",
"      Toramate (TW)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F229168\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Anticonvulsant activity may be due to a combination of potential mechanisms: Blocks neuronal voltage-dependent sodium channels, enhances GABA(A) activity, antagonizes AMPA/kainate glutamate receptors, and weakly inhibits carbonic anhydrase.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F229186\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Good, rapid; unaffected by food",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: 15% to 41% (inversely related to plasma concentrations)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Minor amounts metabolized in liver via hydroxylation, hydrolysis, and glucuronidation; percentage of dose metabolized in liver and clearance are increased in patients receiving enzyme inducers (eg, carbamazepine, phenytoin)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Bioavailability: ~80%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination: Mean: Adults: Normal renal function: 21 hours; shorter in pediatric patients; clearance is 50% higher in pediatric patients; Elderly: ~24 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak, serum: ~1-4 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Urine (~70% to 80% as unchanged drug)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dialyzable: Significantly hemodialyzed; dialysis clearance: 120 mL/minute (4-6 times higher than in adults with normal renal function); supplemental doses may be required",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Bar-Oz B, Nulman I, Koren G, et al, &ldquo;Anticonvulsants and Breast Feeding: A Critical Review,&rdquo;",
"      <i>",
"       Paediatr Drugs",
"      </i>",
"      , 2000, 2(2):113-26.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?5/27/5561/abstract-text/10937463/pubmed\" id=\"10937463\" target=\"_blank\">",
"        10937463",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Bril V, England J, Franklin GM, et al, \"Evidence-Based Guideline: Treatment of Painful Diabetic Neuropathy: Report of the American Academy of Neurology, the American Association of Neuromuscular and Electrodiagnostic Medicine, and the American Academy of Physical Medicine and Rehabilitation,\"",
"      <i>",
"       Neurology",
"      </i>",
"      , 2011, 76(20):1758-65.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?5/27/5561/abstract-text/21482920/pubmed\" id=\"21482920\" target=\"_blank\">",
"        21482920",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Carroll DG, Kline KM, and Malnar KF, \"Role of Topiramate for the Treatment of Painful Diabetic Peripheral Neuropathy,\"",
"      <i>",
"       Pharmacotherapy",
"      </i>",
"      , 2004,  24(9):1186-93.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?5/27/5561/abstract-text/15460179/pubmed\" id=\"15460179\" target=\"_blank\">",
"        15460179",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Chong MS and Libretto SE, \" The Rationale and Use of Topiramate for Treating Neuropathic Pain,\"",
"      <i>",
"       Clin J Pain",
"      </i>",
"      , 2003, 19(1):59-68.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?5/27/5561/abstract-text/12514458/pubmed\" id=\"12514458\" target=\"_blank\">",
"        12514458",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Dib JG, \"Focus on Topiramate in Neuropathic Pain,\"",
"      <i>",
"       Curr Med Res Opin",
"      </i>",
"      , 2004, 20(12):1857-61.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?5/27/5561/abstract-text/15701203/pubmed\" id=\"15701203\" target=\"_blank\">",
"        15701203",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Doose DR, Walker SA, Gisclon LG, et al, &ldquo;Single-Dose Pharmacokinetics and Effect of Food on the Bioavailability of Topiramate, a Novel Antiepileptic Drug,&rdquo;",
"      <i>",
"       J Clin Pharmacol",
"      </i>",
"      , 1996, 36(10):884-91.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?5/27/5561/abstract-text/8930774/pubmed\" id=\"8930774\" target=\"_blank\">",
"        8930774",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Glauser TA, Clark PO, and Strawsburg R, &ldquo;A Pilot Study of Topiramate in the Treatment of Infantile Spasms,&rdquo;",
"      <i>",
"       Epilepsia",
"      </i>",
"      , 1998, 39(12):1324-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?5/27/5561/abstract-text/9860068/pubmed\" id=\"9860068\" target=\"_blank\">",
"        9860068",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Glauser TA, &ldquo;Preliminary Observations on Topiramate in Pediatric Epilepsies,&rdquo;",
"      <i>",
"       Epilepsia",
"      </i>",
"      , 1997, 38(Suppl 1):37-41.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?5/27/5561/abstract-text/9092958/pubmed\" id=\"9092958\" target=\"_blank\">",
"        9092958",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Glauser TA, &ldquo;Topiramate Use in Pediatric Patients,&rdquo;",
"      <i>",
"       Can J Neurol Sci",
"      </i>",
"      , 1998, 25(3):S8-12.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?5/27/5561/abstract-text/9706734/pubmed\" id=\"9706734\" target=\"_blank\">",
"        9706734",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Hershey AD, Powers SW, Vockell AL, et al, &ldquo;Effectiveness of Topiramate in the Prevention of Childhood Headaches,&rdquo;",
"      <i>",
"       Headache",
"      </i>",
"      , 2002, 42(8):810-18.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?5/27/5561/abstract-text/12390646/pubmed\" id=\"12390646\" target=\"_blank\">",
"        12390646",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Krymchantowski AV, Bigal ME, and Moreira PR, &ldquo;New and Emerging Prophylactic Agents for Migraine,&rdquo;",
"      <i>",
"       CNS Drugs",
"      </i>",
"      , 2002, 16(9):611-34.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?5/27/5561/abstract-text/12153333/pubmed\" id=\"12153333\" target=\"_blank\">",
"        12153333",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Mathew NT, Kailasam J, and Meadors L, &ldquo;Prophylaxis of Migraine, Transformed Migraine, and Cluster Headache With Topiramate,&rdquo;",
"      <i>",
"       Headache",
"      </i>",
"      , 2002, 42(8):796-803.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?5/27/5561/abstract-text/12390644/pubmed\" id=\"12390644\" target=\"_blank\">",
"        12390644",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Ohman I, Vitols S, Luef G, et al, &ldquo;Topiramate Kinetics During Delivery, Lactation, and in the Neonate: Preliminary Observations,&rdquo;",
"      <i>",
"       Epilepsia",
"      </i>",
"      , 2002, 43(10):1157-60.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?5/27/5561/abstract-text/12366729/pubmed\" id=\"12366729\" target=\"_blank\">",
"        12366729",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Pascual J, Lainez MJ, Dodick D, et al, &ldquo;Antiepileptic Drugs for the Treatment of Chronic and Episodic Cluster Headache: A Review,&rdquo;",
"      <i>",
"       Headache",
"      </i>",
"      , 2007, 47(1):81-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?5/27/5561/abstract-text/17355498/pubmed\" id=\"17355498\" target=\"_blank\">",
"        17355498",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Raskin P, Donofrio PD, Rosenthal NR, et al, &ldquo;Topiramate vs Placebo in Painful Diabetic Neuropathy: Analgesic and Metabolic Effects,&rdquo;",
"      <i>",
"       Neurology",
"      </i>",
"      , 2004, 63(5):865-73.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?5/27/5561/abstract-text/15365138/pubmed\" id=\"15365138\" target=\"_blank\">",
"        15365138",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Silberstein SD and Goadsby PJ, &ldquo;Migraine: Preventative Treatment,&rdquo;",
"      <i>",
"       Cephalalgia",
"      </i>",
"      , 2002, 22(7):491-512.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?5/27/5561/abstract-text/12230591/pubmed\" id=\"12230591\" target=\"_blank\">",
"        12230591",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Sachdeo RC, &ldquo;Topiramate. Clinical Profile in Epilepsy,&rdquo;",
"      <i>",
"       Clin Pharmacokinet",
"      </i>",
"      , 1998, 34(5):335-46.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?5/27/5561/abstract-text/9592618/pubmed\" id=\"9592618\" target=\"_blank\">",
"        9592618",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Story JR, Calder CS, Hart DE, et al, &ldquo;Topiramate in Migraine Prevention: A Double-Blind, Placebo-Controlled Study,&rdquo;",
"      <i>",
"       Headache",
"      </i>",
"      , 2001, 41(10):968-75.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?5/27/5561/abstract-text/11903524/pubmed\" id=\"11903524\" target=\"_blank\">",
"        11903524",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Thienel U, Neto W, Schwabe SK, et al, &ldquo;Topiramate in Painful Diabetic Polyneuropathy: Findings from Three Double-Blind Placebo-Controlled Trials,&rdquo;",
"      <i>",
"       Acta Neurol Scand",
"      </i>",
"      , 2004, 110(4):221-31.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?5/27/5561/abstract-text/15355485/pubmed\" id=\"15355485\" target=\"_blank\">",
"        15355485",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Westin AA, Nakken KO, Johannessen SI, et al, \"Serum Concentration/dose Ratio of Topiramate During Pregnancy,\"",
"      <i>",
"       Epilepsia",
"      </i>",
"      , 2009, 50(3):480-5.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?5/27/5561/abstract-text/19178558/pubmed\" id=\"19178558\" target=\"_blank\">",
"        19178558",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Young WB, Hopkins MM, Shechter AL, et al, &ldquo;Topiramate: A Case Series Study in Migraine Prophylaxis,&rdquo;",
"      <i>",
"       Cephalalgia",
"      </i>",
"      , 2002, 22(8):659-63.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?5/27/5561/abstract-text/12383061/pubmed\" id=\"12383061\" target=\"_blank\">",
"        12383061",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 10006 Version 46.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-115.25.216.6-41F16B85B6-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_27_5561=[""].join("\n");
var outline_f5_27_5561=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F229206\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F229207\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F229242\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F229211\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F229228\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F229212\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F229213\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F229214\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F229180\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F229165\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7874884\">",
"      Medication Guide",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F229184\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F229183\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F229238\">",
"      Use - Unlabeled",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F229250\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F229240\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F229187\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F229169\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F229235\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F229174\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F229202\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F229176\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F229191\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F229218\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F229192\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F229190\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F229178\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F229193\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F229168\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F229186\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/10006\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/10006|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?8/31/8694?source=related_link\">",
"      Topiramate: Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?20/60/21448?source=related_link\">",
"      Topiramate: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f5_27_5562="Impaired healthcare provider";
var content_f5_27_5562=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Impaired healthcare provider",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?5/27/5562/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?5/27/5562/contributors\">",
"     Kenneth Thompson, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?5/27/5562/contributors\">",
"     Scott A Teitelbaum, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?5/27/5562/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?5/27/5562/contributors\">",
"     Richard Saitz, MD, MPH, FACP, FASAM",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?5/27/5562/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?5/27/5562/contributors\">",
"     Richard Hermann, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?5/27/5562/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Aug 16, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The term \"impaired healthcare provider\" refers to physicians and other clinicians with mental health issues including chemical dependence. Physician peers, hospital systems, and practice managers are often ill prepared to deal with issues involving the impaired physician, although substance abuse and mental health disorders are prevalent among clinicians. Physicians not only commonly neglect their own mental health issues, but also fail to consider the mental health problems of their peers.",
"   </p>",
"   <p>",
"    Although the prevalence of impairment in physicians is not significantly different from the general population, issues of denial, self treatment, shame, and the potential professional consequences of drug use place physicians in a special category. &nbsp;Public tolerance for a clinician with substance abuse issues is minimal; most patients feel that total abstinence should be the norm for a practicing physician [",
"    <a class=\"abstract\" href=\"UTD.htm?5/27/5562/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Physician colleagues have a duty to patients, colleagues and their profession to act when the symptoms of substance use disorder (SUD) or other psychological illness are present in another clinician. The potential ramifications of not intervening with the affected clinician are multiple: foremost are issues related to patient safety, but potential sanctions by the legal system and Board of Medicine, and the long-term impact of SUD on families and careers can also be profound [",
"    <a class=\"abstract\" href=\"UTD.htm?5/27/5562/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    When appropriately assessed and treated, the prognosis for a physician with chemical dependence is excellent [",
"    <a class=\"abstract\" href=\"UTD.htm?5/27/5562/abstract/3-8\">",
"     3-8",
"    </a>",
"    ]. Physicians do better in recovery than the general population, and typically can return to productive careers and satisfying personal lifestyles [",
"    <a class=\"abstract\" href=\"UTD.htm?5/27/5562/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The number of physicians assessed and treated for a substance use disorder (SUD) has increased significantly in the last decade [",
"    <a class=\"abstract\" href=\"UTD.htm?5/27/5562/abstract/10\">",
"     10",
"    </a>",
"    ]. This is attributed to enhanced awareness of the prevalence of SUD in physicians and the increased emphasis on risk management. In addition to substance use disorders, co-morbid psychiatric conditions requiring hospitalization for physicians appears to be increasing [",
"    <a class=\"abstract\" href=\"UTD.htm?5/27/5562/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Recognition of physician health and impairment issues in the US was brought to the forefront in 1972 with publication of a landmark policy paper by the AMA council on Mental Health, promoting the need for individual state programs to help the impaired physician [",
"    <a class=\"abstract\" href=\"UTD.htm?5/27/5562/abstract/12\">",
"     12",
"    </a>",
"    ]. An AMA consensus statement acknowledges that too little has been done to address mental health issues among physicians [",
"    <a class=\"abstract\" href=\"UTD.htm?5/27/5562/abstract/13\">",
"     13",
"    </a>",
"    ]. The AMA Code of Medical Ethic's promotes physician wellness, in addition to addressing issues of impairment [",
"    <a class=\"abstract\" href=\"UTD.htm?5/27/5562/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Most physicians are poorly informed regarding the nature of addiction and are even less familiar with the nuances of physician impairment. Few physicians received education regarding addiction during their training although some US medical schools have recently instituted mandatory clerkships in addiction medicine.",
"   </p>",
"   <p>",
"    This topic will address identification, intervention and treatment of the impaired healthcare provider. An overview of drug abuse is presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/58/5033?source=see_link\">",
"     \"Substance use disorders: Principles for recognition and assessment in general medical care\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     DEFINITION OF IMPAIRMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The American Medical Association defines impairment as the inability to practice medicine with reasonable skill and safety to patients by reason of physical or mental illness, including alcoholism or drug dependence [",
"    <a class=\"abstract\" href=\"UTD.htm?5/27/5562/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Impairment as applied to health professionals is used most commonly in reference to the inability to practice according to accepted standards as a result of substance use, abuse, or dependency [",
"    <a class=\"abstract\" href=\"UTD.htm?5/27/5562/abstract/16\">",
"     16",
"    </a>",
"    ]. It may also refer to physical problems, neurological problems, infectious issues such as HIV or hepatitis C, or incapacitation from other medical illness. Sexual boundary issues have become a prominent topic in professional and lay settings.",
"   </p>",
"   <p>",
"    Another recognized category of impairment is \"the disruptive physician\". This term is used when a physician's behavior causes contention and dysfunction in the workplace. The dysfunctional behaviors (eg, irritability, aggression, yelling) may be the result of chemical impairment, but more often result from other mental health issues, including bipolar disorder, or personality disorder with narcissistic and antisocial components.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     ADDICTION AS A DISEASE",
"    </span>",
"    &nbsp;&mdash;&nbsp;A majority of physicians, medical scientists, and professional and health organizations support the concept that addiction is a disease, like any other medical disease [",
"    <a class=\"abstract\" href=\"UTD.htm?5/27/5562/abstract/17\">",
"     17",
"    </a>",
"    ]. The World Health Organization acknowledged alcoholism as a serious medical problem in 1951, and the American Medical Association declared alcoholism a treatable illness in 1956, bringing alcoholism out of the \"dark ages\" when it had been thought to be a moral problem [",
"    <a class=\"abstract\" href=\"UTD.htm?5/27/5562/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The Joint Committee of the National Council on Alcoholism and Drug Dependence and the American Society of Addiction Medicine define alcoholism and other addiction as: \"&hellip;a primary, chronic disease with genetic, psychosocial, and environmental factors influencing its development and manifestations. The disease is often progressive and fatal. It is characterized by impaired control over drinking",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    drug use, preoccupation with the",
"    <span class=\"nowrap\">",
"     drug/alcohol,",
"    </span>",
"    use of drugs or alcohol despite adverse consequences, and distortions in thinking, most notably denial. Each of these symptoms may be continuous or periodic\" [",
"    <a class=\"abstract\" href=\"UTD.htm?5/27/5562/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The conceptual model for substance abuse posits that addictive substances produce changes in the brain that result in loss of control over substance use, the heralding feature of addictive illness. Functional scanning techniques have demonstrated differences of control, reward in the addicted brain and gene expression as compared to a normal brain [",
"    <a class=\"abstract\" href=\"UTD.htm?5/27/5562/abstract/20-26\">",
"     20-26",
"    </a>",
"    ]. Biomolecular studies have identified primary receptors for the major classes of abused drugs, as well as receptors responsible for activation, pleasure, withdrawal and craving. Mechanisms of underlying drug-seeking behaviors have been identified, and animal models for self administration have been developed [",
"    <a class=\"abstract\" href=\"UTD.htm?5/27/5562/abstract/27-31\">",
"     27-31",
"    </a>",
"    ]. These findings suggest that the brain of the addicted individual may be fundamentally different than the brain of non-addicted individuals.",
"   </p>",
"   <p>",
"    Understanding addiction as a disease with a diverse but reproducible set of symptoms, resulting from genetically predisposed biochemical alterations in the brain's reward system, serves to reduce social prejudice and the fallacy that drug or alcohol addiction is attributable to a weak character or lack of will power. Appreciation that addiction (chemical dependence) is a disease promotes treatment and rehabilitation, and fosters a therapeutic, rather than punitive, approach to the impaired clinician. It is generally accepted by agencies such as the Federation of State Physician Health Providers, state physician health programs (PHPs), and treatment professionals that treatment is facilitated by recognizing the physician as impaired, and that sanctioning that physician impedes entry into treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?5/27/5562/abstract/32\">",
"     32",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Prevalence",
"    </span>",
"    &nbsp;&mdash;&nbsp;The prevalence of addiction in the population of US physicians is generally reflective of the general population [",
"    <a class=\"abstract\" href=\"UTD.htm?5/27/5562/abstract/4,33,34\">",
"     4,33,34",
"    </a>",
"    ]. Current estimates are that approximately 15 percent of physicians will be impaired at some point in their careers [",
"    <a class=\"abstract\" href=\"UTD.htm?5/27/5562/abstract/35-39\">",
"     35-39",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, there are significant differences between clinicians and the general population in types of drugs used and premorbid history. The selection process for entry into professional schools, and the challenge of completing professional education, are likely to eliminate persons who present at an early age with more aggressive forms of substance abuse disorders. Physicians are as likely to have experimented with illicit substances as their age peers, but are less likely to be current users of illicit substances [",
"    <a class=\"abstract\" href=\"UTD.htm?5/27/5562/abstract/40\">",
"     40",
"    </a>",
"    ]. In general, healthcare professionals drink less than the general population, although alcohol is still the most frequently abused drug among physicians [",
"    <a class=\"abstract\" href=\"UTD.htm?5/27/5562/abstract/41\">",
"     41",
"    </a>",
"    ]. Physicians tend to have higher rates of abuse of prescription drugs, notably benzodiazepines and opioids [",
"    <a class=\"abstract\" href=\"UTD.htm?5/27/5562/abstract/42\">",
"     42",
"    </a>",
"    ]. These drugs are usually self-prescribed under the pretense of self treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?5/27/5562/abstract/42\">",
"     42",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The following distribution of abused drugs were reported by 109 physicians receiving care through one state PHP in 2007 [",
"    <a class=\"abstract\" href=\"UTD.htm?5/27/5562/abstract/43\">",
"     43",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Alcohol - 39.5 percent",
"     </li>",
"     <li>",
"      Opioids - 33.9 percent",
"     </li>",
"     <li>",
"      Cocaine - 11.9 percent",
"     </li>",
"     <li>",
"      Sedatives - 3.7 percent",
"     </li>",
"     <li>",
"      Marijuana - 2.8 percent",
"     </li>",
"     <li>",
"      Inhalants - 1.8 percent",
"     </li>",
"     <li>",
"      Amphetamines - 1.8 percent",
"     </li>",
"     <li>",
"      Other - 4.6 percent",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Use of illicit drugs, other than tranquilizers, has often begun before medical school and residency [",
"    <a class=\"abstract\" href=\"UTD.htm?5/27/5562/abstract/44-46\">",
"     44-46",
"    </a>",
"    ], and may increase during medical school [",
"    <a class=\"abstract\" href=\"UTD.htm?5/27/5562/abstract/47\">",
"     47",
"    </a>",
"    ], though this finding is not found consistently [",
"    <a class=\"abstract\" href=\"UTD.htm?5/27/5562/abstract/48\">",
"     48",
"    </a>",
"    ]. In one survey, cocaine was used by 17 percent of respondents during medical school [",
"    <a class=\"abstract\" href=\"UTD.htm?5/27/5562/abstract/48\">",
"     48",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Alcohol is the most frequently abused substance for all specialties of physicians. Alcohol use among medical students in the US is somewhat lower than their age peers, although about one third reported drinking excessively in the prior month [",
"    <a class=\"abstract\" href=\"UTD.htm?5/27/5562/abstract/49\">",
"     49",
"    </a>",
"    ]. Students who drank excessively were less likely to provide alcohol screening and counseling for patients.",
"   </p>",
"   <p>",
"    Drug use, particularly prescription drug abuse, may be initiated during residency, and often begins as self-treatment rather than for \"recreational\" purposes [",
"    <a class=\"abstract\" href=\"UTD.htm?5/27/5562/abstract/50\">",
"     50",
"    </a>",
"    ]. However, the traditional view of an impaired physician as a \"therapeutic addict\" self-medicating various ills and stress has been challenged [",
"    <a class=\"abstract\" href=\"UTD.htm?5/27/5562/abstract/7\">",
"     7",
"    </a>",
"    ]. With increasing use of recreational illicit substances in the general population, the contemporary physician is more likely to use drugs for their euphoria and more likely to have used multiple illicit substances than in the past [",
"    <a class=\"abstract\" href=\"UTD.htm?5/27/5562/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Family practice, emergency medicine and anesthesia physicians are overrepresented in data from PHP programs [",
"    <a class=\"abstract\" href=\"UTD.htm?5/27/5562/abstract/51,52\">",
"     51,52",
"    </a>",
"    ]. Emergency residents are more likely to admit to current use of cocaine and marijuana [",
"    <a class=\"abstract\" href=\"UTD.htm?5/27/5562/abstract/50\">",
"     50",
"    </a>",
"    ]. Female surgeons have a higher incidence of alcohol use than other female physicians [",
"    <a class=\"abstract\" href=\"UTD.htm?5/27/5562/abstract/53\">",
"     53",
"    </a>",
"    ]. Anesthesia has a particularly high incidence of substance abuse as reported by PHP programs, although this may in part reflect heightened drug vigilance and awareness for anesthesia programs and their directors (",
"    <a class=\"graphic graphic_table graphicRef71105 \" href=\"UTD.htm?12/55/13179\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?5/27/5562/abstract/54,55\">",
"     54,55",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H7\">",
"     'Anesthesia specialty'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Etiology",
"    </span>",
"    &nbsp;&mdash;&nbsp;Physicians share many of the predisposing factors to addiction with the general population, but there are also significant differences in presentation, history and consequences from impairment. Education, professional stature and responsibility do not lead to immunity to drug addiction. In fact, a physician's educational experience and familiarity with drugs may contribute to abuse because of overconfidence about use of drugs.",
"   </p>",
"   <p>",
"    Physicians have a higher incidence of prescription drug abuse than the general population, in part due to ready access and the common practice of self-treatment. The stress of being a physician has been postulated as a cause of substance abuse, but is not a consistent factor associated with physician SUD [",
"    <a class=\"abstract\" href=\"UTD.htm?5/27/5562/abstract/7\">",
"     7",
"    </a>",
"    ]. In one study of anesthesiologists, stress was not a factor associated with increased drug abuse [",
"    <a class=\"abstract\" href=\"UTD.htm?5/27/5562/abstract/56\">",
"     56",
"    </a>",
"    ]. In a survey of surgeons from 1978 till 2002, despite high job satisfaction, 32 percent had major health issues and 7 percent reported alcohol dependence [",
"    <a class=\"abstract\" href=\"UTD.htm?5/27/5562/abstract/57\">",
"     57",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The very factors which may predict success in a professional career (ie, strong drive for achievement, conscientiousness, and ability to deny personal problems) may make physicians more susceptible to mental health problems [",
"    <a class=\"abstract\" href=\"UTD.htm?5/27/5562/abstract/9\">",
"     9",
"    </a>",
"    ]. Additionally, training programs may be faulted for modeling behaviors that ultimately worsen a physician's health, and by promoting skills and attributes which interfere with a physician obtaining help and responding to treatment for mental health conditions (",
"    <a class=\"graphic graphic_table graphicRef74318 \" href=\"UTD.htm?31/48/32523\">",
"     table 2",
"    </a>",
"    ). Characterologic and behavioral changes that are cultivated from training may promote self medication, create barriers to seeking help, and may interfere with a physician's progress in treatment which requires honesty, open-mindedness and willingness.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Anesthesia specialty",
"    </span>",
"    &nbsp;&mdash;&nbsp;Anesthesia's over-representation has become the focus of recent study [",
"    <a class=\"abstract\" href=\"UTD.htm?5/27/5562/abstract/58\">",
"     58",
"    </a>",
"    ]. Many experts consider opioid abuse or dependence an 'occupational hazard' among anesthesiologists. Risk for relapse is relatively high, as is risk for accidental opioid overdose. Despite awareness of drug addiction in anesthesiology, the use of controlled substances has not significantly declined [",
"    <a class=\"abstract\" href=\"UTD.htm?5/27/5562/abstract/59\">",
"     59",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Anesthesiologists are more likely to abuse opioid drugs, and more likely to use drugs intravenously, than other medical specialties [",
"    <a class=\"abstract\" href=\"UTD.htm?5/27/5562/abstract/55\">",
"     55",
"    </a>",
"    ]. Drug abuse among anesthesiologists has been attributed to increased access to potent drugs There may also be those who enter the field because of the increased access to the most potent drugs.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/52/38730?source=see_link\">",
"     Fentanyl",
"    </a>",
"    is the controlled substance most often abused by anesthesiologists [",
"    <a class=\"abstract\" href=\"UTD.htm?5/27/5562/abstract/59\">",
"     59",
"    </a>",
"    ]. It is generally accepted that drugs that enter and exit the brain's reward system most rapidly, such as fentanyl, are the most addictive; simple experimentation can rapidly lead to addiction due to the highly euphorogenic nature of the drugs.",
"   </p>",
"   <p>",
"    It is also hypothesized that aerosol exposure to small amounts of addictive substances like",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/52/38730?source=see_link\">",
"     fentanyl",
"    </a>",
"    in the operating room may be a factor in setting the stage for future opioid abuse [",
"    <a class=\"abstract\" href=\"UTD.htm?5/27/5562/abstract/56-58\">",
"     56-58",
"    </a>",
"    ]. Fentanyl and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/25/17816?source=see_link\">",
"     propofol",
"    </a>",
"    can be detected in operating room air in a bioactive form, raising the possibility of skin exposure and absorption [",
"    <a class=\"abstract\" href=\"UTD.htm?5/27/5562/abstract/60\">",
"     60",
"    </a>",
"    ]. It has also been suggested that second hand exposure to operating room gases may lead to unintended neuronal sensitization, and an increased risk for developing addiction [",
"    <a class=\"abstract\" href=\"UTD.htm?5/27/5562/abstract/61\">",
"     61",
"    </a>",
"    ]. Second hand exposure may also be a factor in relapse of previously addicted anesthesiologists. The issue of second hand fentanyl inhalation should be considered in recommendations for addicted physicians returning to the operating room, and a need for evaluating the anesthesiologists work habits and work environment.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Physician health, depression and suicide",
"    </span>",
"    &nbsp;&mdash;&nbsp;Mental health issues are as common among physicians as in the general population, and may occur as isolated problems, or coexistent with a substance use disorder [",
"    <a class=\"abstract\" href=\"UTD.htm?5/27/5562/abstract/34\">",
"     34",
"    </a>",
"    ]. The prevalence of psychiatric comorbidity (substance abuse and mental health disorder) may be increasing among physicians, comparing data from the 1980s with the 1990s [",
"    <a class=\"abstract\" href=\"UTD.htm?5/27/5562/abstract/11\">",
"     11",
"    </a>",
"    ]. It is speculated that physicians entering treatment may be more impaired in recent years, similar to trends seen in treatment centers for the general population.",
"   </p>",
"   <p>",
"    Mental health problems frequently begin prior to medical training. In one study, greater than 30 percent of physicians had preexisting mental health or substance use disorders prior to their professional career [",
"    <a class=\"abstract\" href=\"UTD.htm?5/27/5562/abstract/62\">",
"     62",
"    </a>",
"    ]. Mental health may worsen during training [",
"    <a class=\"abstract\" href=\"UTD.htm?5/27/5562/abstract/63\">",
"     63",
"    </a>",
"    ]. Almost 50 percent of medical students reported \"burnout\" due to school stresses and personal life circumstances [",
"    <a class=\"abstract\" href=\"UTD.htm?5/27/5562/abstract/64\">",
"     64",
"    </a>",
"    ]. A review of 40 studies revealed that medical students were likely to have higher levels of depression and anxiety than the general population [",
"    <a class=\"abstract\" href=\"UTD.htm?5/27/5562/abstract/65\">",
"     65",
"    </a>",
"    ]. This distress may lead to self medication, substance abuse, poor relationships, and suicide [",
"    <a class=\"abstract\" href=\"UTD.htm?5/27/5562/abstract/63\">",
"     63",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Suicide rates among physicians are 40 percent higher in males and 130 percent higher in females than age-matched peers in the general population [",
"    <a class=\"abstract\" href=\"UTD.htm?5/27/5562/abstract/66,67\">",
"     66,67",
"    </a>",
"    ]. Although physicians enjoy lower all-cause mortality rates, physicians are more likely to die from cerebrovascular disease, accidents, and suicide than age-matched cohorts [",
"    <a class=\"abstract\" href=\"UTD.htm?5/27/5562/abstract/68,69\">",
"     68,69",
"    </a>",
"    ]. Among physicians, anesthesiologists have higher rates of suicide [",
"    <a class=\"abstract\" href=\"UTD.htm?5/27/5562/abstract/70-72\">",
"     70-72",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Doctors who attempt suicide are more likely to succeed than non physicians, which contributes to the increased suicide rate [",
"    <a class=\"abstract\" href=\"UTD.htm?5/27/5562/abstract/66\">",
"     66",
"    </a>",
"    ]. However, suicides among physicians may also be underreported, as suicides may be \"generously\" reported as accidents by pathologist or medical examiner colleagues or erroneously reported as accidental poisonings or drug-related deaths.",
"   </p>",
"   <p>",
"    Physician suicides have been directly connected with drug abuse [",
"    <a class=\"abstract\" href=\"UTD.htm?5/27/5562/abstract/73\">",
"     73",
"    </a>",
"    ]. Risk factors for women physicians who attempt suicide include smoking, alcohol abuse, sexual abuse, domestic violence or harassment, chronic fatigue syndrome or an eating disorder, a family history of psychiatric disorders, and being single or childless [",
"    <a class=\"abstract\" href=\"UTD.htm?5/27/5562/abstract/74\">",
"     74",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     IDENTIFICATION OF THE IMPAIRED PHYSICIAN",
"    </span>",
"    &nbsp;&mdash;&nbsp;Features of addiction or mental illness in physicians are the same as in the general population, though physicians may be more skilled at \"covering up.\" Alcohol dependence may exist for more than 15 years before progression of the illness leads to a point where the user or associates recognize need for treatment. In contrast, drugs such as IV",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/52/38730?source=see_link\">",
"     fentanyl",
"    </a>",
"    may cause substantial consequences that require intervention within a few months to one year.",
"   </p>",
"   <p>",
"    Addiction is a progressive disease. The earliest symptom of addiction is discord in a primary relationship. Isolation and avoidance of peers and friends is common. The impaired physician suffers emotionally and may exhibit signs of depression, irritability, mood swings, inappropriate levels of response, and disillusionment. The risk of suicide becomes real.",
"   </p>",
"   <p>",
"    Physicians are adept at being able to \"suit up\" and even a significantly depressed physician will likely minimize symptoms. Denial is the most notable symptom in persons with addiction. The physical examination in impaired physicians is most often normal, although there may be evidence of intoxication or withdrawal.",
"   </p>",
"   <p>",
"    With progression of the addiction or other mental health issue, there is an increasing impact on social life, health and finances. Excessive spending is common, perhaps as a means to self-medicate. Legal issues may ensue, such as arrests, domestic abuse, and charges of driving while under the influence (DUI) [",
"    <a class=\"abstract\" href=\"UTD.htm?5/27/5562/abstract/75\">",
"     75",
"    </a>",
"    ]. Spiritual problems exist although are seldom identified. Addicted physicians engage in actions contrary to their values. Shame is always present and a pervasive pessimism arises.",
"   </p>",
"   <p>",
"    Clinical performance is usually the last thing to be impacted, but eventually, the impaired clinician loses the ability to maintain pretenses. By the time there is evidence of work related impairment, the illness is severe and warrants prompt action on the part of concerned persons.",
"   </p>",
"   <p>",
"    Colleagues must play the primary role in identification of the impaired physician. Reports to physician health programs may come from many sources, including patients, families, hospital staff, coworkers, peers and the legal system. Many states allow for anonymous reporting of physicians. Nearly all states have legal requirements that physicians report impaired colleagues to Boards of Medicine or PHPs [",
"    <a class=\"abstract\" href=\"UTD.htm?5/27/5562/abstract/76\">",
"     76",
"    </a>",
"    ]. A large majority of physicians responding to a national survey indicated they would report (or have reported) another healthcare professional for impairment [",
"    <a class=\"abstract\" href=\"UTD.htm?5/27/5562/abstract/77\">",
"     77",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Colleagues who suspect impairment in a physician should not attempt to establish or confirm a diagnosis, which should be left to the professional evaluator. Rather, it is important to note and document the behaviors and events suggestive of impairment (",
"    <a class=\"graphic graphic_table graphicRef65813 \" href=\"UTD.htm?38/53/39773\">",
"     table 3",
"    </a>",
"    ). Those involved (colleagues, administrators, and family members) should record details of aberrant behaviors, performance deficiencies, and psychosocial problems. Vague or generalized assertions about problems should be avoided. First hand observations are the most powerful.",
"   </p>",
"   <p>",
"    Routine drug testing of physicians is a controversial issue resisted by many medical organizations. Mandatory testing is performed in other professions where public safety is an issue, such as transportation. Consideration of random drug testing in the medical profession, with initial attention to the high risk fields of anesthesiology, surgery and emergency medicine, has been suggested by some experts in the field [",
"    <a class=\"abstract\" href=\"UTD.htm?5/27/5562/abstract/78\">",
"     78",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Barriers to getting help",
"    </span>",
"    &nbsp;&mdash;&nbsp;Multiple barriers related to the profession of medicine impede impaired clinicians from recognizing need for help or being referred for help:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Doctors are trained and conditioned to be self-reliant and self-sufficient, and are subsequently more likely to self treat than the general population [",
"      <a class=\"abstract\" href=\"UTD.htm?5/27/5562/abstract/40\">",
"       40",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The ability to perform under great stress and with great personal difficulties is a hallmark of the profession. Physicians have difficulty admitting their impairment and often perceive that they are still providing excellent medical care.",
"     </li>",
"     <li>",
"      Physicians often have sophisticated denial with elaborate justification and rationalization, making intervention more difficult. When confronted, they may deny any impairment or insist that too much is being made of it. Bargaining is often attempted.",
"     </li>",
"     <li>",
"      Gender prejudices impact women substance users, and female physicians do not appear to be referred for treatment as frequently as male physicians [",
"      <a class=\"abstract\" href=\"UTD.htm?5/27/5562/abstract/79,80\">",
"       79,80",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Reporting an impaired colleague and friend is difficult [",
"      <a class=\"abstract\" href=\"UTD.htm?5/27/5562/abstract/77\">",
"       77",
"      </a>",
"      ]. The desire to avoid confrontation and a fear that one is doing serious damage to the physician's career and reputation are strong barriers.",
"     </li>",
"     <li>",
"      Families and friends become enablers. An enabler is someone who by action or omission shields the impaired person from consequences resulting in the continuation of the abnormal behaviors.",
"     </li>",
"     <li>",
"      Concerned colleagues may engage in their own form of denial or \"conspiracy of silence\" and avoid the issue until the problem can no longer be ignored or denied. It is human nature to be an enabler, often under the guise of giving the person a second chance or soothing them.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The perceived",
"    <span class=\"nowrap\">",
"     risk/benefit",
"    </span>",
"    of intervening on a fellow physician influences referral for treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?5/27/5562/abstract/81\">",
"     81",
"    </a>",
"    ]. When a physician is finally admitted to treatment, it is not uncommon to find that colleagues had known something was wrong for many months prior to admission.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     The family",
"    </span>",
"    &nbsp;&mdash;&nbsp;The family of the impaired physician is always affected. The relationship that develops between the physician and the drug supersedes the primary relationships with spouse, children and parents, making it difficult to demonstrate love and concern for family members. Family emotional and physical health is compromised.",
"   </p>",
"   <p>",
"    In addition to emotional turmoil, the family is often left to fend for itself dealing with day to day stressors, financial issues, and shame. Children of addicted parents have significant psychosocial issues including a predilection for drug abuse [",
"    <a class=\"abstract\" href=\"UTD.htm?5/27/5562/abstract/82\">",
"     82",
"    </a>",
"    ]. Aggressive family intervention and treatment may help prevent further morbidity [",
"    <a class=\"abstract\" href=\"UTD.htm?5/27/5562/abstract/16\">",
"     16",
"    </a>",
"    ]. Most programs for impaired physicians have programs for the family and children that focus on education about the disease of addiction, family dynamics of addiction, and encourage family participation in recovery programs such as the 12-step Alanon program.",
"   </p>",
"   <p>",
"    Families are often reluctant to harm the impaired physician",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    fear potential loss for themselves. The na&iuml;ve evaluator, in obtaining collateral information, must be careful about the reliability of information from families that purport that everything is okay.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     INTERVENTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The essential element necessary to address the problem of the impaired clinician is a person with expertise in dealing with impaired clinicians. The classic approach for impaired healthcare professionals involves a formal intervention, as discussed below. Impaired physicians tend to hide their abuse and addictions, and therefore go undetected until their addictions are quite advanced.",
"   </p>",
"   <p>",
"    However, in certain circumstances, where the impairment is not associated with high denial and does not directly threaten judgment or patient care (ie, an isolated incidence of driving under the influence after a weekend party), less coercive techniques such as motivational enhancement or brief intervention may be appropriate.",
"   </p>",
"   <p>",
"    Intervention is the process of presenting facts to the addict about his or her behavior in a way that lessens denial and encourages entering into a program for diagnosis and treatment. The aim is to get the physician to agree to voluntarily enter a residential treatment program. Intervention can be particularly effective in physicians because of the potential threat of loss of licensure and professional career.",
"   </p>",
"   <p>",
"    Numerous studies support that coercion can have effective outcomes [",
"    <a class=\"abstract\" href=\"UTD.htm?5/27/5562/abstract/79,83,84\">",
"     79,83,84",
"    </a>",
"    ]. This is commonly referred to as artificially raising the \"bottom\" and serves to force the addict to accept help before hitting the ultimate bottom and losing everything: family, friends, occupation, possessions and finances, and possibly life or freedom. There are no studies of suicidality among physicians who have received intervention, but the interventionist needs to be aware of the potential for physician self harm.",
"   </p>",
"   <p>",
"    Successful intervention requires careful preparation and a leader, a person familiar with intervening for professionals. The interventionist should expect resistance, anger and possible threats of legal action. Denial affects all persons involved in the intervention and the intervention can readily fail without experienced leadership.",
"   </p>",
"   <p>",
"    The intervention team may include recovering physicians as well as peers and family members [",
"    <a class=\"abstract\" href=\"UTD.htm?5/27/5562/abstract/83\">",
"     83",
"    </a>",
"    ]. Mornings may be the best time to schedule the intervention, when there is the least likelihood of physician intoxication.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Guide for intervention",
"    </span>",
"    &nbsp;&mdash;&nbsp;Initiating an intervention is emotionally stressful for the referring clinician. Recognizing a number of caveats and issues related to the intervention can be helpful in addressing this stress (",
"    <a class=\"graphic graphic_table graphicRef72133 \" href=\"UTD.htm?7/51/7995\">",
"     table 4",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    A prescribed approach for intervention, with involvement of the state PHP when available, is recommended [",
"    <a class=\"abstract\" href=\"UTD.htm?5/27/5562/abstract/82\">",
"     82",
"    </a>",
"    ]. Components of this approach include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Avoid confronting the physician alone. Ask several others, including colleagues, staff, administrators, family, and PHP professionals, to participate. Make certain that they recognize the need for the intervention, and support the plan of action. One enabling or ambivalent person at an intervention can sabotage the process.",
"     </li>",
"     <li>",
"      Express positive regard for",
"      <span class=\"nowrap\">",
"       his/her",
"      </span>",
"      abilities.",
"     </li>",
"     <li>",
"      Describe specific observable problem behaviors and incidents that have led to the need for the intervention (a script is helpful).",
"     </li>",
"     <li>",
"      Avoid accusation or blame.",
"     </li>",
"     <li>",
"      Avoid arguing or negotiating; be kind and empathic.",
"     </li>",
"     <li>",
"      Have a specific plan of action which includes a setting for professional assessment and treatment, ideally one endorsed by the state's PHP.",
"     </li>",
"     <li>",
"      Clearly indicate the consequences of not following through with the plan of action. Involvement with a PHP may be helpful in providing the \"hammer\" to coerce follow through.",
"     </li>",
"     <li>",
"      Insist upon immediate action.",
"     </li>",
"     <li>",
"      Provide for safe transition and transportation to the next step in the plan, which is often a professional assessment program.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     ASSESSMENT AND TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The organizing principle in treating impaired health providers is to evaluate and treat them like other patients. At the same time, it is important to consider issues specific to healthcare practitioners such as consideration for the safety of patients, and the proximity to drugs as well as the clinician&rsquo;s ability to practice with reasonable skills and safety upon returning to practice. Inadequate assessment or treatment can have significant consequences for the clinician and the clinician's family, and can result in potential patient endangerment.",
"   </p>",
"   <p>",
"    Following intervention, the physician patient is best evaluated by an addiction specialist with expertise in the assessment and treatment of healthcare professionals [84]. Often, assessment and treatment need to be done outside of their own medical community to avoid issues of transference [85] and enabling that could cloud the judgment of peers and create professional conflicts.&nbsp;An exception may be indicated when the treating physician both has expertise in treating the impaired physician and has no collegial relationship with the patient.&nbsp; Psychiatric assessment including psychological testing and neurocognitive testing as well as appropriate pharmacotherapy and",
"    <span class=\"nowrap\">",
"     /or",
"    </span>",
"    counseling are imperative.&nbsp;Neurocognitive assessment also needs to consider that the premorbid intellectual scores are often in the superior range when interpreting impairment.",
"   </p>",
"   <p>",
"    If the patient is in withdrawal, inpatient detoxification may be necessary. Detoxification alone does not change long-term outcome and is insufficient by itself in the management of substance abuse disorders. Detoxification does not address triggers for relapse, reinforcing factors, cravings or post acute withdrawal symptoms, nor does it address comorbid psychiatric issues.",
"   </p>",
"   <p>",
"    Treatment often begins in a structured setting to remove the addict from the environmental triggers associated with drug abuse, and to establish rapport with treatment providers. Physicians have traditionally participated in abstinence-oriented treatment. As an example, maintenance treatment with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/57/36761?source=see_link\">",
"     methadone",
"    </a>",
"    is rare for opioid-addicted physicians.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/53/41816?source=see_link\">",
"     Buprenorphine",
"    </a>",
"    is used more frequently, but abstinence remains the primary end point of treatment.",
"   </p>",
"   <p>",
"    One illustrative model for treatment is the Impaired Professionals Program at the University of Florida College of Medicine. Components of this program include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Initial assessment to determine level of care. Available levels of care include residential, partial hospitalization and intensive outpatient (IOP). ASAM guidelines can help in this determination [",
"      <a class=\"abstract\" href=\"UTD.htm?5/27/5562/abstract/85\">",
"       85",
"      </a>",
"      ], though physicians have typically been more aggressively treated for longer periods of time than the general population. Length of treatment is variable, but for physicians it may last three to six months, depending on treatment response.",
"     </li>",
"     <li>",
"      A team consisting of addiction medicine specialists, psychiatrists, counselors, nurses and psychologists guides treatment modalities, length of treatment and level of care.",
"     </li>",
"     <li>",
"      The impaired physician enters a community of other recovering professionals. Having peers in treatment provides tremendous benefit in reducing shame, and reassuring mutual respect of confidentiality issues which can interfere with self disclosure in group settings [",
"      <a class=\"abstract\" href=\"UTD.htm?5/27/5562/abstract/86\">",
"       86",
"      </a>",
"      ]. Further, having other professionals in treatment helps prevent physicians in treatment from taking a professional rather than a patient role with their peers.",
"     </li>",
"     <li>",
"      Mentoring and support by other physicians who have long term sobriety, and provide encouragement, hope, and a model of essential behaviors and attitudes for life in recovery. A \"professionals meeting\" is conducted regularly, which includes professionals living in the area that have successfully completed treatment and returned to work.",
"     </li>",
"     <li>",
"      Treatment usually involves group and individual therapy, educational lectures and family therapy. Specialized family programs are considered essential elements of a strong professional treatment program. Group dynamics provide a powerful means to confront denial. Physicians learn to identify and express emotions and learn from others in the group. Feedback is encouraged.",
"     </li>",
"     <li>",
"      Psychiatric assessment and appropriate psychiatric pharmacotherapy",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      counseling is imperative. The prevalence of comorbid psychiatric conditions in physicians is high [",
"      <a class=\"abstract\" href=\"UTD.htm?5/27/5562/abstract/11,34,74,87\">",
"       11,34,74,87",
"      </a>",
"      ], with estimates from 25 to 75 percent.",
"     </li>",
"     <li>",
"      The program provides a range of therapeutic interventions including cognitive behavioral and insight oriented therapies, but is rooted in principles of 12-step recovery programs. Early engagement of participants in Alcoholics Anonymous and Narcotics Anonymous assists in the development of a future support network. Multiple studies have addressed the benefits and most conclude an overwhelming benefit of programs like Alcoholics Anonymous in promoting sobriety [",
"      <a class=\"abstract\" href=\"UTD.htm?5/27/5562/abstract/5,88-92\">",
"       5,88-92",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Drugs such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/22/1381?source=see_link\">",
"     acamprosate",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?5/27/5562/abstract/93-95\">",
"     93-95",
"    </a>",
"    ] and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/16/39173?source=see_link\">",
"     naltrexone",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?5/27/5562/abstract/96\">",
"     96",
"    </a>",
"    ] may have benefit in the alcohol dependent physician, although their effect may be difficult to detect given the greater than 80 percent abstinence rate reported by impaired professional programs in the US [",
"    <a class=\"abstract\" href=\"UTD.htm?5/27/5562/abstract/97\">",
"     97",
"    </a>",
"    ]. Naltrexone may also have an important role for the opioid dependent physician and was actually first approved on the basis of efficacy demonstrated in physicians [",
"    <a class=\"abstract\" href=\"UTD.htm?5/27/5562/abstract/98\">",
"     98",
"    </a>",
"    ]. Maintenance with naltrexone may be of particular importance for anesthesiologists, because of their risks for relapse and documentation of aerosolized opioids in the operating rooms [",
"    <a class=\"abstract\" href=\"UTD.htm?5/27/5562/abstract/58\">",
"     58",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/52/29514?source=see_link\">",
"     \"Treatment of opioid abuse and dependence\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/48/19209?source=see_link\">",
"     \"Pharmacotherapy for alcohol abuse and dependence\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24244203\">",
"    <span class=\"h2\">",
"     Physician health programs",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment for physicians with substance use disorders is coordinated by state Physician Health Programs (PHP) in the US. Treatment typically features intensive&nbsp;clinical management combined with professional support and frequent random drug testing for five or more years",
"   </p>",
"   <p>",
"    PHP programs in some states are directly linked to the Boards of Medicine, while others operate independently and can maintain physician anonymity. The direct link of some PHPs to their respective state's agencies may result in a punitive policy, where the first action of the Board of Medicine is the immediate suspension of the physician's medical license followed by other sanctions. Moreover, anonymity may not be preserved.",
"   </p>",
"   <p>",
"    Although the general public may feel that the punitive approach provides the best protection against being treated by an impaired physician, in actuality this approach may result in less desirable outcomes.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Treatment and prevention are critical to maintaining patient safety [",
"      <a class=\"abstract\" href=\"UTD.htm?5/27/5562/abstract/14\">",
"       14",
"      </a>",
"      ]. Colleagues are more reluctant to report a doctor they suspect has a problem if there will be immediate and severe consequences.",
"     </li>",
"     <li>",
"      The addicted physician may go underground and seek treatment not designed for treating professionals, resulting in suboptimal treatment.",
"     </li>",
"     <li>",
"      Addicted physicians at risk of punitive action are more likely to maintain denial and to resort to legal action than to accept help and begin recovery.",
"     </li>",
"     <li>",
"      Patient safety is further jeopardized because the addict stays in practice longer, often until health disintegrates to incapacitation, they commit suicide or die of complications, or are involved in serious legal or malpractice issues.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The typical and optimal PHP forces the impaired physician to engage into a sophisticated assessment and treatment program, and works with the Board of Medicine so that the physician cannot return to practice until skill and safety can be assured. Failure to comply with the PHP recommendations results in the physician being turned over to the Board or state licensure agency, in which the case might become public.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Risk factors for relapse",
"    </span>",
"    &nbsp;&mdash;&nbsp;A study from the Washington Physicians Health Program found that risk for relapse was associated with [",
"    <a class=\"abstract\" href=\"UTD.htm?5/27/5562/abstract/99\">",
"     99",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Potent opioid use (including",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/52/38730?source=see_link\">",
"       fentanyl",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?14/47/15094?source=see_link\">",
"       sufentanil",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?19/31/19962?source=see_link\">",
"       morphine",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?11/44/11976?source=see_link\">",
"       meperidine",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Coexisting psychiatric disorders",
"     </li>",
"     <li>",
"      Family history of addiction.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The use of multiple drugs in healthcare professionals has also been associated with failed treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?5/27/5562/abstract/100\">",
"     100",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Positive prognosticators include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Involvement or strong sense of affiliation with Alcoholics Anonymous [",
"      <a class=\"abstract\" href=\"UTD.htm?5/27/5562/abstract/37,88,101,102\">",
"       37,88,101,102",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Acceptance of addiction as a disease",
"     </li>",
"     <li>",
"      Ability to be honest",
"     </li>",
"     <li>",
"      Acceptance of spiritual principles [",
"      <a class=\"abstract\" href=\"UTD.htm?5/27/5562/abstract/101\">",
"       101",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Alcoholics Anonymous and other 12 step recovery programs can help secure a stable recovery [",
"    <a class=\"abstract\" href=\"UTD.htm?5/27/5562/abstract/89,90,92,103\">",
"     89,90,92,103",
"    </a>",
"    ], and provide a support network [",
"    <a class=\"abstract\" href=\"UTD.htm?5/27/5562/abstract/102\">",
"     102",
"    </a>",
"    ]. However, referral to 12 step programs should be in addition to, and not a replacement for, intensive treatment modalities [",
"    <a class=\"abstract\" href=\"UTD.htm?5/27/5562/abstract/104\">",
"     104",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Return to work",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment programs must assess the ability of the recovering physician to return to work and practice medicine with \"reasonable skill and safety\" (Florida Statutes). Generally, this requires an assessment of their recovery quality and durability, and the risk for relapse. Comorbid psychiatric conditions must also be assessed.",
"   </p>",
"   <p>",
"    Performance issues related to physical or mental conditions may require specific assessments and interventions, including neuropsychological testing and neurological consultation. A few programs in the US are capable of a detailed assessment of performance and competency in a given specialty, including determination of a physician's knowledge base and clinical skills.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     LONG TERM MONITORING",
"    </span>",
"    &nbsp;&mdash;&nbsp;Following successful completion of treatment, physicians enter into a contract with the PHP outlining conditions for return to practice. Although the treated physician may balk at this, many experts feel the contract, including randomized drug testing and important consequences of violations, is an important component of the overall better prognosis for physicians.",
"   </p>",
"   <p>",
"    Length of the contract terms vary between states, typically ranging from two to five years. Contracts often include the following requirements:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Avoidance of all mood altering drugs, including over the counter drugs that can cause stimulation or sedation",
"     </li>",
"     <li>",
"      Random drug testing. Tests are often weekly, but testing frequency may depend on drug(s) utilized. In many states, physicians are required to call a specific phone number regularly to be given information on when the next test will be performed. The drug screens must include the drugs most likely abused by the physician, and are usually specially designed panels. Hair testing is also done. Testing frequency can decline through the years of the contract, provided tests are not positive.",
"     </li>",
"     <li>",
"      The PHP program utilizes qualified practitioners to assess positive tests often in lieu of a Medical Review Officer. Medical Review Officers are trained to report tests negative if a legitimate prescription for a controlled substance is presented. However, when dealing with recovering physicians, it is important to consider any positive test an issue that needs to be scrutinized by the PHP. Confirmed positive tests are regarded as serious violations prompting immediate evaluation. Sometimes permission to practice may be revoked.",
"     </li>",
"     <li>",
"      Participation in weekly monitored group sessions with other physicians under contract, facilitated by an addictions counselor who reports directly back to the PHP. This allows for direct observation of a physician's behavior. Attendance is rarely excused; failure to attend is a serious violation and may trigger on the spot drug test and re-evaluation.",
"     </li>",
"     <li>",
"      Attendance in a weekly professional group, such as Caduceus or IDAA (International Doctors in Alcoholics Anonymous), is encouraged. The structure and format of these groups varies, from traditional 12 step philosophy, to counselor facilitated groups, or simple peer support and open sharing.",
"     </li>",
"     <li>",
"      Attendance at Alcoholics Anonymous or Narcotics Anonymous is required or strongly encouraged.",
"     </li>",
"     <li>",
"      Work or practice monitoring may be required, if ordered by the Board of Medicine or as part of a specific treatment recommendation. This could include monitoring of prescriptions for controlled substances.",
"     </li>",
"     <li>",
"      Professional follow-up with an addiction specialist.",
"     </li>",
"     <li>",
"      Individual",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      family therapy as indicated",
"     </li>",
"     <li>",
"      Psychiatric follow-up as indicated for medication management",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      therapy.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     TREATMENT OUTCOMES",
"    </span>",
"    &nbsp;&mdash;&nbsp;In general, the prognosis for physicians treated for substance abuse disorders is better than the general population [",
"    <a class=\"abstract\" href=\"UTD.htm?5/27/5562/abstract/5,8,51,97,105-107\">",
"     5,8,51,97,105-107",
"    </a>",
"    ] and physicians are more likely than the general population to return to a productive life [",
"    <a class=\"abstract\" href=\"UTD.htm?5/27/5562/abstract/9\">",
"     9",
"    </a>",
"    ]. The need to make certain that the physician is safe to practice with reasonable skill and safety, necessitating longer and more intensive treatment than the general population, is assumed to lead to this better prognosis.",
"   </p>",
"   <p>",
"    PHPs report high rates of professionals returning to work safely in multiple studies [",
"    <a class=\"abstract\" href=\"UTD.htm?5/27/5562/abstract/8,107,108\">",
"     8,107,108",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    As an example, a retrospective study of 904 participants in 16 state PHPs found an overall return to work rate of 79 percent over five years [",
"    <a class=\"abstract\" href=\"UTD.htm?5/27/5562/abstract/97\">",
"     97",
"    </a>",
"    ]. The study reviewed five years of chart and urine testing records of 904 physicians consecutively admitted to the PHPs. After five years:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      81 percent of the 802 physicians in the sample with known outcomes completed a contracted period of treatment and supervision",
"     </li>",
"     <li>",
"      79 percent of the 802 physicians were licensed without restriction and practicing medicine or working in a non-clinical capacity",
"     </li>",
"     <li>",
"      19 percent of physicians who completed treatment and resumed practicing had a toxicology test indicating alcohol or drug misuse",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Only 20 percent of physicians with a positive test had more than one such test result",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      15 percent of physicians were no longer practicing",
"     </li>",
"     <li>",
"      11 percent of physicians lost their medical license",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Elements common to PHP programs that may facilitate the maintenance of long term recovery of physicians include [",
"    <a class=\"abstract\" href=\"UTD.htm?5/27/5562/abstract/109\">",
"     109",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Contingency contracts &mdash; These agreements require physicians to follow through with the PHP requirements. In return for their compliance, the physician receives PHP advocacy for their return to work. However, there are immediate consequences for the physician who fails to comply",
"     </li>",
"     <li>",
"      Frequent drug testing",
"     </li>",
"     <li>",
"      Tight linkage with 12 step recovery programs and adherence to abstinence",
"     </li>",
"     <li>",
"      Active management of relapses, with modification of treatment and contract",
"     </li>",
"     <li>",
"      A strong continuing care approach",
"     </li>",
"     <li>",
"      A focus on life-time recovery rather than brief treatment and aftercare",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Prognosis for physicians with alcohol problems is thought to be more favorable than those physicians using the more potent opioids. Physicians who did not return to work were more likely to be anesthesiologists, and more likely to use opioids and intravenous drugs [",
"    <a class=\"abstract\" href=\"UTD.htm?5/27/5562/abstract/6\">",
"     6",
"    </a>",
"    ]. These outcomes data may underestimate the relapse rate of physicians, and depend on drug screens as measures of abstinence, and data from PHP programs [",
"    <a class=\"abstract\" href=\"UTD.htm?5/27/5562/abstract/107\">",
"     107",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Data from anesthesiology residency programs are less favorable than for overall physician composite data.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In one survey of 159 anesthesiology training programs, 34 percent of opioid users, and 70 percent of nonopioid abusers, were able to successfully return to anesthesia [",
"      <a class=\"abstract\" href=\"UTD.htm?5/27/5562/abstract/110\">",
"       110",
"      </a>",
"      ]. There were 14 cases of suicide or lethal overdose among those allowed to return to anesthesia training; death was the initial indicator of relapse in 16 percent of the cases.",
"     </li>",
"     <li>",
"      Nineteen percent of anesthesia residency training programs reported having at least one pretreatment fatality in another survey [",
"      <a class=\"abstract\" href=\"UTD.htm?5/27/5562/abstract/3\">",
"       3",
"      </a>",
"      ]. Among treated residents, 46 percent successfully completed residency in anesthesiology and 40 percent trained in another specialty; the mortality rate for the remaining anesthesiology residents was 9 percent.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Reports from PHP programs generally present a more favorable outcome, possibly reflecting those anesthesiologists who were referred to professional treatment programs and monitored more closely. Nevertheless, the surveys are disconcerting and might support consideration for a change in medical specialties for anesthesia residents addicted to opioids [",
"    <a class=\"abstract\" href=\"UTD.htm?5/27/5562/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H547823849\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Healthcare provider impairment refers to the inability to practice according to accepted standards as a result of substance use, abuse, or dependency, as well as impairment related to mental or physical illness. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Definition of impairment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Genetic, biomolecular, and pharmacogenetic studies support the concept of addiction as a disease. A therapeutic, rather than punitive, approach to clinicians with substance abuse promotes recognition and rehabilitation of the impaired clinician. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Addiction as a disease'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Alcohol is the most frequently abused drug among physicians, though physicians have higher rates of prescription drug abuse than non-physicians. Anesthesiologists have higher reported rates of drug use, particularly",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/52/38730?source=see_link\">",
"       fentanyl",
"      </a>",
"      , than other specialists. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Epidemiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Physicians are adept at masking their substance abuse problems, and clinical performance is usually the last thing to be impacted. Colleagues have a responsibility to identifying the impaired physicians, but should not be directly involved in diagnosis. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Identification of the impaired physician'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Intervention is the process of presenting facts about behavior to the impaired provider in a way that lessens denial and encourages them to enter a program for treatment. Successful intervention requires careful preparation and an experienced leader. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Intervention'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Treatment is best provided in a structured setting outside of the clinician's own medical community. Treatment usually involves abstinence, group therapy, psychiatric assessment, and 12-step programs. The prognosis for successful treatment of impaired providers is excellent. Most treated physicians return to practice and lead stable and productive lives. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Assessment and treatment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Following treatment, physicians are often required to enter into a long-term contingency contract as a condition of return to practice. Random drug testing and participation in ongoing treatment groups are mandated by the contract. (See",
"      <a class=\"local\" href=\"#H17\">",
"       'Long term monitoring'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/27/5562/abstract/1\">",
"      Desbiens NA, Panda M, Doshi N, Peterman J. Public perceptions of alcohol use by physicians. South Med J 2005; 98:5.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/27/5562/abstract/2\">",
"      Berge KH, Seppala MD, Schipper AM. Chemical dependency and the physician. Mayo Clin Proc 2009; 84:625.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/27/5562/abstract/3\">",
"      Collins GB, McAllister MS, Jensen M, Gooden TA. Chemical dependency treatment outcomes of residents in anesthesiology: results of a survey. Anesth Analg 2005; 101:1457.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/27/5562/abstract/4\">",
"      O'Connor PG, Spickard A Jr. Physician impairment by substance abuse. Med Clin North Am 1997; 81:1037.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/27/5562/abstract/5\">",
"      Gallegos KV, Lubin BH, Bowers C, et al. Relapse and recovery: five to ten year follow-up study of chemically dependent physicians--the Georgia experience. Md Med J 1992; 41:315.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/27/5562/abstract/6\">",
"      Hall, JD, Pomm, R, Frost-Pineda, K, Gold, MS. Treatment of alcohol dependent physicians: Impact of alcohol use during medical school. Biol Psychiatry 2002; 51:197S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/27/5562/abstract/7\">",
"      Kleber HD. The impaired physician: changes from the traditional view. J Subst Abuse Treat 1984; 1:137.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/27/5562/abstract/8\">",
"      Morse RM, Martin MA, Swenson WM, Niven RG. Prognosis of physicians treated for alcoholism and drug dependence. JAMA 1984; 251:743.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/27/5562/abstract/9\">",
"      Boisaubin EV, Levine RE. Identifying and assisting the impaired physician. Am J Med Sci 2001; 322:31.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/27/5562/abstract/10\">",
"      Broquet KE, Rockey PH. Teaching residents and program directors about physician impairment. Acad Psychiatry 2004; 28:221.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/27/5562/abstract/11\">",
"      Angres DH, McGovern MP, Shaw MF, Rawal P. Psychiatric comorbidity and physicians with substance use disorders: a comparison between the 1980s and 1990s. J Addict Dis 2003; 22:79.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/27/5562/abstract/12\">",
"      The sick physician. Impairment by psychiatric disorders, including alcoholism and drug dependence. JAMA 1973; 223:684.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/27/5562/abstract/13\">",
"      Center C, Davis M, Detre T, et al. Confronting depression and suicide in physicians: a consensus statement. JAMA 2003; 289:3161.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/27/5562/abstract/14\">",
"      Taub S, Morin K, Goldrich MS, et al. Physician health and wellness. Occup Med (Lond) 2006; 56:77.",
"     </a>",
"    </li>",
"    <li>",
"     The Federation of State Physicians Health Programs 1995.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/27/5562/abstract/16\">",
"      Baldisseri MR. Impaired healthcare professional. Crit Care Med 2007; 35:S106.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/27/5562/abstract/17\">",
"      McLellan AT, Lewis DC, O'Brien CP, Kleber HD. Drug dependence, a chronic medical illness: implications for treatment, insurance, and outcomes evaluation. JAMA 2000; 284:1689.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/27/5562/abstract/18\">",
"      Hyman SE. Addiction: a disease of learning and memory. Am J Psychiatry 2005; 162:1414.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/27/5562/abstract/19\">",
"      Morse RM, Flavin DK. The definition of alcoholism. The Joint Committee of the National Council on Alcoholism and Drug Dependence and the American Society of Addiction Medicine to Study the Definition and Criteria for the Diagnosis of Alcoholism. JAMA 1992; 268:1012.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/27/5562/abstract/20\">",
"      Baler RD, Volkow ND. Drug addiction: the neurobiology of disrupted self-control. Trends Mol Med 2006; 12:559.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/27/5562/abstract/21\">",
"      Volkow ND, Wang GJ, Telang F, et al. Cocaine cues and dopamine in dorsal striatum: mechanism of craving in cocaine addiction. J Neurosci 2006; 26:6583.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/27/5562/abstract/22\">",
"      Gatley SJ, Volkow ND, Wang GJ, et al. PET imaging in clinical drug abuse research. Curr Pharm Des 2005; 11:3203.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/27/5562/abstract/23\">",
"      Kalivas PW, Volkow ND. The neural basis of addiction: a pathology of motivation and choice. Am J Psychiatry 2005; 162:1403.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/27/5562/abstract/24\">",
"      Volkow ND, Li TK. Drug addiction: the neurobiology of behaviour gone awry. Nat Rev Neurosci 2004; 5:963.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/27/5562/abstract/25\">",
"      Volkow ND, Fowler JS, Wang GJ. The addicted human brain viewed in the light of imaging studies: brain circuits and treatment strategies. Neuropharmacology 2004; 47 Suppl 1:3.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/27/5562/abstract/26\">",
"      Volkow N. Drug dependence and addiction, III: Expectation and brain function in drug abuse. Am J Psychiatry 2004; 161:621.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/27/5562/abstract/27\">",
"      Little HJ, Stephens DN, Ripley TL, et al. Alcohol withdrawal and conditioning. Alcohol Clin Exp Res 2005; 29:453.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/27/5562/abstract/28\">",
"      Spanagel R. [The role of the glutamatergic system in alcohol addiction]. Fortschr Neurol Psychiatr 2003; 71 Suppl 1:S33.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/27/5562/abstract/29\">",
"      Patkar AA, Gopalakrishnan R, Naik PC, et al. Changes in plasma noradrenaline and serotonin levels and craving during alcohol withdrawal. Alcohol Alcohol 2003; 38:224.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/27/5562/abstract/30\">",
"      Heinz A, L&ouml;ber S, Georgi A, et al. Reward craving and withdrawal relief craving: assessment of different motivational pathways to alcohol intake. Alcohol Alcohol 2003; 38:35.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/27/5562/abstract/31\">",
"      Weiss F, Ciccocioppo R, Parsons LH, et al. Compulsive drug-seeking behavior and relapse. Neuroadaptation, stress, and conditioning factors. Ann N Y Acad Sci 2001; 937:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/27/5562/abstract/32\">",
"      Gualtieri AC, Cosentino JP, Becker JS. The California experience with the diversion program for impaired physicians. JAMA 1983; 249:226.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/27/5562/abstract/33\">",
"      Brewster JM. Prevalence of alcohol and other drug problems among physicians. JAMA 1986; 255:1913.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/27/5562/abstract/34\">",
"      McGovern MP, Angres DH, Leon S. Characteristics of physicians presenting for assessment at a behavioral health center. J Addict Dis 2000; 19:59.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/27/5562/abstract/35\">",
"      Brooke D. Why do some doctors become addicted? Addiction 1996; 91:317.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/27/5562/abstract/36\">",
"      Hughes PH, Storr CL, Brandenburg NA, et al. Physician substance use by medical specialty. J Addict Dis 1999; 18:23.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/27/5562/abstract/37\">",
"      Lloyd G. One hundred alcoholic doctors: a 21-year follow-up. Alcohol Alcohol 2002; 37:370.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/27/5562/abstract/38\">",
"      Schuckit MA. New findings in the genetics of alcoholism. JAMA 1999; 281:1875.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/27/5562/abstract/39\">",
"      Gastfriend DR. Physician substance abuse and recovery: what does it mean for physicians--and everyone else? JAMA 2005; 293:1513.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/27/5562/abstract/40\">",
"      Hughes PH, Brandenburg N, Baldwin DC Jr, et al. Prevalence of substance use among US physicians. JAMA 1992; 267:2333.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/27/5562/abstract/41\">",
"      Kenna GA, Wood MD. Alcohol use by healthcare professionals. Drug Alcohol Depend 2004; 75:107.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/27/5562/abstract/42\">",
"      Hughes PH, Storr C, Baldwin DC Jr, et al. Patterns of substance use in the medical profession. Md Med J 1992; 41:311.",
"     </a>",
"    </li>",
"    <li>",
"     Professional Resource Network, Florida PHP, participant survey December 2007, personal communication.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/27/5562/abstract/44\">",
"      Baldwin DC Jr, Hughes PH, Conard SE, et al. Substance use among senior medical students. A survey of 23 medical schools. JAMA 1991; 265:2074.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/27/5562/abstract/45\">",
"      Conard S, Hughes P, Baldwin DC Jr, et al. Substance use by fourth-year students at 13 U.S. medical schools. J Med Educ 1988; 63:747.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/27/5562/abstract/46\">",
"      Conard SE, Hughes P, Baldwin D, et al. Substance use and the resident physician: a national study. Res Med Educ 1988; 27:256.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/27/5562/abstract/47\">",
"      Newbury-Birch D, Walshaw D, Kamali F. Drink and drugs: from medical students to doctors. Drug Alcohol Depend 2001; 64:265.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/27/5562/abstract/48\">",
"      Schwartz RH, Lewis DC, Hoffmann NG, Kyriazi N. Cocaine and marijuana use by medical students before and during medical school. Arch Intern Med 1990; 150:883.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/27/5562/abstract/49\">",
"      Frank E, Elon L, Naimi T, Brewer R. Alcohol consumption and alcohol counselling behaviour among US medical students: cohort study. BMJ 2008; 337:a2155.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/27/5562/abstract/50\">",
"      Milling TJ. Drug and alcohol use in emergency medicine residency: an impaired resident's perspective. Ann Emerg Med 2005; 46:148.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/27/5562/abstract/51\">",
"      Winter RO, Birnberg B. Working with impaired residents: trials, tribulations, and successes. Fam Med 2002; 34:190.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/27/5562/abstract/52\">",
"      Talbott GD, Gallegos KV, Wilson PO, Porter TL. The Medical Association of Georgia's Impaired Physicians Program. Review of the first 1000 physicians: analysis of specialty. JAMA 1987; 257:2927.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/27/5562/abstract/53\">",
"      Rosta J, Aasland OG. Female surgeons' alcohol use: a study of a national sample of norwegian doctors. Alcohol Alcohol 2005; 40:436.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/27/5562/abstract/54\">",
"      Merlo LJ, Gold MS. Prescription opioid abuse and dependence among physicians: hypotheses and treatment. Harv Rev Psychiatry 2008; 16:181.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/27/5562/abstract/55\">",
"      Gallegos KV, Browne CH, Veit FW, Talbott GD. Addiction in anesthesiologists: drug access and patterns of substance abuse. QRB Qual Rev Bull 1988; 14:116.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/27/5562/abstract/56\">",
"      Lutsky I, Hopwood M, Abram SE, et al. Psychoactive substance use among American anesthesiologists: a 30-year retrospective study. Can J Anaesth 1993; 40:915.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/27/5562/abstract/57\">",
"      Harms BA, Heise CP, Gould JC, Starling JR. A 25-year single institution analysis of health, practice, and fate of general surgeons. Ann Surg 2005; 242:520.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/27/5562/abstract/58\">",
"      McAuliffe PF, Gold MS, Bajpai L, et al. Second-hand exposure to aerosolized intravenous anesthetics propofol and fentanyl may cause sensitization and subsequent opiate addiction among anesthesiologists and surgeons. Med Hypotheses 2006; 66:874.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/27/5562/abstract/59\">",
"      Booth JV, Grossman D, Moore J, et al. Substance abuse among physicians: a survey of academic anesthesiology programs. Anesth Analg 2002; 95:1024.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/27/5562/abstract/60\">",
"      Merlo LJ, Goldberger BA, Kolodner D, et al. Fentanyl and propofol exposure in the operating room: sensitization hypotheses and further data. J Addict Dis 2008; 27:67.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/27/5562/abstract/61\">",
"      Sv&auml;rdsudd K, Wedel H, Gordh T Jr. Mortality rates among Swedish physicians: a population-based nationwide study with special reference to anesthesiologists. Acta Anaesthesiol Scand 2002; 46:1187.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/27/5562/abstract/62\">",
"      Fletcher CE, Ronis DL. Satisfaction of impaired health care professionals with mandatory treatment and monitoring. J Addict Dis 2005; 24:61.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/27/5562/abstract/63\">",
"      Dyrbye LN, Thomas MR, Shanafelt TD. Medical student distress: causes, consequences, and proposed solutions. Mayo Clin Proc 2005; 80:1613.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/27/5562/abstract/64\">",
"      Dyrbye LN, Thomas MR, Huntington JL, et al. Personal life events and medical student burnout: a multicenter study. Acad Med 2006; 81:374.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/27/5562/abstract/65\">",
"      Dyrbye LN, Thomas MR, Shanafelt TD. Systematic review of depression, anxiety, and other indicators of psychological distress among U.S. and Canadian medical students. Acad Med 2006; 81:354.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/27/5562/abstract/66\">",
"      Schernhammer E. Taking their own lives -- the high rate of physician suicide. N Engl J Med 2005; 352:2473.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/27/5562/abstract/67\">",
"      Schernhammer ES, Colditz GA. Suicide rates among physicians: a quantitative and gender assessment (meta-analysis). Am J Psychiatry 2004; 161:2295.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/27/5562/abstract/68\">",
"      Frank E, Biola H, Burnett CA. Mortality rates and causes among U.S. physicians. Am J Prev Med 2000; 19:155.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/27/5562/abstract/69\">",
"      Torre DM, Wang NY, Meoni LA, et al. Suicide compared to other causes of mortality in physicians. Suicide Life Threat Behav 2005; 35:146.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/27/5562/abstract/70\">",
"      Alexander BH, Checkoway H, Nagahama SI, Domino KB. Cause-specific mortality risks of anesthesiologists. Anesthesiology 2000; 93:922.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/27/5562/abstract/71\">",
"      Carpenter LM, Swerdlow AJ, Fear NT. Mortality of doctors in different specialties: findings from a cohort of 20000 NHS hospital consultants. Occup Environ Med 1997; 54:388.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/27/5562/abstract/72\">",
"      Lew EA. Mortality experience among anesthesiologists, 1954-1976. Anesthesiology 1979; 51:195.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/27/5562/abstract/73\">",
"      Roy A. Suicide in doctors. Psychiatr Clin North Am 1985; 8:377.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/27/5562/abstract/74\">",
"      Frank E, Dingle AD. Self-reported depression and suicide attempts among U.S. women physicians. Am J Psychiatry 1999; 156:1887.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/27/5562/abstract/75\">",
"      Eells MA. Interventions with alcoholics and their families. Nurs Clin North Am 1986; 21:493.",
"     </a>",
"    </li>",
"    <li>",
"     American Medical Association. Council on Ethical and Judicial Affairs, Reporting impaired, incompetent or unethical colleagues, American Medical Association, Chicago 1992. p.28.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/27/5562/abstract/77\">",
"      Farber NJ, Gilibert SG, Aboff BM, et al. Physicians' willingness to report impaired colleagues. Soc Sci Med 2005; 61:1772.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/27/5562/abstract/78\">",
"      Gold MS, Frost-Pineda K. Problem doctors: is there a system-level solution? Ann Intern Med 2006; 144:861.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/27/5562/abstract/79\">",
"      Wunsch MJ, Knisely JS, Cropsey KL, et al. Women physicians and addiction. J Addict Dis 2007; 26:35.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/27/5562/abstract/80\">",
"      Frank E, Brogan D, Schiffman M. Prevalence and correlates of harassment among US women physicians. Arch Intern Med 1998; 158:352.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/27/5562/abstract/81\">",
"      Monahan G. Drug use/misuse among health professionals. Subst Use Misuse 2003; 38:1877.",
"     </a>",
"    </li>",
"    <li>",
"     Ross, S. Clinical Pearl: Identifying an Impaired Physician. In: Ethics Journal of the American Medical Association, Ross, S (Ed), American Medical Association, Chicago 2003.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/27/5562/abstract/83\">",
"      Verghese A. Physicians and addiction. N Engl J Med 2002; 346:1510.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/27/5562/abstract/84\">",
"      Fowlie DG. Doctors' drinking and fitness to practise. Alcohol Alcohol 2005; 40:483.",
"     </a>",
"    </li>",
"    <li>",
"     ASAM Patient Placement Criteria, 2nd ed. American Society of Addiction Medicine, Chevy Chase, MD 2000.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/27/5562/abstract/86\">",
"      Roback HB, Moore RF, Waterhouse GJ, Martin PR. Confidentiality dilemmas in group psychotherapy with substance-dependent physicians. Am J Psychiatry 1996; 153:1250.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/27/5562/abstract/87\">",
"      Wijesinghe CP, Dunne F. Substance use and other psychiatric disorders in impaired practitioners. Psychiatr Q 2001; 72:181.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/27/5562/abstract/88\">",
"      Galanter M, Talbott D, Gallegos K, Rubenstone E. Combined Alcoholics Anonymous and professional care for addicted physicians. Am J Psychiatry 1990; 147:64.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/27/5562/abstract/89\">",
"      Chappel JN, DuPont RL. Twelve-step and mutual-help programs for addictive disorders. Psychiatr Clin North Am 1999; 22:425.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/27/5562/abstract/90\">",
"      Khantzian EJ, Mack JE. How AA works and why it's important for clinicians to understand. J Subst Abuse Treat 1994; 11:77.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/27/5562/abstract/91\">",
"      Moos RH, Moos BS. Paths of entry into alcoholics anonymous: consequences for participation and remission. Alcohol Clin Exp Res 2005; 29:1858.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/27/5562/abstract/92\">",
"      Vaillant GE. Alcoholics Anonymous: cult or cure? Aust N Z J Psychiatry 2005; 39:431.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/27/5562/abstract/93\">",
"      Pelc I, Verbanck P, Le Bon O, et al. Efficacy and safety of acamprosate in the treatment of detoxified alcohol-dependent patients. A 90-day placebo-controlled dose-finding study. Br J Psychiatry 1997; 171:73.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/27/5562/abstract/94\">",
"      Sass H, Soyka M, Mann K, Zieglg&auml;nsberger W. Relapse prevention by acamprosate. Results from a placebo-controlled study on alcohol dependence. Arch Gen Psychiatry 1996; 53:673.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/27/5562/abstract/95\">",
"      Paille FM, Guelfi JD, Perkins AC, et al. Double-blind randomized multicentre trial of acamprosate in maintaining abstinence from alcohol. Alcohol Alcohol 1995; 30:239.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/27/5562/abstract/96\">",
"      Volpicelli JR, Alterman AI, Hayashida M, O'Brien CP. Naltrexone in the treatment of alcohol dependence. Arch Gen Psychiatry 1992; 49:876.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/27/5562/abstract/97\">",
"      McLellan AT, Skipper GS, Campbell M, DuPont RL. Five year outcomes in a cohort study of physicians treated for substance use disorders in the United States. BMJ 2008; 337:a2038.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/27/5562/abstract/98\">",
"      Washton AM, Gold MS, Pottash AC. Naltrexone in addicted physicians and business executives. NIDA Res Monogr 1984; 55:185.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/27/5562/abstract/99\">",
"      Domino KB, Hornbein TF, Polissar NL, et al. Risk factors for relapse in health care professionals with substance use disorders. JAMA 2005; 293:1453.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/27/5562/abstract/100\">",
"      Gossop M, Stephens S, Stewart D, et al. Health care professionals referred for treatment of alcohol and drug problems. Alcohol Alcohol 2001; 36:160.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/27/5562/abstract/101\">",
"      Long MW, Cassidy BA, Sucher M, Stoehr JD. Prevention of relapse in the recovery of Arizona health care providers. J Addict Dis 2006; 25:65.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/27/5562/abstract/102\">",
"      Carlson HB, Dilts SL, Radcliff S. Physicians with substance abuse problems and their recovery environment: a survey. J Subst Abuse Treat 1994; 11:113.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/27/5562/abstract/103\">",
"      Galanter M. Spirituality and addiction: a research and clinical perspective. Am J Addict 2006; 15:286.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/27/5562/abstract/104\">",
"      Walsh DC, Hingson RW, Merrigan DM, et al. A randomized trial of treatment options for alcohol-abusing workers. N Engl J Med 1991; 325:775.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/27/5562/abstract/105\">",
"      Herrington RE, Benzer DG, Jacobson GR, Hawkins MK. Treating substance-use disorders among physicians. JAMA 1982; 247:2253.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/27/5562/abstract/106\">",
"      Ganley OH, Pendergast WJ, Wilkerson MW, Mattingly DE. Outcome study of substance impaired physicians and physician assistants under contract with North Carolina Physicians Health Program for the period 1995-2000. J Addict Dis 2005; 24:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/27/5562/abstract/107\">",
"      Pelton C, Ikeda RM. The California Physicians Diversion Program's experience with recovering anesthesiologists. J Psychoactive Drugs 1991; 23:427.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/27/5562/abstract/108\">",
"      Bohigian GM, Bondurant R, Croughan J. The impaired and disruptive physician: the Missouri Physicians' Health Program--an update (1995-2002). J Addict Dis 2005; 24:13.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/27/5562/abstract/109\">",
"      DuPont RL, McLellan AT, White WL, et al. Setting the standard for recovery: Physicians' Health Programs. J Subst Abuse Treat 2009; 36:159.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/27/5562/abstract/110\">",
"      Menk EJ, Baumgarten RK, Kingsley CP, et al. Success of reentry into anesthesiology training programs by residents with a history of substance abuse. JAMA 1990; 263:3060.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7806 Version 9.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-122.72.76.133-AC55A795B2-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_27_5562=[""].join("\n");
var outline_f5_27_5562=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H547823849\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      DEFINITION OF IMPAIRMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      ADDICTION AS A DISEASE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Prevalence",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Etiology",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Anesthesia specialty",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Physician health, depression and suicide",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      IDENTIFICATION OF THE IMPAIRED PHYSICIAN",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Barriers to getting help",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      The family",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      INTERVENTION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Guide for intervention",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      ASSESSMENT AND TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24244203\">",
"      Physician health programs",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Risk factors for relapse",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Return to work",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      LONG TERM MONITORING",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      TREATMENT OUTCOMES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H547823849\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PSYCH/7806\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PSYCH/7806|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?12/55/13179\" title=\"table 1\">",
"      Spec rep in PHP",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?31/48/32523\" title=\"table 2\">",
"      MD training",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?38/53/39773\" title=\"table 3\">",
"      Behav and impairment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?7/51/7995\" title=\"table 4\">",
"      Caveats",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/48/19209?source=related_link\">",
"      Pharmacotherapy for alcohol abuse and dependence",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/58/5033?source=related_link\">",
"      Substance use disorders: Principles for recognition and assessment in general medical care",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/52/29514?source=related_link\">",
"      Treatment of opioid abuse and dependence",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f5_27_5563="Differential diagnosis for lateral elbow pain";
var content_f5_27_5563=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F73460&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F73460&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Differential diagnosis for lateral elbow pain",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td>",
"       Epicondylitis",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Loose bodies",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Osteochondral defect (radiocapitellar joint)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Arthritis (posterior osteophytes)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Valgus extension overload",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Radial tunnel syndrome",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Inflammatory arthritis",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Lateral synovial plica",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Cervical radiculopathy",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Thoracic outlet syndrome",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Myofascial pain",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_27_5563=[""].join("\n");
var outline_f5_27_5563=null;
var title_f5_27_5564="Clinical classification of ONJ related to bone modifying agents";
var content_f5_27_5564=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F69275&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F69275&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Classification of osteonecrosis of the jaw (ONJ) in patients receiving therapy with a bone modifying agent",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        BRONJ stage",
"       </td>",
"       <td class=\"subtitle1\">",
"        Description",
"       </td>",
"       <td class=\"subtitle1\">",
"        Treatment strategies",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        At risk category",
"       </td>",
"       <td>",
"        No apparent necrotic bone in patients who have been treated with either oral or IV bisphosphonates",
"       </td>",
"       <td>",
"        No treatment",
"        <br/>",
"        Patient education",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Stage 0",
"       </td>",
"       <td>",
"        No clinical evidence of necrotic bone, but non specific clinical findings and symptoms",
"       </td>",
"       <td>",
"        Systemic therapies including pain medications and antibiotics",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Stage I",
"       </td>",
"       <td>",
"        Non-symptomatic lesions with bone exposure in absence of&nbsp;signs of infection",
"       </td>",
"       <td>",
"        Topical antiseptic therapy",
"        <br/>",
"        Follow-up",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Stage II",
"       </td>",
"       <td>",
"        Bone exposure with pain, infection, and swelling in the area of the&nbsp;lesion",
"       </td>",
"       <td>",
"        Oral antibiotics, antibacterial mouth rinse, pain control",
"        <br/>",
"        Superficial debridement to relieve soft tissue irritation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Stage III",
"       </td>",
"       <td>",
"        Bone exposure, pain, inflammation, maxillary sinus involvement, cutaneous fistulas, and pathological fractures",
"       </td>",
"       <td>",
"        Antibacterial mouth rinse",
"        <br/>",
"        Antibiotic therapy and pain control",
"        <br/>",
"        Surgical debridement and resection for longer term palliation of infection and pain",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     BRONJ: bisphosphonate-induced osteonecrosis of the jaw; AAOMS: American Association of Oral and Maxillofacial Surgeons; IV: intravenous.",
"    </div>",
"    <div class=\"reference\">",
"     Reprinted by permission of Edizioni Minerva Medica from: Vescovi P, Nammour S. Bisphosphonate-related osteonecrosis of the jaw (BRONJ) therapy. A critical review. Minerva Stomatol 2010; 59:181. Copyright &copy; 2010.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_27_5564=[""].join("\n");
var outline_f5_27_5564=null;
var title_f5_27_5565="Comparison of weight loss surgeries";
var content_f5_27_5565=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PI%2F73045&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PI%2F73045&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Comparison of weight loss surgeries",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        &nbsp;",
"       </td>",
"       <td class=\"subtitle1\">",
"        Gastric band",
"       </td>",
"       <td class=\"subtitle1\">",
"        Gastric bypass",
"       </td>",
"       <td class=\"subtitle1\">",
"        Gastric sleeve",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        How high must my BMI be?",
"       </td>",
"       <td>",
"        Higher than 35",
"       </td>",
"       <td>",
"        Higher than 35",
"       </td>",
"       <td>",
"        Higher than 35",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        How quickly will I lose weight?",
"       </td>",
"       <td>",
"        Gradually",
"       </td>",
"       <td>",
"        Usually quickly",
"       </td>",
"       <td>",
"        Less quickly",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Can it be done through a scope?",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Will my intestines be re-routed?",
"       </td>",
"       <td>",
"        No",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"       <td>",
"        No",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Will a device stay in my body?",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"       <td>",
"        No",
"       </td>",
"       <td>",
"        No",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Will I be able to return to my normal activities after surgery?",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        How often will I have follow-up visits?",
"       </td>",
"       <td>",
"        Often in first year",
"       </td>",
"       <td>",
"        Less often",
"       </td>",
"       <td>",
"        Less often",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Will I need regular follow up with a nutritionist?",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        About what percentage of my extra weight can I expect to lose after 1 year?",
"       </td>",
"       <td>",
"        40 to 53",
"       </td>",
"       <td>",
"        62 to 68",
"       </td>",
"       <td>",
"        33",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        About what percentage of my extra weight can I expect to lose after 2 to 3 years?",
"       </td>",
"       <td>",
"        45 to 75",
"       </td>",
"       <td>",
"        50 to 75",
"       </td>",
"       <td>",
"        66",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Should I expect my other medical problems to improve?*",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Will I have trouble absorbing nutrients and medicines?",
"       </td>",
"       <td>",
"        No",
"       </td>",
"       <td>",
"        Some",
"       </td>",
"       <td>",
"        Minimal if any",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Will it be possible to adjust the size of my stomach or how much I can eat?",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"       <td>",
"        No",
"       </td>",
"       <td>",
"        No",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        What are the chances I will need more surgery?",
"       </td>",
"       <td>",
"        Higher",
"       </td>",
"       <td>",
"        Lower",
"       </td>",
"       <td>",
"        Unknown",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Will it affect my heartburn symptoms?",
"       </td>",
"       <td>",
"        May make heartburn worse depending on cause",
"       </td>",
"       <td>",
"        May help",
"       </td>",
"       <td>",
"        May help with symptoms in the long term",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Other concerns",
"       </td>",
"       <td>",
"        Requires frequent needle adjustments",
"       </td>",
"       <td>",
"        Patients may develop dumping syndrome",
"        <sup>",
"         &bull;",
"        </sup>",
"       </td>",
"       <td>",
"        Insurance coverage can be an issue for some patients",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * Other medical problems (comorbidities) include diabetes, high blood pressure, sleep apnea, and high cholesterol.",
"     <br>",
"      <span class=\"bullet\">",
"       &bull;",
"      </span>",
"      Dumping syndrome causes nausea, shaking, sweating, diarrhea, and other symptoms soon after eating.",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_27_5565=[""].join("\n");
var outline_f5_27_5565=null;
var title_f5_27_5566="Prednisone metabolism toxicity";
var content_f5_27_5566=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ENDO%2F59504&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ENDO%2F59504&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Prednisolone metabolism may influence side effects",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 427px; height: 319px; background-image: url(data:image/gif;base64,R0lGODlhqwE/AeYAAP///4CAgAAAAEBAQMDAwP8AAAAzmf+AgHBwcNDQ0BAQEKCgoDAwMCAgIICZzP/AwP9AQEBms/8gIP8QEODg4P+goFBzuf/g4FBQUP9gYLCwsPDw8P/w8MDN5pCQkP9QUKCz2SBNphBAn7DA33CNxvDz+ZCm02CAv/9wcNDZ7DBZrODm8/+wsP/Q0P8wMP+QkGBgYN8GE+8DCZ8TOV8fX08jaW8cVr8MJl9fn492o68wT48WQr8sRq9gf49Gc+8TGQ8vj+DW49+2wx8shc8ZLIBAQICJvK+gv58jSX85bK8/XzBJnF9Qj89pfH8ZTDA5jC8pfM+JnH8gIM9ZbO4jKc8JHK8PL29MhYBwcGBwrz9GkwAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAACH5BAAAAAAALAAAAACrAT8BAAf/gACCg4SFhoeIiYqLjI2Oj5CRkpOUlZaXmJmam5ydnp+goaKjpKWmp6ipqqusra6vsLGys7S1tre4ubq7vL2+v8DBwsPExcbHyMnKy8zNzs/Q0dLT1NXW19jZ2tvcuwQE3eHi468BAeTo6eqf5uvu7/CP7fH09fTz9vn64/j7/v/W+gEcSJCZwIIIEwo7qLChQ1wMH0qc6CoixYsYSVnMyLGjpo0eQ4qEBHKkyZOGSqJcaVIly5cdXcKcSVEmzZsNbeLcSVAnz5/7fAIdeu8c0aMJhSJdSk4p06fANhCgMIiChwAaBm1YEGDBBkVOoYrVRQCDAKMUFChgIACBILYD/wQwAGt0rN1kAvIaRSDAAwAFAjZoEIABgNmsiMLeXSwrwFlBccFFdnyOMgAK5jJrZsyZmGUAkUELIGDZMmbNmYs86Mz61+fDANgm8NAWAF+/iaVAaM2bLAwBMMAtIDy4wWUBDQg0EEA1MRYZF3pLr5W3uiAEgBkkELRgeYMFdDOgmE7emTkhE8qrV9buB4v18Iu1a/Ihvv1g7YIUiH6//655PLzg34AQGRWFBAQmSMs8K8SwmoIQVlSXEhlEaOEq+BxRAAcXdmgKPiXcUIGHJIrSTw8ulKiiJ/2AIEMLK8aYiUBIjCfjjZQIlEN6OPZIUl2CjFDFiD4WuchBSexm5P+FVnWlFVde0WWIEfstGWECasH1lgBxzZXIQSnMcICVEDrmVl4ADFYYbIkBOcgVCJKZIJaECQBeaY+RhloAA7gpiAkxvCfngBQw0ABgMACA5zl6otbnISvYUOGg/plFwAbLEUCbW7d96acgOGxIaX+/waABYBRQgJxyzHmKCAhWCDiqfRuYJRdi3SEHnquHlFBDnLPiaNEJLwYr7KdB7jCpsTFu9MQEHDK74kYniCjttMgKkgINSl5LIkhLQOftt9kK4sAMNo670wZXmbPrKCCtAAWP6uIUV3UDlFKSCoHWi5Nc3xCwnUbl/mlDff7SxEDBLDJcAhBVJgwTAg1k9q7/iQwDYMEMskrM0r155UtwIyD86vFLCQQssL4ZAyCCgye/tPKHLZ/gxLIxj0SnXF+N3MgIQ4ia80gNVIxdoj43EgIRRA4d0miC8MnyIyTQkKLTITWAAQEaMIA0vC0DkIIIE8CIdUfD5aXAwGBDooIO6Z6dUQIBeNDcI03uulVXPbcJiQlM0Cv3RJemHDDbjAynwACFxcalXFI+soIBVDQ9+EOjgcylI6o20LeahgmA2CE6ReBDt5c7FAAFXFnsCG0MAObXogA0qtmjkHSQRQFakDBC6g8l0JzwjjhmKqq0254Z7pFkMAUJKhhggQkrAI8Q7lI3Qts5kW1qW1+8RvJA/5wrgGCBCCH4br07ZQ3gvluDJDCAAg24vzjnyJ2qwAads3p3SmErhAQENYgOQE96JkjB+sgBGHwRggDVUdvoEuedgeXqO5GTxAtwRogSgOAE6DvBCEqwQG4oAH6IQMDFpjaJCwgtESlwQPQikMASYmMBAzicIdjluqRJ4gMdW4QHQRgCEZLQhtL4jQMLYauQsXASLADWI2IYAQNEwAEKRKIz5NJDQrQlcwGsRFjKRokSjOAEIRDBCUBwRC0iYwAoPMRoFIAZkbWtEijg4CRSYIIqqgCLbjQGDBb3PkMoYAEYOJQdMWaJC0BLE2ZEoxrZGMhgaG6R3FkAltb2REpA4P8A0doEHy1gABWQoAOVTEYCENfJSTzABRPIgNk6MQISpNECIKheKm/ROncZwn2pUIwgWoCCCbigAqHkxApMQEpTonKXs7ikIboWzDAuogIQiOUsPVHLW1IPmq8wHAEO+csIYhIUwjTEBYp5zGR2onznS9/vwOkKxhkCAe4rpA87gU1tjsKA0ZueLulJitbx5ZzEA0BC7xiKdRoTmaOAJ/rUR9BQaG6CkDFK9hg6in7KshQdkKEVa1hRTojzfwqdX/3md052WLOR7IQoKYYYwhGWFBMIiOMDIygABWAUnS/FhEe3OYoYzpCkN5UEDFo6CBVWsxUOlcAL3CkKmhbRpkn/fZ0CukgIcbISqLDAZgEy8KBT8NGPgMyqIqRZCL4skaOuWKcEpErVUUQyjWtso1rjp7Kv9pSroUgnJ1jwgbGWFRVnLWVa95qm1QXgqxV7qi0ucIC5TnUVd53kQEvq1rJ8rak5/MZXXaoLwhq2Fcts5ilLqgAYMIA052QrXG9BWcvW9RTdFAEuN1vJzBFgqYbopZP2WdrCkvUVqS3lais5AEOZBTeFkIp0W8mL2tIVFrVUgW6/icSdMaBvg0gbARigU7AOw7THhYVE5YlEAiwApYJogKFgS11gWPcA/IEFQBHI27MNwFR58SsBcojP+grDtB8goHrNN9F5nk10A5Dv/2fj69oAnNDAw7jAC+aKX1qE9KhZzNkcYbDRQQxGbfAlbTMekIECJLgWVjXiyQzVF+Aagm52oxk0OLBhCXS4FkYdaYjVNU4GpAW6g8DAXNIS1EgINhcsdrGCZxFjSjpNdNdhaieerAseczi/QO6jYocsMSzbRsuc4DIvovxiXGQ2rxLDwAk7RVxqeNnHYLZFYv9IZmklYDk8wzA12DxlW5jRlrrN5bhmFolv9GxvUQofN+6MgjzfIrnOxBFPnRjddg3XEeLdUpcyKI4oQ8ByusjtbleUz1aXV7aMSEtewAE6NpGuyc/gMSwr7QtML3dJABPtI/IJteTtiU+4jkYLMv8wgVMDY78CfUYHpv1MSIAgAn0WWwRA0IwEYCCf5V2YJDxAx9AYe0/McwcHKrBrS+tivRRVhgHmbQARZDsRDjBAtQmxAgfsOxlseWtTK+bLRmhuNN6j863tsexmo7oX0OauMeYNABNIDwAgcMAyV1ACB0TAAvNMgQUiUMUO9LuWVwRAv1FZAhKQ3AF/+vg8HQCCPp7giNem4SzsJAAAkLicAleE4djiAf6tajkpjlqyr7HudgsD3lgVBsU7YEUAVFEE+tauSFOwAhGIwOP6proVsQ4CqsM8jQ6wJQBIYAASkPJ381ZBCAxwgrW3nZQmkMVoklPgQoiT0Y4IDQAuuML/QqiZGg139jCCTMN752LeIuV2FUmYAis64AQGcIDFuZ3vaWceACPIvNldpkaNu0wFACjBxauu+gi4LAQOyLfrY1ExJTbO73VLesMG0vQJ8HoYMY66LuZNcm5b3QCCoPoVYx9SfQOg86M3++hFPncRTG72Va86ALIP+9gbHxarrBUGwMud6nCyzvtI/MOBwXik3oLihKjiILxedhOUXXodKHn0Rf/5beffACJnACOQb3mnfVVHSv6Wcb6gAFvTNbfHSAnRex9VDEMUAkVkZbQAf4Mgf9pCSgYQAr/DdiIQPZ4Hc9L3eR4YAtxWAqQkAiQgCAboeiUAQvUGc6+QOeZk/whQoyhotgmH1w0N107HsGeLBRUDkAD4BG6GYCgBgB3lpWIPIYFEBXxnhFcYyBQJtVDx00DfJWgI4VBCiAxE6Hg7gT1MBXizNRFDpQyHdkuK9hPyQz/2c05Kdhlb5YUOAYYylQy+9m+lEAEvSAguJwkzCIjPR3LGAEER5FM6iBh9l4YZsYbMoGpvSAo0VwgcCAmYRwIgAALSY4OLkIm24FSJYGaPCIEmoYe3VQy+5mCakAIn8HGcZ3wj8HFzl3wjRwJ6BQAdkIsl0AFz529VdAKo1IuAiHO5OALBiEojMHLE2AtyllPgg34hIYnNEHH9JQmT80cnYAHb53qh90e3GP96FsB23jgI5GiOIIB12zZ3KgAC6Xhx+WYBDlBE7NiJn0iPNzhgOeh3gNaF1CgSqvgMUFcJlZc+JkBCB2gA1SN/CFiPyDcID3mLHNh5GpN5EPl6glACJcCBFvdH39cKR5iE+mQIaIiKM+FRh3WNBxRtkVCLWId6VceB8ldFsRd78YeROFmRzmeTN/mNOTkIYNd28PCDBRFVlwUN5UNEMsYIHSBCHeB1QJlvDqCMyGdxFtABZ0QIWKmVdceTqNSVW4l3vfh/I8BHp+SJ5xhO31aSEjIUFWBcK+kM7UeGKxA9paRArFdFFhiREHlxhPCX3giW5jJ3FzeDWBcCKzACWGf/AlYpPbvICoDGaeWwdBlhXUkZDcEXmQBBGIugAY41Wru3FOg1l89QlwWBAU/YVLOGARNmXkyBmavIDG92hfkwSEpYCK31WiUWWJZpEqV5DWOoD7AmCL5lY5C4FLJ5DbXJmfvQXFozjcn5FMGJDUToh+KwOsJVeN5FfrDJGcuZDZSYjdqAg0E3CCfpm9KBXoVWDX0YDoXTVzfWlnCEh3ZxX+5WDeMJD5O5OQHZGQjWntaQWiMYb+jgmahglDhxZz/GDdhIDqopWfZBaOJQkNGQhfCFm26pnv7BoPmJDQ/aDGYIdJSJkv5BoeOwlDXlnMAQhyt1P7CgoEvhoeiAmsSg/4jm91MKlXs6diEoSg6bOQykiAhp01OiuWW/yRo0mg6MV4S94FWG1IAM8IAcWiJstn7h0Jy84FYlapzgwIP2mSBe5nsf2g3DiQt/VXCEwIROGKYQYmpYKg5aSguRlQjd6aYR0nu/5w6jpFzYuQr4pEOHkJ7f6SPqRw/7KZL9qHSoUXhQuCR6WqYpykx+ugrb6UWb1oMfkaQEcqj1oGp/GgqgiRmIozKCOp1FEqn2UD6h+gmd5ZqIQKiPOiueuhO7SV9+x4XeOavBoqo3cZznVDRN2Fp4uiTqN5shAZ3PpYNf2puF6i1SiDK6aghawzVeU6yDEoR7eBKEWqTnh6reYv+NIVGHTHYIOKZ7SIo1A+kRpnhOC+AVsIqt0iKuF9Gu1OoBSoRkVSo360oR0ahwgzAaDABHmjojnDoq9NoQf5YXAEkIW3UWzsqrl9OvDkGonXWt/yk3CTsQwJQI7KIBG/BY8hozFAsQEVs7G/B3R5pmB6suYpVeAHFQbmmeXfqsboSUyOoOsKadmuGoo0lP1ckYMuov4UkPCcAWyqGvg9dA/gmulRS07xA7CkAApygIgJGbTptKRasOEIarDrua+7pXUMtAHjAAGtAAr4kAr5m19LS14eAY1fGlhFCcNstYADC23FC2GKCjJFmfGatWmCmpA0E3nwZpuzoIQ7s+Aar/DXxxh7/UahuqCBEEP3ABOZJmt4qAn9ZwYrOmg5n6COCRAGhSa2a2cJj7CCzQYm0mDQHgOZiCLMkhCD8HCZ2jKI9hGcpjDul2uo2wpM8QAK81XsHhV7hRtYwAG+fmKC1bUT9qEJ9bCHHRXMDxCBsQF7uScNIJQLxbCb6bDDgEueVVK3kxfpwDF+aQKkfXKn6zvZbQvNUgXZfiCDjauYRHauxLCd0bDeJFXiN7v4bgvs4gX8lxsunqv5qQv8vgW8YrsQbcvi2meMyAtgtzYX/bwJEwpnuKDJxLR/1rwYvAYg6nDOfaox78Cb5KDDkloSUMCrUaDMhJwiscCifsC+QG/1h1G8Oe0MK7QLcMjMMmzG5kygsq28E+PAk6bAugmWNEXMSTMMOzwKXfaqJMfApBaJquQBhcw4BLPMXcWwFW3AqvFTUFiwmJy8XAgE+62yc+64PLa8bEcHBNe8NunA1/J2xSPMciUcZ47A56vMfq0Mcx8wCC/MWJgE1TCAAtAME50caDUwCOXABk9AgHUACmSVmEbLKMLDeODAAv4GIAcAAV0AJjwgEHAAFt1gIfAAEQQMmUxQIo8EkAYMkAwAGvDMucbMqCAsovAAEZEC3YBAFB9LaZfDab/AAFsBuQvMmwdAAuUAAt4EgTUMqUbMzHPAEF4MUFMCYSEM0ogCAoUP8AKFBY7+HILiABYwUA3xzOBRDM3ADIJ+PIzHzNAFAAV9MCx3wALXYAnTwikyzI2Xy32WzMYzIBsdRhxjTLnnzMCL0bE+Bjk4w63eDOHuPIqkwkCg0AxvxJB3AAD9DPnzzN/yzQAo3IH2DOE+BCSqLQF63SDg3KTTHMWLPJhHDRAEDQXvwC2PwBD7DK/jwmIv3Pp7bTzizOkywgK70bhcXRFTAm/ADTTiPTg0DTqOzIA4TOkNzMPY3RAf3PhVUAEjAiHFBYvicIRz3LzAbJTJ2dTu3Hf7zWbI0OEv3WEe3Wcq3WbA0BcYPOEO0IpbwbLKDKhzzXbO3ShLDKklABLob/X/TcoIng0dQQ10R7AK5sy8uG1+5Ey6o8JoT91yVdAILwAKmMAu4E2pZ9AatMVg88IheQAbxsNnGJ14k8ViNCWLx8ycMA2fVCzdl0zY7kAgdw0ISwzQfQzfPs14ttzgD9Ad+MMILAAi623C1gzsfUzBJQacb02+kxyR9QWRtGzyiA2Nu93eZB1x4z0s6tzwXwHt+8TQSdAR2m0IUVHYad1JXl2YNA38jt0SPdye7N0w0tCBxAypTMyYsdp8aA2+oy0gLt0Y49TJ190gpt2ABg2Ku80Rtd2Nls4R+9GiM9ye690ShNCI4tzeA83ryr4Nlszzq9zYUQ1Ktsz7sxyZKN/9ydrNOpSwg1/gA3rt//bM8uwAIPgAJT/QKg3dEB/QIo8ADgbeKni+JjUgHSTVRd/dXFPcurPFf2Xd+eLOLm7Mk8ztQs0Mz0fAEccNYScAEXYM4J1uUfkLMLQd513c5wHufagOB0Xg12fufTkOd6Hg183ue/O+eA/tiCPuisW+iGDg1/nujsgeiM3gyL/ujHEOmSLh+OXunJQOmY/uabjhCa3umucemg7hmiPuqcbur/8Omorgsy+g2g4Oq+AOu9IOuxLre8QOvZIKNGqeqm2wu8vr6+XuoYksm7LuyM8OuGZ+yNgOyEwOxhW8A/ywvOrnT4oez2iw263sbTrijWfv+50t7twL4MhnvtLCvHtbDt207tvpDujlC5XhLu0V7u6w7uvT7vod4MpKujYnxs/N7v/u4+/h7wAQ/wAl/wBn/w/E7wCL/wDP/vfdLwEB/xt/PwEl/xCL+7yEA7sWrxHN/xHv/xIB/yIj/yJF/yBW/rmX67j7Hq9IC9Ssvy6tA/SAfz9FC/NH/zOJ/zOj8RTaLvlTAbfCMI424Je2MUQx8LjNYkRWdiPAoLjLY3Sy8ISYyupqD04JUydzP1rgD0kXb0Wg8NabEWtbEJ/ejulkAnESZqlhtOjmFHIOMlfCG1VD8KdOOfG1C5+/M9cv8Kb7+FKx/3ajH3oVD2jwP3chH/+NDQKYBxuJMAHqrSc/leCcvBNpHP95QJspgyGhvQUwDgPYrqnxA0F5Gx+QrQ+WPfCpifKVvyGKRv+mBbUMcB+Z55GK3v+c4QGoKnCVSr8pWx8pIgukXjmRr/ChAUrMxR/LUTx6uA/ABw93KBtsmfL8wPCzNvYXzBKJsz/ct//bbb+wGA/NrPDLi/g5qAQ7Ux/I0GMGzBFbyP9MrvPeCv/KrA/BswSMvxXfE/xqPgPaILCBoBAgEABAIDhogAjI2Oj5CRkpMACwMCCACDhZuHiZ6UoaKjpKWPGAIaAAwCCaaklwQemAAIAh6vjQmLm7OZtri5wqGgjbYwjLsMABoC/xjD0JDFs4WoAcrMztHbxgLImgLh4dcCy83P3NuxvrW32Ofp8fKMC87NDfIEDAG2AhQUAhoQaOAPGkENrAgAFEiQwrxhCWYxILABAKoGAQIQAHAQ1YKHryKWo1hvIquPHQV8BGnqYkaFBAjA8OYw5UqWxPb1+xdwYEGbOIOaQqCgnKt4FFgFVFWJYIObwhKwUrBygVOoQkNdErdR3DgAUgUoyJRVq9eNRAMWAjuVbFlKXgk12pSs7VtJScM1YGo14MqwY+8KHky4sOHDiBMrXsy4sePHkCNLnky5suXLmDNr3sy5s+fPoEOLHk26tOnTqFOrXs26tevXsGPLni0pZvdFsAprJaLNu7dvyOFwAZS7YC0sAb+TK18+TG874oUoBNCAYEB0jQCkxySInQCGAQgqJoAxAANW5ujTww6YSgF3AJcUISq64FAh+wuKDlhwzhYGgPvAgI56BBaoGiIYKKAAXfHZl41GcjkYn0WEBEDQLg0g4MFtBnboYWiINIMAg8g5aJ+Jck14SUYZMTNAUct8KOOMmS1CEYmK3EfILguuCF8qImFAgAYwyKQBAQrSqOSSkS3CCI4oFmJLAzMVokFRuFgYzn9KMXAUk2CGKeaYZJZp5plopqnmmmy26eabcMYp55x01mnnnXjmqeeefPbp55+AfhYIADs=);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Disappearance curves of tritiated prednisolone in five patients who did not develop side effects while taking prednisone and in eight who did. The patients who developed side effects cleared prednisolone from the circulation more slowly.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from: Kozower M, Veatch L, Kaplan MM. Decreased clearance of prednisolone, a factor in the development of corticosteroid side effects.&nbsp;J Clin Endocrinol Metab 1974; 38:407.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_27_5566=[""].join("\n");
var outline_f5_27_5566=null;
var title_f5_27_5567="Algorithm for the evaluation of proteinuria";
var content_f5_27_5567=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEPH%2F85792&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEPH%2F85792&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 478px\">",
"   <div class=\"ttl\">",
"    Algorithm for the evaluation of proteinuria",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 458px; height: 733px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_27_5567=[""].join("\n");
var outline_f5_27_5567=null;
